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Abstract 1 
Background 2 
People with traumatic brain injuries (TBIs) commonly report memory impairments. These are 3 
persistent, debilitating, and reduce quality of life, but patients do not routinely receive 4 
memory rehabilitation after discharge from hospital. 5 
Objectives 6 
To assess the clinical and cost-effectiveness of a group memory rehabilitation programme for 7 
people with TBI. 8 
 9 
Design 10 
Multi-centre, pragmatic, cluster randomised controlled trial. Qualitative and health economic 11 
evaluations were also undertaken. 12 
 13 
Setting 14 
Community settings in nine sites in England. 15 
 16 
Participants 17 
Participants were aged 18-69 years, with TBI more than 3 months prior to recruitment, 18 
reported memory problems, who were able to travel to a site to attend group sessions, 19 
communicate in English, and gave informed consent. 20 
 21 
Randomisation and blinding 22 
Clusters of 4 to 6 participants were randomised to intervention or control on a 1:1 ratio. 23 
Randomisation was based on a computer generated pseudo-random code using random 24 
permuted blocks of randomly varying size, stratified by study site.   25 
 26 
Participants and therapists were aware of the treatment allocation; outcome assessors were 27 
blinded. 28 
 29 
Interventions 30 
Ten weekly sessions of a manualised memory rehabilitation programme were provided in 31 
addition to usual care. Participants were taught restitution strategies to retrain impaired 32 
13 
 
memory functions and compensation strategies to enable them to cope with memory 33 
problems. The control arm received usual care only. 34 
 35 
Outcomes 36 
Outcomes were assessed at 6 and 12 months after randomisation. Primary: Patient-completed 37 
Everyday Memory Questionnaire (EMQ-p) at 6-month follow-up. Secondary: Rivermead 38 
Behavioural Memory Test-3, General Health Questionnaire-30, European Brain Injury 39 
Questionnaire, Everyday Memory Questionnaire-relative version, individual goal attainment. 40 
Costs (based on a UK NHS and PSS perspective) were collected using a service use 41 
questionnaire, with the EQ-5D 5L used to derive Quality Adjusted Life Years. A Markov 42 
model was developed to explore cost-effectiveness at 5 and 10 years, with 3.5% discount 43 
applied.   44 
 45 
Results 46 
We randomised 328 participants (intervention: n=171; control: n=157), with 129 in the 47 
intervention arm and 122 in the control arm included in the primary analysis. We found no 48 
clinically important difference on the EMQ-p between the two arms at 6-month follow-up 49 
(adjusted difference in means -2.1, 95% CI -6.7 to 2.5, p=0.37). For secondary outcomes, 50 
differences favouring the intervention arm were observed at 6-month follow-up for RBMT 51 
and goal attainment, but remained only for goal attainment at 12-month follow-up. There 52 
were no differences between arms in mood or quality of life. Qualitative results suggested 53 
positive experiences of participating in the trial and of attending the groups. Participants 54 
reported that memory rehabilitation was not routinely accessible in usual care.  The primary 55 
health economics outcome at 12-months found memory rehabilitation to be £26.89 cheaper 56 
than usual care but less effective with an incremental QALY loss of 0.007.  Differences in 57 
costs and effects were not statistically significant and non-parametric bootstrapping 58 
demonstrated considerable uncertainty in these findings. No safety concerns were raised and 59 
no deaths reported. 60 
 61 
Limitations 62 
As a pragmatic trial, we had broad inclusion criteria, therefore there was considerable 63 
heterogeneity within the sample. The study was not powered to perform further sub-group 64 
analyses. Participants and therapists could not be blinded to treatment allocation.  65 
 66 
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Conclusions 67 
The group memory rehabilitation delivered in this trial is very unlikely to lead to clinical 68 
benefits or to be a cost-effective treatment for people with TBI in the community.  69 
 70 
Future work 71 
Future studies should examine the inclusion and selection of participants who may benefit 72 
most from memory rehabilitation. 73 
 74 
Registration 75 
ISRCTN65792154 76 
 77 
Funding 78 
National Institute for Health Research, Health Technology Assessment 79 
 80 
Word count: 56181 
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Scientific Summary 
 
Background 
Traumatic brain injury (TBI) is a major cause of mortality and morbidity. The most common 
cause of TBI is road traffic accidents, which tend to produce diffuse injury. Impairments of 
memory are commonly reported by people with TBIs. They are persistent, debilitating, and 
reduce quality of life. Many people with memory impairment do not routinely receive 
memory rehabilitation after discharge from hospital, yet continue to have problems in daily 
life. Cognitive rehabilitation is a structured set of therapeutic activities designed to retrain an 
individual’s memory and other cognitive functions. A narrative review found cognitive 
rehabilitation to be beneficial for treating cognitive deficits following brain damage. Some 
randomised controlled trials (RCTs) have demonstrated the effectiveness of cognitive 
rehabilitation following brain injuries. These have mainly focussed on attention, executive 
functions, and visual neglect; but memory rehabilitation has not been sufficiently researched. 
Most evidence for the effectiveness of memory rehabilitation comes from single case 
experimental design studies and controlled clinical trials. The few RCTs and quasi RCTs in 
this area have offered some support for the effectiveness of intervention, but many have had 
methodological limitations.  
We conducted a small scale RCT (n=72) to evaluate a group memory rehabilitation 
programme. Patients with memory problems were randomly allocated to one of three group 
treatment programmes: compensation strategy training, restitution, or a self-help attention 
placebo control. The results showed that there were no statistically significant differences in 
outcome. However, the qualitatively analysed participant feedback interviews indicated the 
interventions seemed worthy of further evaluation. 
Objectives 
The primary objective of the ReMemBrIn trial was to determine whether attending a group 
memory rehabilitation programme was associated with subjective reports of reduced 
frequency of forgetting in daily life when compared to a usual care control. The secondary 
objectives were to assess whether the intervention was associated with improvements in 
objectively assessed memory abilities, participants’ ability to achieve individually set goals, 
mood, health-related quality of life, and cognitive, emotional and social wellbeing. The cost-
16 
 
effectiveness of the intervention was also investigated. A qualitative evaluation sought to 
explore participants’ experiences of the trial and the intervention. 
 
Methods 
We conducted a multi-centre, pragmatic, cluster RCT with follow up at six and 12 months 
after randomisation. A subset of participants took part in a qualitative study that explored the 
perceived benefits of the intervention and experiences of being involved in the trial. A health 
economic evaluation was also conducted. 
 
Participants were recruited from community settings in nine sites in England. We included 
participants with a TBI more than three months prior to recruitment, who had participant-
reported or objectively assessed memory problems, were 18 to 69 years of age, were able to 
travel to one of our sites and attend group sessions, and who spoke English and gave 
informed consent. We excluded those who were considered unable or unsuitable to engage in 
group treatment if allocated, were involved in other psychological intervention studies or who 
had language impairments.  
 
Once four to six participants had been recruited at a site, who could all notionally attend the 
intervention sessions at the same time, they were randomly allocated as a cluster to 
intervention or usual care on a 1:1 ratio. The randomisation was based on a computer 
generated pseudo-random code using random permuted blocks of randomly varying size and 
stratified by study site.   
 
Those allocated to intervention received ten weekly sessions of a manualised group memory 
rehabilitation programme in addition to their usual care. Participants were taught restitution 
strategies to retrain impaired memory functions and compensation strategies to enable them 
to cope with their memory problems. Some sessions were video recorded to check the fidelity 
of the intervention. 
 
Outcomes were assessed 6- and 12-month follow-up after randomisation. The primary 
outcome was the Everyday Memory Questionnaire – patient version (EMQ-p) at 6-month 
follow-up. Secondary outcomes included the Rivermead Behavioural Memory Test-3 
(RBMT-3) to objectively assess memory ability, General Health Questionnaire-30 (GHQ-30) 
17 
 
to assess mood, European Brain Injury Questionnaire (EBIQ) to assess cognitive, emotional 
and social wellbeing, the Everyday Memory Questionnaire – relative version (EMQ-r) , and 
individual goal attainment, with the EQ-5D-5L and a service use questionnaire used to inform 
the economic evaluation. 
 
A sample size of 312 was required to detect a minimum clinically relevant difference in 
means of 12 points on the EMQ-p with a type 1 error of 0.05 and 90% power assuming a 
standard deviation of 21.9, and accounting for 20% loss to follow-up and the potential for 
clustering due to the group intervention. 
 
The main approach to analysis was modified intention-to-treat, that is, analysis according to 
randomised arm regardless of adherence to allocation and including only participants who 
provided outcome data at follow-up. We estimated the difference in mean outcome scores 
between the two arms using a multi-level linear model with site and baseline score (if 
measured) as covariates with a random effect for cluster in the intervention arm, and allowing 
the participant-level variance to differ between arms. A planned exploratory sub-group 
analysis on the primary outcome was performed according to memory impairment at 
baseline. 
 
We undertook a within-trial analysis, comprising a cost-utility (incremental cost per QALY 
gain) analysis at 12 months and secondary analysis at 6 months. Incremental cost-
effectiveness analyses were also conducted based on the EMQ-p and GHQ-30 at these time 
horizons. A UK NHS and personal social services perspective was adopted. An exploratory 
model-based analysis considered longer-term cost effectiveness at 5 years, with 3.5% 
discounting applied. 
 
A subset of participants was interviewed from each arm and different participating sites. The 
purposive selection strategy was designed to include participants with varying levels of 
memory impairments and with varying social situations. The interviews were conducted by a 
researcher who was not involved with the participants’ assessment or treatment. 
 
18 
 
Results 
There were 4023 people with TBI who were invited to participate between February 2013 
and December 2015. Of these, 1710 (43%) did not respond to the invitation, 1129 (28%) 
were not eligible, 718 (18%) were not enrolled for other reasons, and 466 (12%) gave 
consent. Of those who gave consent 328 (70%) were randomised. The main reasons 
participants were not randomised after consent were non-eligibility and recruitment being 
closed at the site. In total, 171 participants were randomised to the intervention arm and 157 
to the usual care arm. 
 
The mean age of participants was 45 years (SD 12), 239 (73%) were men and 314 (96%) 
were white. The median time since TBI was just over four years. The mean EMQ-p score at 
baseline was 48.7 (SD 22.8). Characteristics assessed at baseline were well balanced between 
the arms.  
 
Attendance at the memory rehabilitation groups was good. Participants attended a mean of 
6.3 sessions (SD 3.5) and 131 (77%) attended four or more sessions. At 6-month follow-up, 
260 participants (79%) returned the questionnaire booklet and 276 participants (84%) 
completed the assessment visit. Questionnaire booklet return and visit completion was similar 
in the two arms. At 12-month follow-up, 238 (73%) participants returned the questionnaire 
booklet and 256 (78%) completed the assessment visit; completion was again similar in the 
two arms. There were 122 (78%) participants in the usual care arm and 129 (75%) in the 
memory rehabilitation arm included in the primary analysis.  
 
There was no clinically important difference on the EMQ-p between the two arms at the 6-
month follow-up (adjusted difference in means -2.1 [95% CI -6.7 to 2.5], p=0.37). There was 
no evidence of a difference in the effect of the group memory rehabilitation sessions across 
sub-groups based on baseline RBMT-3; the p-value for interaction effect was 0.12. Although 
the difference in mean EMQ-p score in the sub-group of those with borderline/moderate 
memory impairment favoured the memory rehabilitation arm (adjusted difference in means -
7.1 [95% CI -13.9 to -0.3], n = 102), there was no statistical evidence of any overall sub-
group effect. 
 
19 
 
Memory ability on the RBMT-3 favoured the memory rehabilitation arm at six months 
however there was no evidence of a difference at 12-month follow-up (adjusted difference in 
means at 6 months 2.5 [95% CI 0.1 to 4.8] and 12 months 0.5 [95% CI -2.6 to 3.6]). There 
was no evidence of a difference between the arms in mood on the GHQ-30 at 6 months (-1.6, 
95% CI -5.3 to 2.1) or 12 months (-0.2, 95% CI -4.5 to 4.1). Scores from all subscales of the 
EBIQ for both participant and relative/friend versions were similar in the two arms at both 6- 
and 12-month follow-up. Goal attainment scores favoured the memory rehabilitation arm at 
both 6-month follow-up (short term goal adjusted difference in means 0.6 [95% CI 0.3 to 
0.9], long term goal 0.5 [95% CI 0.2 to 0.7]) and 12-month follow-up (short term goal 
adjusted difference in means 0.3 [95% CI 0.0 to 0.5], long term goal 0.4 [95% CI 0.1 to 0.6]). 
No safety concerns were raised and no deaths reported. 
 
The cost of the memory rehabilitation programme was estimated at £167 per participant. The 
base case analysis (incremental cost per QALY gained at 12-months), showed the 
intervention to be slightly less effective but less costly than usual care; with a reported ICER 
of £2,445. At 6 months, the intervention was slightly less costly and slightly more effective 
with numerically small, statistically non-significant difference in costs and QALY gains. The 
health economic analyses showed uncertainty, with results changing depending on the 
outcomes, time horizon, and imputation method used. Overall, it was unlikely that memory 
rehabilitation, as provided by the trial, could be considered cost-effective compared to usual 
care. Exploration of the longer-term cost-effectiveness at five and 10 years did not change the 
conclusions.  
 
Thirty-two participants from both intervention and control arms were interviewed. Four main 
themes were identified: feedback on the trial, experience of the rehabilitation group, strategy 
use, and usual care. Participants were positive about their experiences of taking part in the 
trial. Those who received the intervention found it helpful, and the format and content of the 
intervention were appropriate, with specific benefits identified of being part of a group. 
Participants reported little systematic training in strategy use before the intervention and had 
developed memory coping strategies themselves. Participants reported that there was a lack 
of support or specific training for those with memory problems provided as part of their usual 
care.  
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Conclusions 
Implications for practice 
i. People who have had a TBI continue to report memory problems following discharge 
from hospital or rehabilitation services. 
ii. This trial did not show any benefit of this late stage group memory rehabilitation for 
people with TBI late after their injury. 
iii. However, participant feedback based on interviews was positive, with some 
participants reporting benefits of attending memory rehabilitation.  
iv. Clinicians need to identify what interventions may be useful at this late stage after 
TBI. 
 
Recommendations for research 
1. There need to be more small scale efficacy studies to establish appropriate selection 
criteria for group memory rehabilitation programmes, so that the intervention is 
tailored to those who may benefit most. 
2. Further research may also need to consider the required ‘dose’ of the intervention to 
effect changes.  
3. There needs to be more information on usual care for people with memory problems 
following TBI so that group memory rehabilitation can be evaluated in those who 
have not already been taught the strategies covered in the group programme. 
 
Word count: 1856
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Plain English Summary 
 
People with brain injuries often report memory problems. These difficulties can continue 
long after the injury, causing complications in daily life. Many people do not receive specific 
help for these memory problems after leaving hospital.  
 
Our study explored whether receiving ‘memory rehabilitation’ (a group treatment to help 
people deal with memory difficulties) was better than the treatment people usually receive at 
reducing frequency of forgetting in daily life. 
 
We recruited 328 people who had memory problems following brain injury. About half were 
allocated at random to receive memory rehabilitation and half did not have any extra memory 
treatments, but everyone continued to receive their usual care. Those who had memory 
rehabilitation were offered ten group sessions teaching strategies to help them cope with 
memory problems. We asked all participants to complete memory tests and questionnaires at 
the start of the study, and again 6 and 12 months afterwards to find out whether the memory 
rehabilitation had any effect. Some participants were also interviewed about the study.  
 
At the 6 and 12 month assessments, there were no differences between those who received 
memory rehabilitation and those who did not in terms of how often participants reported 
memory problems in their daily lives or in how well they performed on memory tests. We 
also did not find any differences in participants’ mood or quality of life. However individual 
goals set by the participants at the start of the study were a little better met by those who 
received memory rehabilitation than those who did not. The memory rehabilitation did not 
represent value for money. In interviews, participants reported positive experiences of taking 
part in the study and of attending the group sessions. 
 
This group memory rehabilitation programme is unlikely to help people with memory 
problems following a brain injury any more than the usual treatment people receive. Some 
people may benefit from memory rehabilitation more than others, but this needs further 
investigation. 
 
Word count: 320  
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Chapter One:  Introduction 
 
Background 
Traumatic brain injuries (TBIs) are defined as an alteration in brain function, or other 
evidence of brain pathology, caused by an external force.1 In 2013-14, the total number of 
people who were admitted for a TBI in the UK was 162,544 (254 per 100,000).2 Apart from 
TBIs that civilians sustain in daily life, TBI amongst military personnel has also been a major 
contributor to mortality and morbidity.3, 4 The epidemiological variations seen in TBI 
observed in the armed forces are due to different approaches in screening, definition of TBI 
and reporting.5  
 
Costs of morbidity due to TBI are incurred by the healthcare system and those outside it (in 
terms of loss of productivity due to short-term sick leave and early retirement), and through 
non-medical costs (e.g., transformations of house or work environments, etc.).  In addition, 
informal care by family or friends also add to the costs of care for affected individuals.  For 
TBI, the direct medical costs and indirect costs were estimated at $60 billion in the United 
States in 2000.6 The full costs of dealing with memory problems caused by TBI in the UK are 
not known. Care costs escalate when interventions are provided on an inpatient basis, but 
Salazar et al.7 demonstrated that the benefits of inpatient and home cognitive rehabilitation 
programmes for TBI, in terms of return to duty (for military personnel) or employment, were 
similar. 
 
Impairments of memory are one of the most common cognitive deficits reported by people 
with TBIs, affecting 40-60% of patients.8, 9 These memory problems are not only persistent, 
but are debilitating and difficult to treat.10 Memory deficits may also affect the extent to 
which patients engage with other interventions and rehabilitation. The safety of such patients 
can also be compromised, making them vulnerable citizens in the home (e.g., forgetting to 
turn the stove off), community (e.g., forgetting road rules), and work (e.g., forgetting 
important documents) settings. Memory problems consequently have a devastating effect on 
the psychological wellbeing of the individuals and others around them.11 
 
Cognitive rehabilitation is a structured set of therapeutic activities designed to retrain an 
individual’s cognitive functions. Memory rehabilitation is a domain-specific type of cognitive 
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rehabilitation that focuses on improving memory and helping people deal with the 
consequences of memory problems. In the UK, memory rehabilitation is offered by some 
services as a means to help people cope with their cognitive problems. 
 
Research evidence 
Individual studies 
Some randomised controlled trials (RCTs) have demonstrated the effectiveness of cognitive 
rehabilitation following brain injuries. These have mainly focussed on attention, executive 
functions, and visual neglect; but memory rehabilitation specifically has not been sufficiently 
researched.12 Most evidence for memory rehabilitation comes from single case experimental 
design studies and controlled clinical trials, and the few RCTs and quasi-RCTs in this area 
have offered some support for the effectiveness of intervention.  
 
Wilson et al.13 examined an external memory aid, Neuropage. This enabled participants to 
achieve more memory-related goals than when it was not available. Doornhein and de Haan 
14 reported that patients who received a memory training programme performed significantly 
better than those in a pseudo-treatment control group on trained memory tasks but no 
differences were observed on subjective ratings of everyday memory functions. Kaschel et 
al.15 reported that imagery mnemonics significantly improved delayed recall of verbal 
material and reduced observer-rated reports of memory failures. However, systematic reviews 
of memory rehabilitation have not found evidence to support or refute the effectiveness of 
such programmes.16, 17 This lack of evidence is partly due to the paucity of well-designed 
trials, which has led one of the largest meta-analyses to conclude that ‘the results for memory 
rehabilitation are mixed and weak’ 12 (p.33). The authors of this review suggested that 
‘researchers need to reduce reliance on single-subject and single group designs’ (p.34) and 
recommended more RCT evidence; a view supported by others.18 At a symposium on 
disorders of memory, Wilson called for ‘better evaluation of memory rehabilitation 
programmes’ 19 (p.e4-5). This is a conclusion that more recent systematic reviews of memory 
rehabilitation following TBI,17 stroke,20 and multiple sclerosis 21 also reached. This 
conclusion has been attributed mainly to the dearth of high quality randomised controlled 
trials, but may also reflect the lack of common outcomes measures which are responsive to 
the effects of memory rehabilitation. 
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In a small scale RCT (n=72) to evaluate a group memory rehabilitation programme,22 patients 
with memory problems were randomly allocated to one of three group treatment 
programmes: compensation strategy training, restitution, or a self-help attention placebo 
control.  Although the results showed no statistically significant differences in outcomes, they 
indicated the interventions seemed worthy of further evaluation.  This was supported by the 
qualitatively analysed participant feedback interviews,23 which suggested improvements in 
knowledge and skills about memory aid use, amongst other improvements. This small trial 
provided feasibility and pilot data for the current trial. 
 
Literature reviews 
A narrative review 24 found cognitive rehabilitation to be beneficial for treating cognitive 
deficits following brain damage. Cernich et al.25 reviewed evidence for cognitive 
rehabilitation in TBI and recommended that while RCTs have demonstrated the utility of 
specific rehabilitation approaches to attention retraining and retraining of executive 
functioning skills, further research was needed on rehabilitation techniques in other domains 
of cognition (such as memory). They also suggested that training in the use of supportive 
devices to improve an individual’s daily activities was central to their ability to function 
independently. 
 
Systematic reviews, such as that by Cicerone et al., 26 published in 2000, concluded that there 
was strong evidence for the effectiveness of treatments for memory problems after a TBI. 
The updated review,24 published in 2005, continued to endorse this view. These reviews 
included both RCTs and single-case studies. However, Rohling et al.’s 12 more stringent 
meta-analytic re-examination of both Cicerone et al.’s 2000 and 2005 systematic reviews 
included 115 studies of cognitive rehabilitation trials and found mixed, or at best only weak 
support for memory treatment. It is worth noting that of all the included studies (of TBI and 
stroke), only 30 (26.1%) were classified as ‘Class I’ (i.e., well-designed, prospective RCTs), 
and only 14 specifically focussed on memory. Also of note is that these studies were small, 
with an average of 16.9 and 18.5 participants in treatment and control arms, respectively.  
 
Bergquist et al.27 found that people with TBI were not only willing to use the Internet to 
receive cognitive rehabilitation, but were also satisfied with the treatment. Encouraged by 
results from imagining studies that have shown neuroplasticity, Spreij et al.28 conducted a 
systematic review that offered novel insights in remediation-oriented approaches for the 
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rehabilitation of memory deficits following acquired brain injuries. They classified the 15 
studies they included in their review falling within the rubric of: (i) Virtual Reality (VR) 
training, (ii) Computer-Based Cognitive Retraining (CBCR), and (iii) Non-Invasive Brain 
Stimulation (NBS). They concluded that CBCR was the most promising of these 
interventions, with all seven of the CBCR studies they included showing positive effects. 
However, closer inspection of these studies (and the other VR and NBS studies) show that the 
studies are not methodologically robust (some are not RCTs) and the outcomes are mainly 
impairment level measures. Furthermore, most of these studies had mixed diagnosis samples, 
therefore, it was not possible to extract what the specific effects of these interventions are on 
people with a TBI. Therefore, more robust mixed-methods RCTs are still required to evaluate 
the effectiveness of these newer forms of cognitive rehabilitation for people with TBIs. 
 
Another review 29 that focussed specifically on computerised cognitive training (CCT) in 
acquired brain injury (ABI) and on outcomes classified within the framework of the 
International Classification of Functioning, Disability and Health (ICF),30 included 96 
primary studies that evaluated CCT. The authors noted that only 15% of these studies 
represented ‘Level 1’ evidence (i.e., good quality RCTs). Interestingly, the authors also report 
that although TBI was the most studied population, only two of the 31 TBI studies were 
considered offering ‘Level 1’ evidence. Overall, their findings suggest that CCT has limited 
positive impact on outcomes that relate to activity or participation, but only 43% of included 
studies had an outcome measure that assessed activity or participation.  
 
Clinical guidelines 
There are recommendations for the provision of cognitive rehabilitation for people with 
acquired brain injuries. Older national and international guidelines for TBI rehabilitation, 
such as the Brain Injury Interdisciplinary Special Interest Group of the American Congress of 
Rehabilitation Medicine’s published practice guidelines for rehabilitation after TBI and 
stroke;31 European Federation of Neurological Societies Task Force on Cognitive 
Rehabilitation guidelines for stroke and TBI 32, 33 and the national clinical guidelines for 
rehabilitation following ABIs by the British Society of Rehabilitation Medicine and The 
Royal College of Physicians,34 found limited high-quality evidence supporting some forms of 
cognitive rehabilitation, specifically treatments for memory problems after TBI. This was 
mainly due to a lack of RCTs with most evaluations being uncontrolled trials or single case 
experimental designs. 
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The national clinical guidelines for rehabilitation following ABIs by the British Society of 
Rehabilitation Medicine and The Royal College of Physicians 34 recommend that patients 
with persistent cognitive deficits following ABI should be offered cognitive rehabilitation, 
which may include ‘teaching compensatory techniques to overcome their everyday 
problems’, ‘the use of external memory aids to enhance independence in the presence of 
memory deficits’, and that ‘trial-and-error learning should be avoided in patients with 
memory impairment’ (p.43-44). Again, the level of recommendation is low because of low 
quality of evidence. Therefore, it is perhaps unsurprising that most previous 
recommendations have been qualified by the need for more research. 
 
The Scottish Intercollegiate Guidelines Network’s (SIGN) national clinical guidelines for 
brain injury rehabilitation for adults 35 recommend that: 
 
‘Patients with memory impairment after TBI should be trained in the use of 
compensatory memory strategies with a clear focus on improving everyday 
functioning rather than underlying memory impairment. For patients with mild-
moderate memory impairment both external aids and internal strategies… may be 
used. For those with severe memory impairment external compensations with a clear 
focus on functional activities is recommended’ (p.8). 
 
However, this is a ‘Grade D’ recommendation, based on levels 3 (non-analytic studies) and 4 
(expert opinion) evidence, and from extrapolating evidence from level 2 evidence (well-
conducted case control or cohort studies). This SIGN guideline forms the basis for the 
National Institute for Health and Care Excellence (NICE) guidance on head injury.36 
 
More recently, recommendations for management of memory problems following TBI by an 
international team of researchers and clinicians 37 concluded that there is ‘good evidence for 
the integration of internal and external compensatory memory strategies that are implemented 
using instructional procedures for rehabilitation for memory impairments’ but that the 
‘evidence for the efficacy of restorative strategies currently remains weak’ (p.369). However, 
this conclusion was arrived at on the basis of few RCTs, many of which had small samples 
and a large number of outcomes, did not report power analyses, and did not consider the 
longer-term effects of the intervention.  
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On the basis of the foregoing discussion, and in response to a commissioned call by the 
National Institute for Health Research (NIHR) Health Technology Assessment (HTA) 
programme,38 we designed the ReMemBrIn trial to address the concerns raised by authors of 
individual studies, systematic reviews, and clinical guidelines. The trial, funded by the HTA, 
was designed to assess the effectiveness of a group memory rehabilitation programme, on the 
basis of recent research suggestions from researchers and clinicians,18 our own pilot study,22 
and current clinical guidelines 39, 40 and clinical practice in the UK. Furthermore, in line with 
the ‘Better value in the NHS’ report,41 we designed this project to deliver value for money 
through innovative changes to current clinical practice leading to improved patient outcomes.  
 
Rationale 
Currently, patients with TBI experiencing memory problems do not routinely receive 
cognitive rehabilitation after the outpatient rehabilitation phase, even though their abilities 
and needs may change once they are discharged from clinical services. This is in part due to 
the current lack of evidence for the clinical and cost-effectiveness of memory rehabilitation, 
and resource limitations. This study sought to address these issues. 
 
Research question 
What is the clinical and cost-effectiveness of memory rehabilitation for people with memory 
problems following traumatic brain injury? 
 
Objectives 
Primary objective 
The primary objective was to determine whether attending a group-based memory 
rehabilitation programme (the intervention), was associated with improved subjective reports 
of management of memory problems in daily life, as measured on the Everyday Memory 
Questionnaire – patient version (EMQ-p) when compared to usual care control. 
 
Secondary objectives 
The secondary objectives were to assess: 
• Whether the intervention was associated with improvements in participants’: 
- Objectively assessed memory abilities. 
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- Ability to achieve individually set goals. 
- Health-related quality of life. 
- Cognitive, emotional, and social wellbeing. 
• The cost-effectiveness of the intervention. 
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Chapter Two:  Methods 
 
Design 
The ReMemBrIn study was a multi-centre, two-arm, parallel group, randomised controlled 
superiority trial of a group-based memory rehabilitation programme, provided in addition to 
usual care, compared with usual care alone.  Participants were randomised in clusters of 
between four and six.  Clusters were allocated to intervention or control at a ratio of 1:1. 
 
An economic analysis was conducted to determine the costs and cost-effectiveness of group 
memory rehabilitation compared with usual care (see Chapter 4). In addition, a nested 
qualitative sub-study sought to explore participants’ experiences of the group memory 
rehabilitation and usual care (see Chapter 5). 
 
Study setting and participants 
Sites 
The trial was conducted in nine sites in the UK (see Appendix 1). Each site was a National 
Health Service (NHS) Trust providing rehabilitation services for people with TBI. 
 
We initially intended to recruit from four sites, but activated new sites as old ones shut down 
due to their participant pools being exhausted. The original four sites were opened to 
recruitment between February and April 2013. Due to staff turn-over and staff recruitment 
difficulties two of these sites were subsequently closed to recruitment and replaced by two 
new sites that opened in March and November 2014 respectively. To address delays in 
recruitment, a further three additional sites were also opened between March and June 2015. 
 
Identification of participants 
Participants were identified through NHS services at the participating sites. This included 
searching hospital databases and departmental records of people with head injuries from 
rehabilitation medicine, neurosurgery, and clinical psychology and neuropsychology 
departments. In-clinic recruitment also took place from rehabilitation consultant-led clinics 
and outpatient TBI rehabilitation clinics. Participants were also identified from similar 
sources at other NHS Trusts acting as Participant Identification Centres (PICs).  In addition, 
posters were displayed in clinic areas in the hospitals.  Participants were also identified by 
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self-referral as a result of publicity by local and national charities and patient groups (for 
example head injury charities) and advertising to the general public through the study 
website, on various support groups websites and newsletters, and through features on 
television and radio programmes.  In order to include military personnel, participants were 
sought from a military rehabilitation centre and an NHS surgical centre treating personnel 
from the armed forces.  
 
Clinical teams sent invitation letters to individuals who were identified as potential 
participants. This letter included a Participant Information Sheet, a Consent Form, a contact 
details slip, and a prepaid reply envelope. If the potential participant was interested in taking 
part, they were asked to complete the contact slip and return it in the envelope directly to the 
Assistant Psychologist (AP) at their nearest site.  
 
Informed consent 
Written consent was obtained by the AP, and participants were given a copy of the consent 
form for their records.  Participant Information Sheets and Consent Forms were based on 
those developed for the pilot study, and these had been checked for clarity and readability by 
a service user representative. Potential participants had the opportunity to read and discuss 
the study with other clinical staff, family and friends, and the research team before they 
decided to take part. They had a minimum of 24 hours to do this. Potential participants also 
had the opportunity to read the Participant Information Sheet and Consent Forms with the AP 
at their first assessment.  
 
Eligibility criteria 
Eligible participants were those who: 
• Were admitted to hospital with a TBI more than three months prior to recruitment.  
• Had memory problems, defined as a score or 24 or more on the Everyday Memory 
Questionnaire – patient version (EMQ-p) and/or a score below the 25th percentile on the 
Rivermead Behavioural Memory Test (RBMT-3), as assessed at the initial screening 
assessment. The 25th percentile cut-off for the RBMT-3 indicates below average 
objectively assessed memory ability.42 A score of 24 or more on the EMQ-p is two 
standard deviations below the mean for healthy participants (N.B. Lincoln, 2017, personal 
communication). 
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• Were 18 to 69 years of age. The upper age limit was applied in order not to include those 
with age-related memory problems. 
• Were able to travel to one of the study sites and attend group sessions. Participants had to 
live within the geographical area covered by the sites and be able to travel to sites. We 
offered travel expenses to all participants who requested it. They also needed to be 
willing to receive treatment in a group if allocated to intervention. 
• Gave informed consent. 
 
Potential participants were excluded if they: 
• Were unable to engage in group treatment if allocated. This was assessed by the clinicians 
at the recruitment sites, and reasons for exclusion included severe aural sensory problems. 
Those who had behavioural problems that would interfere with group treatment were not 
considered.  
• Were participating in other psychological intervention studies. This was assessed by self-
report.  
• Had impairment of language which would make them unable to take part in the 
rehabilitation group activities, defined as a score of less than 17 on the Sheffield 
Screening Test for Acquired Language Disorders (SST)43 completed at the initial 
screening assessment. In accordance with the test manual, participants who scored 
less than 17 on the SST were considered to have impairment of language which 
would limit their ability to complete the intervention.  
 
 
Study procedures 
We expected participants to be in the study for approximately 13 months from the initial 
screening assessment to the final follow-up visit 12 months from randomisation. The data 
collected at each time point is shown in Appendix 2 and detailed below. Data were collected 
through a combination of self-report questionnaires completed by participants and their 
relative/friend, and face-to-face assessments with participants completed by a Research 
Assistant (RA) during study visits. Visits took place at participants’ homes whenever 
possible. However, if there were concerns about the suitability of the home environment or if 
the participant preferred, assessments were conducted at NHS sites or community venues. 
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Initial screening visit 
At the screening visit, the AP first explained the study and made clear that the initial assessments 
were required to check that the participant met the inclusion criteria, to obtain demographic and 
clinical data, and conduct baseline assessments for those who were eligible. The AP responded to 
queries and obtained informed consent prior to conducting the following initial assessments, 
questionnaire completion and demographic data collection:  
 
• Everyday Memory Questionnaire – patient version (EMQ-p):44 This is a subjective, patient-
centred outcome measure with good ecological and face validity,45, 46 and has been 
previously used in cognitive rehabilitation studies.22, 47 The EMQ-p comprises 28 items 
asking about the frequency of memory failures in everyday life over the past month.  Each 
item is rated on a five-point Likert scale (from ‘once or less in the last month / never’ to 
‘once or more a day’).  Total scores range from 0 to 112 with higher scores indicating more 
frequent memory problems. 
 
• Rivermead Behavioural Memory Test – third edition (RBMT-3):42 The RBMT-3 is a 
standardised objective measure of memory, with adequate psychometric properties. This was 
chosen as an objective measure that closely reflects daily life memory ability, and has been 
used as an outcome measure in other studies of memory rehabilitation.15, 22, 48-51  A General 
Memory Index (GMI) score was derived to provide an assessment of overall memory 
abilities.  GMI values range between 52 and 174 and are standardised on a representative 
sample from the UK 42 to have a mean of 100 (SD 15). Lower scores indicate more 
significant memory impairment. 
 
• National Adult Reading Test (NART):52 Premorbid level of intellectual functioning, required 
to interpret RBMT-3 scores, was estimated using the NART. 
 
• Sheffield Screening Test for Acquired Language Disorders (SST):43 The SST was used to 
assess eligibility for the trial on the basis of language ability. 
 
• General Health Questionnaire – 30-item version (GHQ-30):53 The GHQ-30 is a 30-item 
questionnaire that was designed to detect psychological distress in the general population. It 
assesses the participants’ mood over the past few weeks compared to their usual mood.  The 
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GHQ-30 was chosen as it is suitable for postal administration and is easy to complete. The 
GHQ (12, 28 or 30 item versions) has also been shown to be responsive to the effects of 
psychological interventions in people with neurological conditions 47, 54-56 and has been used 
in previous TBI and rehabilitation studies.22 Likert scoring was used for the GHQ-30 for the 
clinical outcome with scores ranging from 0 to 90 with higher scores indicating more 
psychological distress. The alternative GHQ (0-0-1-1) scoring methodology was applied for 
the health economic evaluation. 
 
In addition, we collected demographic information from participants at the screening assessment. 
This included gender, date of birth, ethnicity, date of TBI (self-reported by participants), the duration 
of the initial hospital stay for their TBI, the participant’s current employment status, living 
arrangements, military status, and highest educational achievement. 
 
The following clinical information on the participant’s brain injury was collected from medical notes 
where these could be accessed at the recruiting site: 
• Severity of injury assessed by the Glasgow Coma Scale (GCS)57 score closest to admission and 
the worst total score 
• Date of TBI (verified from medical notes) 
• Type of brain injury (open or closed) 
• Other neurological conditions 
 
Scores from the EMQ-p, RBMT-3 and SST completed at the initial screening visit were used to 
confirm eligibility for the trial. Participants who did not meet the eligibility criteria following the 
initial screening visit were notified by letter to thank them for their interest in the study and a brief 
report of their test results was provided if requested. Those who met the inclusion criteria were 
invited to continue in the trial, if they were happy to do so, and proceeded to the second assessment 
visit.   
 
Participants continuing in the trial were asked to nominate a relative/friend who knew about their 
memory problems in daily life, if they wished to do so, although this was not a mandatory 
requirement of trial participation. A questionnaire booklet for the relative/friend was sent to eligible 
participants following the initial screening visit. Participants were asked to pass this on to their 
relative/friend and return completed questionnaires at the second assessment visit. 
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Second assessment visit 
The following questionnaires were completed at the second visit, conducted two weeks (+/- one 
week) after the initial screening visit: 
 
• EuroQol Quality of Life – five dimensions questionnaire, five level version (EQ-5D-5L):58 The 
EQ-5D-5L is a validated, generalised health profile questionnaire used to assess health-related 
quality of life.  EQ-5D-5L scores are used to derive utilities, which can be used to calculate 
Quality Adjusted Life Year scores (QALYs). 
 
• Service-use questionnaire (SUQ): We used a bespoke self-report service use questionnaire to 
assess NHS healthcare utilisation. The data collected included use of community-based services, 
such as contacts with General Practitioners (GPs), practice nurses, other community-based 
professionals, and community-based social care services and medication. Use of hospital services 
(including out-patient appointments, Accident and Emergency (A&E) department attendance, 
day care services and hospitalisation) was also captured. We asked participants to report services 
used for their memory problems and for other reasons separately. The period covered by the 
questionnaire was the previous three months. This was considered long enough for people to 
have received a range of services but not so long that they would have forgotten what they had 
received. The SUQ was adapted from previous studies.59, 60 
 
In addition, participants’ nominated relative/friend completed the following questionnaire prior to the 
visit, which was collected by the AP: 
• Everyday Memory Questionnaire – relative version (EMQ-r):44 The EMQ-r is a parallel version 
of the EMQ-p, which offers an independent rating of the memory problems a person experiences 
by a relative/friend. The EMQ-r was included to identify any effect of treatment on daily life 
problems as observed by another person, which might not have been detected by the participants 
themselves.  EMQ-r scores range from 0 to 112 with higher scores indicating more frequent 
memory problems. 
 
Participants were also asked to set the short- and long-term goals that they would like to achieve by 
the end of the study. With the assistance of the AP, each participant set between one and five 
personal short- and long-term goals. The AP also checked participants’ availability to attend for 
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treatment, in the event they were assigned to the intervention group, in order to form clusters of 
participants for randomisation. 
 
Randomisation 
Eligible participants were randomised following screening and baseline data collection. 
 
Formation of clusters 
Clusters of four to six participants were formed by the AP at each site prior to randomisation.  This 
cluster size was selected as we considered this the optimal number of participants for the memory 
rehabilitation group sessions based on our previous experience of delivering the intervention. 
Furthermore, if the cluster sizes were larger participants may have needed to wait longer after 
baseline assessments for a group to be formed. Clusters were based on participants’ availability to 
attend for treatment at the same time and same venue, should they be allocated to the intervention 
arm.  In the period while waiting for group allocation, the AP remained in regular contact with the 
participants to inform them when it was likely that there would be sufficient participants to form a 
group and to maintain their interest in the trial. 
 
Participants who were awaiting randomisation at the time their site closed to recruitment were sent a 
letter informing them that the AP had not been able to recruit enough people to create a group at a 
time and place that was convenient for that participant and that their participation in the trial was 
therefore at an end. 
 
Randomisation 
Participants were randomised in clusters of four to six to intervention or usual care control using a 
1:1 ratio.  The randomisation was based on a computer generated pseudo-random code using random 
permuted blocks of randomly varying size, created by the Nottingham Clinical Trials Unit (NCTU) 
in accordance with their standard operating procedure (SOP) and held on a secure server.  The 
randomisation was stratified by study site.  Access to the sequence was limited to the NCTU IT 
Manager.  The AP at the site accessed the allocation for each cluster by means of a remote, internet-
based randomisation system developed and maintained by the NCTU.  The sequence of treatment 
allocations was concealed from the study statistician until all participants were assigned and 
recruitment, and data collection and all other study-related assessments were complete. 
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Intervention 
Participants were randomised to group memory rehabilitation in addition to usual care or usual care 
alone. 
 
Usual care 
All participants received their usual clinical care during the trial.  Based on our knowledge of the 
recruiting sites, we expected that the majority of participants would no longer be receiving any 
formal rehabilitation but that they may be attending employment rehabilitation services, self-help 
groups or receiving support from specialist charities, such as Headway.  Any additional interventions 
people received were noted in the service use questionnaire completed at the follow-up assessments. 
 
Memory rehabilitation 
The intervention was offered in groups of between four and six participants. Each group was led by 
an AP trained to deliver the intervention. Sessions were held at NHS sites or community venues. 
Participants were offered ten group memory rehabilitation sessions lasting approximately 1.5 hours 
each, planned once a week for ten weeks. However, sessions could be re-arranged if necessary (e.g., 
due to staff or participant absence). The sessions followed a treatment manual.17 The intervention 
included restitution strategies to retrain memory functions, including attention retraining (such as 
letter cancellation), and strategies to improve encoding and retrieval (such as deep-level processing). 
Compensation strategies were taught, including mnemonics (such as chunking, use of first letter 
cues, rhymes), use of external devices (such as diaries, mobile phones, calendars) and ways of 
coping with memory problems. The importance of ‘errorless learning’ (not making errors while 
learning new material, and therefore preventing learning the errors)61 was also taught. The emphasis 
was on identifying the most appropriate strategies to help individuals overcome their memory 
problems, and in providing participants with a range of memory techniques that they could adapt and 
use according to their needs. This intervention provided an opportunity for revision of strategies 
taught during in-patient rehabilitation and discussion of their application in a community setting. 
 
Treatment fidelity 
The fidelity of the group rehabilitation programme was assured in a number of ways: 
 
Manualised treatment:  The group memory rehabilitation programme followed a manual (see 
Supplementary material 1) that was developed and tested in the pilot study.  A detailed description of 
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the manual has been published.17, 22 The manual was accompanied by facilitator notes to guide 
delivery of the sessions (see Supplementary material 2). 
 
Training and supervision:  Staff delivering the intervention (APs) were psychology graduates with 
clinical experience.  A clinical psychologist provided study-specific training on conducting baseline 
assessments and the delivery of the intervention.  In addition, monthly teleconferences between all 
APs, a clinical psychologist, and NCTU staff provided an opportunity for peer group supervision. 
Furthermore, additional monthly one-to-one supervision with a clinical psychologist allowed for 
discussion of specific challenges relating to treatment or assessment. To ensure continuity and 
consistency, when staff changes occurred, old staff completed a ‘handover’ document for new staff, 
who were trained by the same trainers.  
 
Fidelity assessment:  Formal fidelity assessment of the group memory rehabilitation was undertaken 
through analysis of video recordings of treatment sessions.  Intervention sessions were video 
recorded by APs facilitating the groups. APs were asked to video record all treatment groups, unless 
it was the first group run by the AP or participants had not given consent to be recorded. Practices for 
video-recording drew upon guidance on minimizing intrusiveness of the recording.62, 63 
 
Sessions were selected for analysis in order to include sessions from the start, middle and end of the 
ten-week course and from each site. As far as possible only recordings that covered a complete 
session were analysed. A coding schedule was developed based on the components of treatment 
described in the manual, listing possible activities for both the APs and participants (see Appendix 3). 
 
A distinction was made between non-rehabilitation activities (e.g., social chat, information about 
sessions, preparing tasks or materials) and rehabilitation activities (e.g., discussing educational 
material, recap of previous session). An independent researcher coded the videos using a time 
sampling procedure. Observations were made on the minute, every minute throughout the video 
recording. On each observation, the activities of the AP and participants were given the appropriate 
activity code. A sample of coding was checked by another observer and discrepancies were resolved 
by discussion. Data from coding sheets were entered into the SPSS statistics programme for analysis. 
 
Requirements for usual care were not specified so no measures of fidelity were applied.   
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Blinding 
Blinding of APs delivering the intervention and participants to the treatment allocation was not 
possible. Research Assistants (RAs) collecting outcome data at 6- and 12-month follow-up visits 
were blind to treatment allocation. RAs were not involved in the delivery of the intervention. To 
prevent unblinding, at the start of each follow-up visit the RA reminded the participants of the 
importance of the RA remaining blind to treatment allocation, and asked that participants did not 
discuss any aspects of their involvement in the study. At the beginning of each follow-up visit the 
RA recorded whether they had been unblinded prior to the visit and recorded their opinion of the 
participant’s treatment allocation using the categories, definitely control, probably control, probably 
intervention or definitely intervention.  At the end of each visit the RA recorded whether they had 
been unblinded during the visit and again recorded their opinion of the participant’s treatment 
allocation.  
 
Follow-up 
Outcomes were assessed at six and twelve months after randomisation to assess immediate and 
longer-term effects of the intervention. The primary time point of interest was six months after 
randomisation. This time point was chosen to allow time for completing ten group sessions, whilst 
still allowing for one group session to be rescheduled if it had to be cancelled through illness or other 
unforeseen circumstances. The 12-month assessment was to determine whether any treatment gains 
had been maintained over time.  
 
All reasonable attempts were made to contact any participant lost to follow-up during the course of the 
study in order to complete assessments. Participants were contacted by telephone in the first instance 
when follow-up visits were due.  If telephone contact could not be made, a letter was sent to the 
participant’s last known address, so that the participant could contact the outcome assessor to arrange 
the appointment or provide updated contact details.  
 
The following assessments were completed at the follow-up visits: 
• RBMT-3 
• Assessment of individual goal attainment: Each participant’s individual goals were evaluated in 
terms of the degree to which each goal had been met on a 4-point Likert scale: ‘not met at all’, 
‘met a little’, ‘mostly met’, and ‘fully met’.  The participant and researcher discussed the extent 
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to which goals were met, and jointly determined the goal attainment.  The average goal 
attainment score was used as the secondary outcome (with attainment coded as 0 for ‘not met at 
all’ and 3 for ‘fully met’). Goal attainment scaling has been used in memory rehabilitation 
studies, and has been recommended as an outcome measure of choice for cognitive 
rehabilitation.64 
 
In addition, a questionnaire pack was posted to the participant before their 6- and 12-month 
appointments. Participants were asked to complete this questionnaire pack at home and return by 
post to the trial coordinating centre in the prepaid envelope provided as soon as possible.  If 
questionnaires had not been returned by the time of the follow-up visit they were collected by the RA 
at the visit. 
 
The questionnaire pack included the following questionnaires for completion by the participants: 
• EMQ-p 
• GHQ-30 
• EQ-5D-5L 
• SUQ 
• European Brain Injury Questionnaire – patient version (EBIQ-p).66 The EBIQ-p contains 63 
items that assess the subjective experience of the frequency of cognitive, emotional and social 
difficulties experienced by people with brain injury; there are an additional 3 items that ask about 
the impact of the participant’s brain injury on their relative/friend. Each item is rated on a 3-point 
Likert scale: ‘not at all’, ‘a little’, ‘a lot’ according to how much each has been experienced over 
the past month. The EBIQ-p is a clinically reliable measure to determine the subjective wellbeing 
of people with brain injury and to assess change of subjective concerns over time.66, 67 It is used 
in rehabilitation centres as an outcome measure.67 We used the modified sub-scales proposed by 
Bateman et al.68 In this model, EBIQ-p scores range between 1 and 3 on each of seven sub-
scales, with higher scores indicating greater difficulties.  The seven sub-scales are: 
o Somatic (7 items) 
o Cognitive (12 items)  
o Impulsivity (10 items) 
o Depression (5 items) 
o Social interaction (5 items) 
o Fatigue (8 items) 
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o Communication (4 items) 
 
In addition, the following questionnaires, for completion by the participants’ nominated 
relative/friend, were included in the questionnaire pack sent to participants at follow-up. Participants 
were asked to pass these on to their relative/friend for completion. 
• EMQ-r 
• European Brain Injury Questionnaire – relative version (EBIQ-r):66 The EBIQ-r is a parallel 
version of the EBIQ-p, completed by the participant’s relative/friend to assess the cognitive, 
emotional and social difficulties experienced by people with brain injury.  
 
Originally all questionnaires were intended to be returned by post only, however, the procedure was 
changed after an HTA monitoring visit in December 2014 so that follow-up questionnaires were 
collected at the visit by the outcome assessor if these had not been posted back. This was in response 
to a poor return rate due to the previous reliance on postal returns. 
 
The returned questionnaire packs were checked for completeness and participants were telephoned if 
items were missing or we needed clarification about their responses (e.g., unclear marking on 
questionnaires).  Participants were also telephoned if their questionnaire packs were not received 
before the visit. 
 
Qualitative feedback interviews 
A sample of participants was invited to take part in qualitative feedback interviews, conducted within 
two months of the 6-month follow-up appointment.  The interviews were intended to provide 
feedback on the participants’ experience of being involved in the trial, usual care and, for those in the 
intervention groups, the experience of receiving group memory rehabilitation.  The qualitative 
analysis is described in detail in Chapter 5. 
 
End of the study 
Participants left the study when they completed the 12-month follow-up.  The end of the study was 
defined as the last participant’s 12-month follow-up appointment, although questionnaires were 
accepted after completion of the final visit to allow for any delays in return. 
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Premature discontinuation from the intervention or withdrawal from follow-up was reported and 
reasons for withdrawal (if given) were documented.  If a participant discontinued treatment but 
agreed to remain in trial, outcome data collection continued in accordance with the protocol.  
Participants were informed at the start of the study that data collected up to the point of withdrawal 
would be retained and used in the final analysis. We did not replace participants who withdrew. 
 
Outcome measures 
All measures were selected on the basis of their clinical utility, relevant psychometric properties, and 
ease of use for participants. Furthermore, the measures reflect the three levels of the International 
Classification of Function 30 domains: impairment, activity limitations, and participation restrictions, 
thereby embracing the aims and spirit of cognitive rehabilitation.69, 70 
 
Primary outcome 
- Frequency of memory failures in daily life assessed using the EMQ-p at 6-month follow-up. 
 
Secondary outcomes 
- Objective measure of memory problems assessed by the RBMT-3.  
- Mood assessed with the GHQ-30.  
- Individual goal attainment. 
- Subjective experience of brain injury assessed with the EBIQ-p. 
- Subjective report of frequency of memory problems in daily life in the longer term assessed 
using the EMQ-p. The EMQ-p completed at the 6-month follow-up was our primary outcome, 
but the same scale completed at 12-month follow-up was a secondary outcome measure. 
- Subjective report of the importance of memory problems in daily life. To assess this, we added to 
the EMQ-p a measure of how important each item was. The rationale was that, even if some 
items are forgotten less frequently than others, these may be more significant to the participant if 
they view these items are being more important than other items. The 28 EMQ-p items were 
therefore also rated for importance on a five-point Likert scale (from ‘not at all important’ to 
‘very important’). Importance scores range from 0 to 112 with higher scores indicating more 
important memory problems. 
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Relative/friend completed outcomes 
• Relative/friend report of the frequency of participants’ memory problems in daily life 
assessed using the EMQ-r. 
• Relative/friend report of the experience of brain injury assessed with the EBIQ-r. 
 
Health economic outcomes  
• Quality of life assessed using the EQ-5D-5L. 
• Service use assessed using the bespoke SUQ. 
 
 
Research governance 
The study was conducted in accordance with the recommendations for clinicians involved in 
research on human subjects adopted by the 18th World Medical Assembly, Helsinki 1964 and later 
revisions, the NHS Research Governance Framework for Health and Social Care (2nd edition), and 
the principles of the International Conference of Harmonisation Good Clinical Practice (ICH GCP) 
guidelines. 
 
Trial registration 
The study was prospectively registered as ISRCTN65792154 on 17 October 2012.  
 
Ethics 
The National Research Ethics Service (NRES) - East Midlands (Nottingham 1) gave ethical approval 
for the study for NHS participants (Ref. 12/EM/0324), and the Ministry of Defence Research Ethics 
Committee gave approval for recruiting military participants (Ref. 374/PPE/12). 
 
Site initiation and training 
Prior to the commencement of the study, members of the central research team (Chief Investigator 
and/or co-Chief Investigator and NCTU staff) met with study collaborators from each site to discuss 
implementation and training issues to ensure that all members were familiar with all aspects of the 
study. New staff were trained before starting work on the trial. A clinical psychologist and the 
Nottingham Clinical Trials Unit (NCTU) staff provided study-specific training on the trial 
documentation and database.  
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Protocol deviations 
A protocol deviation was defined as an unanticipated or unintentional divergence or departure from 
the expected conduct of the study inconsistent with the protocol, consent document or other study 
procedures. Protocol deviations were recorded on the electronic Case Report Form (eCRF) by APs 
and RAs. Protocol violations were defined as deviations that affected eligibility or outcome 
measures, as assessed by the Trial Management Group (TMG).  
 
Oversight 
We convened a number of oversight groups to monitor study progress and conduct throughout the 
trial.  The general roles and responsibilities of these groups were outlined in the protocol, with 
specific charters also developed for the independent Trial Steering and Data Monitoring Committees. 
 
Trial Management Group 
The Trial Management Group (TMG) comprised the co-chief investigators and members of NCTU 
responsible for the running of the trial who met regularly throughout the trial. This group was 
responsible for the day-to-day running of the trial. 
 
Trial Steering Committee 
The Trial Steering Committee (TSC) was responsible for overseeing the conduct of the study.  The 
TSC had an independent Chair and five independent members. Independent members were 
rehabilitation professionals and patient/carer representatives who were not otherwise involved in the 
trial. Members of the study team, including the Chief Investigator, co-Chief Investigator, service user 
co-applicant and Trial Manager were also part of the TSC. The TSC advised on recruitment 
strategies, monitored progress of recruitment, and checked adherence to the study protocol.  
Observers from the Funder and the Sponsor were invited to TSC meetings. 
 
Data Monitoring Committee  
The Data Monitoring Committee (DMC) was an independent group, the members of which had no 
other involvement with the study. Members of this committee included two rehabilitation 
professionals and an experienced study statistician. The role of the DMC was to safeguard the 
interests of trial participants, with particular reference to safety of the intervention, monitor the 
overall progress and conduct of the trial, and assist and advise the investigators to protect the validity 
and credibility of the trial. 
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The TSC and the DMC met independently of each other, with the DMC providing reports to the 
TSC. 
 
Safety monitoring 
The risks of the study were assessed during protocol development.  The assessment of memory may 
have made participants aware of memory problems that they did not know that they had.  As a result, 
the main risk associated with this trial was considered to be distress caused by this realisation.  
However, such distress was considered unlikely, and any distress caused was deemed likely to be 
mild. Overall, therefore, the risk of the trial was assessed as negligible. As a result, adverse events or 
serious adverse events were not collected in this study. The independent DMC instead were provided 
with a report detailing hospital and GP visits (either related to TBI or otherwise) as recorded from 
participant-reported service use questionnaires for all participants, and any deaths. This was agreed 
by the sponsor, Research Ethics Committee (REC), Data Monitoring Committee (DMC) and Trial 
Steering Committee (TSC). 
 
‘Notable events’ occurring during both assessments and treatment were recorded throughout the trial.  
Notable events were those that were assessed by the APs or RAs as being out of the ordinary, such as 
problems arising during group sessions or issues which may pose a risk to participants or researchers. 
These were reviewed by the study team on an ongoing basis and reported to the DMC/TSC during 
routine meetings. 
 
Patient and public involvement 
During protocol development, service user and carer representatives with experience of TBI and/or 
rehabilitation in NHS services advised on recruitment and dissemination options, and contributed to 
the development of the intervention manual, and the lay summary of the project. One service user 
representative had experience of NHS rehabilitation services following his head injury and 
participated in our pilot study, so was able to provided first-hand experience of the intervention. He 
told us what he and the peers in his group enjoyed and found useful, and what they did not find 
useful. This information enabled us to make some changes to the manual and content of the 
intervention. We also recruited a carer representative who had caring responsibilities for a person 
with TBI. The service user co-applicant and a carer helped us advertise the study by being part of a 
video about our study and a radio and television interview about brain injury and our study. The 
service user co-applicant was involved in project management decisions, project approval through 
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Integrated Research Application System (IRAS), and recruitment and consent (by contributing to the 
development of participant information sheets). 
 
A service user and carer, and representatives from relevant charities (e.g., Headway and Combat 
Stress) were members of the TSC and DMC. Their involvement in these committees enabled us to 
check with them when any amendments to the protocol were required.  
 
We developed participant and public newsletters to keep participants and the public informed about 
the progress of our study. These were sent to participants, clinicians and local head injury charities so 
that they could be cascaded to interested members of the public. We sent the final plain English 
summary of our findings our carer representative to assess its readability and we made changes 
where these were required. All service user involvement was resourced appropriately.  
 
Payments to participants 
Participants were not paid to take part in the trial but reasonable travel expenses for attendance at 
trial assessments and intervention sessions were reimbursed.  
 
 
Statistical methods 
Sample size 
The sample size calculation was based on the primary outcome measure (EMQ-p) at six months 
post-randomisation. The main study aim was to detect a minimum clinically relevant difference in 
mean EMQ-p score of 12 between the memory intervention arm and the usual care arm. In the 
absence of any agreed and published minimum clinical relevant differences on the EMQ-p, we 
deemed a 12-point difference on this measure to be a clinically significant change, based on our pilot 
data 17 and clinical interviews. A common standard deviation (SD) of 21.9 from the pilot gave us an 
effect size of 0.55. For the sample size calculation, two-sided type 1 error of 0.05 and power of 90%, 
and a fixed effects model at the level of the four original planned sites was used, with 10% of the 
total variation due to between-site variation. The participants were cluster randomised and a cluster 
size of six was used for the sample size calculation with an intracluster correlation coefficient (ICC) 
of 0.1. Using the ‘Optimal Design’ software with these parameters, the calculation gave 10 clusters 
(5 clusters for each allocation) per site (40 in total). Data from the pilot study and taking account that 
the control arm only received usual care suggested a possible dropout rate of 20%. Therefore, we 
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needed 26 clusters of each allocation (52 in total), which amounted to 312 participants randomised in 
total. 
 
Statistical analysis 
Analyses are detailed in the Statistical Analysis Plan (SAP), which was finalised prior to database 
lock and release of the treatment allocation codes for analysis. All analyses were carried out using 
Stata/SE 13.1. 
 
Preliminary analysis 
We used descriptive statistics of demographic and clinical measures to examine balance between the 
two arms. The internal consistency of the EMQ-p, EMQ-r and GHQ-30 were also evaluated using 
Cronbach’s alpha. 
 
Analysis populations 
The main approach for the analysis was to analyse participants as randomised regardless of the 
number of memory rehabilitation sessions attended (intention-to-treat) for all primary and secondary 
outcomes.  
 
Data used at each time point were as follows: 
- the outcomes at 6 months were questionnaires/visits completed within 9 months of randomisation 
(i.e., within 275 nights of randomisation) 
- the outcomes at 12 months were questionnaires/visits completed within 15 months of 
randomisation (i.e., within 456 nights of randomisation) 
 
Outcomes completed outside of these time periods were not used, other than in a sensitivity analysis 
for the primary outcome. The main analyses were based on participants with available data with no 
imputation for participants with missing outcomes.  
 
Descriptive analyses 
We described the adherence to the intervention by tabulating the attendance at each session and 
summarising the number of sessions that each participant attended. The reasons for non-attendance at 
sessions were also described and summarised. 
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The number of participants returning the questionnaire booklet and completing the 6- and 12-month 
follow-up visit was summarised in the two arms along with the number of days between 
randomisation and completion. The pattern of missing outcome data was explored, overall and in the 
two arms, and the baseline characteristics compared between participants with/without primary 
outcome data. 
 
Missing data in questionnaires 
We imputed missing items in questionnaires by the mean of the completed items if less than 10% of 
the items in the questionnaire were not completed.  Scores were therefore calculable where: 25 or 
more of the 28 items were completed on the EMQ-p and EMQ-r, 27 or more of the 30 items were 
completed on the GHQ-30, 11 or more of the 12 items in the EBIQ-p and EBIQ-r cognitive subscale 
were completed, and 9 or more of the 10 items in the EBIQ-p and EBIQ-r impulsivity subscale were 
completed. Scores for all other EBIQ-p and EBIQ-r subscales were only calculable if all items in the 
subscale were completed. If more than 10% of items were missed, outcomes were treated as missing. 
 
If scores from the questionnaires remained missing at baseline after the process outlined above (or 
other baseline information was missing), in order to be able to include all participants in the 
regression analysis of the outcome score, we imputed this baseline data using the mean score at each 
site. These simple imputation methods are superior to more complicated imputation methods when 
baseline variables are included in an adjusted analysis to improve the precision of the treatment 
effect.71 Note this imputation was only done for the regression analyses and not for summarising the 
baseline scores.  
 
Primary outcome 
For the primary analysis we estimated the difference in mean score of the EMQ-p score at 6-month 
follow-up between the two arms using a multi-level linear model with baseline EMQ-p score and site 
as covariates. Although participants were randomly allocated in clusters, individuals in the usual care 
arm had no contact with each other and outcomes in this arm were therefore assumed to be 
independent. However, participants in the intervention arm received memory rehabilitation sessions 
together in groups, which needed to be accounted for in the analysis. We therefore used a fully 
heteroscedastic model as suggested by Roberts and Roberts 72 for analysis of trials comparing group-
based treatments with individual-based treatment as usual, when, as is the case here, there is 
adjustment for individual level covariates. This model estimates group-level residual variance in the 
intervention arm, and also permits individual-level residual variance to differ between intervention 
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and control arm.72, 73 Assumptions for the multi-level linear model were checked using diagnostic 
plots. The intracluster correlation coefficient in the intervention arm was estimated using the 
estimates of the group level residual variance and individual residual variance in the intervention 
arm.73  
 
Sensitivity analyses for the primary outcome 
We conducted the following sensitivity analyses: 
- Including all 6-month questionnaires: We repeated the analysis described above including 
participants whose 6-month questionnaires were returned after the 9-month post-randomisation 
window. 
- Additional adjustment for baseline variables with an observed imbalance: We included baseline 
variables with an observed imbalance (based on comparison of summary statistics only, not 
statistical testing) as additional covariates in the multi-level model for the 6-month EMQ-p score. 
- Multiple imputation of missing primary outcome data: We performed multiple imputation using 
chained equations separately for each arm, under the assumption that missing data was missing at 
random.74 Variables included in the imputation model were site, age and gender, baseline 
variables identified as predictive of drop-out (by examination only), prognostic baseline variables 
(EMQ-p, RBMT-3 GMI and GHQ-30), RBMT-3 GMI at the 6- and 12-month visit and 12-month 
EMQ-p score. In addition for the intervention arm, the number of intervention sessions attended 
was included. Forty datasets were included and the results of the analyses on the imputed datasets 
combined using Rubin rules.74  
- Estimation of the complier average causal effect: We used instrumental variable regression to 
estimate the effect of the intervention for participants who would comply with the allocated 
treatment whichever arm they were randomised to.75, 76 Participants in the intervention arm were 
classified as adherent if they attended at least four memory rehabilitation sessions. The 
instrumental variable regression model included baseline EMQ-p score and recruiting site and 
used a clustered sandwich estimator to estimate the variance to allow for correlation between 
randomisation clusters (vce cluster option in Stata). We estimated the complier average causal 
effect using both the observed data and the multiply imputed data.  
 
We performed a pre-specified exploratory sub-group analysis for the primary outcome according to 
memory impairment at baseline (using the RBMT-3 GMI score, an objective measure of memory) by 
including an interaction term in the model for the primary analysis. The RBMT-3 GMI at baseline 
was split into three groups, according to classifications provided by the test publisher:77 Significant 
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memory impairment (≤ 69), borderline/moderate memory impairment (70 to 84), and average and 
above average range (≥ 85). 
 
During the trial, a Rasch analysis of the Everyday Memory Questionnaire was performed using an 
independent dataset of patients with TBI (R. Johnson, R. das Nair, N.B. Lincoln, 2017, personal 
communication). We performed an exploratory analysis using this Rasch conversion of the EMQ-p 
scores and compared these between the two arms using the multi-level model described above.  
 
After the planned analyses were conducted, at two meetings with collaborators and investigators time 
since TBI was raised as a potentially important factor in whether patients could benefit from the 
intervention. We therefore conducted a post hoc sub-group analysis for time since TBI, using the 
methods described above.  
 
Secondary outcomes at six and twelve months 
We analysed the secondary outcomes using the multi-level model described for the primary outcome. 
Estimates of the intervention effect are presented as difference in means with 95% confidence 
intervals (CI). For the goal attainment outcome, the numbers of goals set was additionally included 
as a covariate. Estimates of the intra-cluster correlation coefficient in the intervention arm for each 
outcome calculated from the multi-level models are given in Appendix 4. 
 
Of the seven subscales from the EBIQ-p (and EBIQ-r), the cognitive, depression, communication 
and difficulties in social interaction subscales were used in a formal comparison between arms as the 
content of the group memory intervention was most likely to have an impact on these subscales. The 
other subscales (impulsivity, somatic and fatigue) were summarised using descriptive statistics only.  
 
Sensitivity analyses for goal attainment secondary outcomes 
Participants set at least one short- and long-term goal but could set up to five. An interaction term 
between the number of goals set (one or more than one) and treatment arm was included in the model 
for the goal attainment score to explore whether there was evidence of any differential effect of the 
intervention according to the number of goals set at baseline. We hypothesised that it could be harder 
for participants who set more than one goal to meet all their goals compared to the participants who 
set, and so focussed on, one individual goal.  
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Goals set at the start of the trial should have been SMART goals (i.e., Specific, Measurable, 
Assignable, Realistic and Time-related) in order that they could be assessed at the 6- and 12-month 
follow-up visits as met or not met. During the trial it became apparent that not all goals set by the 
APs at baseline were measurable. As a sensitivity analysis, each goal was classified as SMART or 
not by one of the trial APs and a sample independently checked by the chief investigator. We then 
repeated the analysis for goal attainment including only SMART goals.  
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Chapter Three:  Results 
 
Recruitment  
Recruitment commenced in February 2013 and continued until December 2015 when the recruitment 
target was met (see Appendix 5). The original planned recruitment period was extended by eight 
months because recruitment rates were lower than expected. This was in part due to staff turnover 
and delays in recruiting new staff causing a number of sites to be inactive during the recruitment 
period. 
 
Between February 2013 and December 2015, we screened 4023 people and consented 466. Of the 
3557 people screened but not consented, the main reason was not replying to the letter of invitation 
(n=1710, 43%); 1129 (28%) people were not eligible for the trial and 718 (18%) were not enrolled 
for other reasons (see Figure 1). Further details are provided in Appendix 6. 
 
Of the 466 people who gave consent, 328 (70%) were randomised. Non-randomisation after consent 
was due to non-eligibility, recruitment being closed at the site (either due to the site closing during 
the trial or at the end of recruitment in December 2015), and participants withdrawing consent or no 
longer being contactable (see Figure 1).  
 
Of the 328 participants randomised, 157 (48%) were randomised to usual care and 171 (52%) to 
memory rehabilitation in addition to usual care (see Figure 1). The mean size of the cluster 
randomised was five. The randomisation target of 312 was exceeded due to the requirement to 
randomise clusters of participants who could attend the intervention sessions at the same time, if 
allocated to intervention, at the five sites remaining open at the end of recruitment.  
 
Participants were randomised in clusters of four to six and the randomisation was stratified by site. 
The number of clusters randomised to each arm within each site was well balanced (see Appendix 7). 
More participants were randomised to the memory rehabilitation arm. 
 
Participants waited a median of 18 days between the second assessment and randomisation (see 
Appendix 7). However, a small number of participants (n=23) waited for six months or more to be 
randomised due to both waiting for other participants who could attend the intervention sessions at 
the same time and the availability of AP within the site to deliver the intervention.  
52 
 
  
Figure 1: Participant flow 
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Baseline data  
The mean age of participants was 45 years (SD 12), 239 (73%) were men and almost all (96%) were 
white (see Table 1). We randomised 31 participants (2%) who were serving or had served in the 
military, including Territorial Army and reservists (see Table 1). There was a wide variation in the 
time since the TBI at randomisation from 3 months to almost 49 years. The median time since TBI 
was just over 4 years (see Table 1). 
 
Characteristics assessed at baseline were well balanced, although a greater proportion of participants 
in the memory rehabilitation arm had a degree or higher degree compared to the usual care arm, and 
the median time since TBI was slightly longer in the memory rehabilitation arm (approximately 4 
years in usual care arm and approximately 5 years in the memory rehabilitation arm). 
 
Information from memory, mood, and quality of life assessments prior to randomisation are shown in 
Table 2. Scores were well balanced between arms. However when the RBMT-3 GMI was 
categorised into levels of memory impairment a smaller percentage of participants in the memory 
rehabilitation arm were classified as having a significant impairment compared to the usual care arm; 
39% in the usual care arm and 29% in the memory rehabilitation arm (see Table 2). 
 
The internal consistency of the EMQ-p and GHQ-30 at baseline using Cronbach’s alpha was 0.93 for 
EMQ-p and 0.95 for the GHQ-30.  
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Table 1: Participant baseline characteristics 
  
Usual care 
 (n = 157) 
Memory 
Rehabilitation  
(n = 171) 
 
Total 
(n = 328) 
    
Age (years)    
Mean [sd] 45.1 [12.5] 45.8 [11.5] 45.4 [12] 
Median [25th, 75th centile] 45 [36, 55] 47 [38, 54] 46 [36, 54] 
Min, max 19, 69 20, 68 19, 69 
 n (%) n (%) n (%) 
Gender    
Men 116 (74%) 123 (72%) 239 (73%) 
Women 41 (26%) 48 (28%) 89 (27%) 
    
Ethnicity     
White 147 (94%) 167 (98%) 314 (96%) 
Black  6 (3%) 2 (1%) 8 (2%) 
Mixed Race 3 (2%) 1 (1%) 4 (1%) 
Other 1 (1%) 1 (1%) 2 (1%) 
    
Residential status     
Lives alone 44 (28%) 43 (25%) 87 (27%) 
Lives with others 106 (68%) 120 (70%) 226 (69%) 
Living with informal carer 2 (1%) 1 (1%) 3 (1%) 
Living with formal carer 2 (1%) 0  2 (1%) 
Living in care home 3 (2%) 7 (4%) 10 (3%) 
    
Highest educational attainment     
Below GCSE 26 (17%) 29 (17%) 55 (17%) 
GCSE 54 (34%) 49 (29%) 103 (31%) 
A-Level 42 (27%) 34 (20%) 76 (23%) 
Degree 24 (15%) 41 (24%) 65 (20%) 
Higher Degree 10 (6%) 17 (10%) 27 (8%) 
Not known 1 (1%) 1 (1%) 2 (1%) 
    
Employment status at screening (not mutually 
exclusive)    
Not employed 80 (51%) 85 (50%) 165 (50%) 
Employed full-time  25 (16%) 38 (22%) 63 (19%) 
In education full-time 2 (1%) 1 (1%) 3 (1%) 
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Usual care 
 (n = 157) 
Memory 
Rehabilitation  
(n = 171) 
 
Total 
(n = 328) 
Voluntary full-time 1 (1%) - 1 (<0.5%) 
Retired 17 (11%) 15 (9%) 32 (10%) 
Employed part-time 25 (16%) 19 (11%) 44 (13%) 
Voluntary part-time 9 (6%) 17 (10%) 26 (8%) 
    
Current military service1     
Military 4 (3%) 0  4 (1%) 
TA/reservist 0  2 (1%) 2 (1%) 
Non-military 153 (97%) 169 (99%) 322 (98%) 
    
Previous military service     
Military 14 (9%) 11 (6%) 25 (8%) 
TA/reservist 2 (1%) 4 (2%) 6 (2%) 
Non-military 141 (90%) 156 (91%) 297 (91%) 
    
TBI during service  3 (2%) 1 (1%) 4 (1%) 
    
Time since TBI (months)2    
Mean [sd] 99 [114.8] 102.6 [113.4] 100.9 [113.9] 
Median [25th, 75th centile] 46 [23, 116] 58 [24, 148] 52 [24, 129.5] 
Min, max 4, 520 3, 587 3, 587 
    
Length of initial hospital stay for TBI (days)3    
Mean [sd] 81.8 [108.6] 86.5 [143.5] 84.2 [127.7] 
Median [25th, 75th centile] 35 [7, 120] 35.5 [10, 93.5] 35 [9, 116] 
Min, max4 0, 468 0, 999 0, 999 
n 148 160 308 
Length of hospital stay unknown – n (%) 9 (6%) 11 (6%) 20 (6%) 
1 – All participants reporting current military service also indicated that they had previous military service. 
2 – Based on participant-reported date of TBI for 108 participants in usual care arm and 132 participants in memory rehabilitation arm 
and clinical notes for 49 participants in usual care arm and 39 participants in memory rehabilitation arm.  
3 – Estimated for 84 participants in usual care arm and 105 participants in memory rehabilitation arm. 
4 – Maximum truncated at 999. 
Note: The other clinical information collected at baseline is not shown here due to large amounts of missing data.  It is reported in full 
in Appendix 8. 
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Table 2: Assessments completed prior to randomisation 
  
Usual care 
 (n=157) 
Memory 
Rehabilitation  
(n=171) 
 
Total 
(n=328) 
EMQ-p – frequency of problems    
Mean [sd] 50.1 [24.6] 47.4 [21] 48.7 [22.8] 
Median [25th, 75th centile] 50 [33, 65.2] 47.7 [30, 63] 48 [32, 64] 
Min, max 0, 105 5, 102 0, 105 
n1 156 171 327 
    
EMQ-p – importance of problems    
Mean [sd] 70.6 [22.4] 65.7 [23.5] 68 [23] 
Median [25th, 75th centile] 72 [56, 87] 69 [51, 83] 70.5 [54, 84] 
Min, max 2, 112 0, 112 0, 112 
n 152 170 322 
    
RBMT-3 GMI    
Mean [sd] 76.3[14.5] 77.7 [13.6] 77 [14] 
Median [25th, 75th centile] 75 [65, 85] 77 [67, 85] 76 [66.5, 85] 
Min, max 53, 114 53, 127 53, 127 
n 157 171 328 
    
Level of memory impairment based on RBMT-3 n (%) n (%) n (%) 
Significant memory impairment (≤ 69) 61 (39%) 50 (29%) 111 (34%) 
Borderline/moderate memory impairment (70 to 
84) 54 (34%) 77 (45%) 131 (40%) 
Average or above average (≥85) 42 (27%) 44 (26%) 86 (26%) 
    
GHQ-30    
Mean [sd] 35.3 [16.3] 36.1 [15.4] 35.8 [15.8] 
Median [25th, 75th centile] 33 [21, 47] 34 [25, 45] 33 [24, 45.3] 
Min, max 6, 90 6, 84 6, 90 
n 154 170 324 
    
Estimated premorbid IQ from NART    
Mean [sd] 106.5 [10] 108.1 [10.2] 107.4 [10.1] 
Median [25th, 75th centile] 103 [99, 116] 109.5 [100, 117] 105 [100, 117] 
Min, max 86, 126 87, 128 86, 128 
n 155 170 325 
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Usual care 
 (n=157) 
Memory 
Rehabilitation  
(n=171) 
 
Total 
(n=328) 
SST     
Mean [sd] 19.3 [0.9] 19.4 [0.9] 19.4 [0.9] 
Median [25th, 75th centile] 20 [19, 20] 20 [19, 20] 20 [19, 20] 
Min, max 17, 20 17, 20 17, 20 
n 157 171 328 
    
EMQ-r – frequency of problems    
Mean [sd] 46.4 [24.4] 42 [28.4] 44.1 [26.6] 
Median [25th, 75th centile] 46.7 [27, 65] 35.3 [18.7, 64] 38.5 [22, 64.5] 
Min, max 0, 107 0, 108 0, 108 
n 95 105 200 
    
EMQ-r – importance of problems    
Mean [sd] 71.5 [24.5] 71.8 [21] 71.7 [22.7] 
Median [25th, 75th centile] 76 [64, 87] 72 [60, 88] 75 [60, 87] 
Min, max 0, 112 4, 112 0, 112 
n 90 101 191 
    
1 One participant did not complete five items on the EMQ-p, 23 items completed summed to a total of 27. 
EMQ scores range from 0 to 112 with higher scores indicating more frequent/important memory problems. 
RBMT-3 GMI scores range between 52 and 174 and has been standardised to have a mean of 100 and an SD of 15 on a 
demographically representative sample from the UK. 
GHQ-30 score ranges from 0 to 90 with higher scores indicating increased psychological distress. 
A total SST score of 17 or more was required to participate in the trial. Maximum score 20.   
 
 
Relative/friend participation in trial 
In total, 210 relatives or friends of participants agreed to take part in the trial by returning a 
questionnaire at baseline or follow-up (64% in each arm). The scores from the EMQ-r were similar 
in the two arms at baseline (see Table 2). The internal consistency of the EMQ-r using Cronbach’s 
alpha was 0.96. 
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Group memory rehabilitation sessions 
Attendance at group sessions 
Participants attended a mean of 6.3 sessions (SD 3.5) and 131 (77%) attended four or more sessions 
(see 
 
Table 3). There were several reasons that participants did not attend sessions, these are shown in  
 
Table 3. 
 
Attendance at sessions decreased over time. Some groups were well attended throughout. In one 
group, the final four sessions were not attended by any participants (see Appendix 9). 
 
Table 3: Summary of attendance at group memory rehabilitation sessions 
 Memory Rehabilitation 
 n=171 
Number of sessions attended  
Mean [sd] 6.3 [3.5] 
Median [25th, 75th centile] 8 [4, 9] 
Min, max 0, 10 
  
0 to 2 36 (21%) 
3 to 7 44 (26%) 
8 to 10 91 (53%) 
  
Attended at least 4 sessions 131 (77%) 
  
Total number of sessions missed 627 
Reason sessions missed1 Total number of sessions Number of participants 
Did not want to continue 122  16 
Withdrew from study 52  7 
Lost to follow-up (unable to contact) 70  7 
Forgot to attend  11  10 
Unwell 83  40 
Holiday 59  36 
Work/family commitments 114  34 
No reason given 94  23 
Other2 22  16 
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1 – Reasons sessions missed not mutually exclusive. 
2 – Other reasons given for participants missing group rehabilitation sessions were: prior engagements for five participants, 
transport/traffic problems for four participants and moved away for one participant (note: Reasons are not mutually exclusive). There 
were also seven participants included in the other category where the reason for missing sessions is not known.  
In total 17 APs delivered group sessions during the trial. The number of sessions each AP ran ranged 
between 1 and 47 with a median of 20 [25th, 75th centile = 10, 28]. 
 
 
Analysis of treatment fidelity 
Full numbers of videos retrieved from each site are shown in Appendix 10, Table 35. No videos were 
retrieved from three sites. Sites two and four only recruited one intervention group each and 
therefore the sessions were not recorded as it was the first group conducted by the APs at those sites. 
At Site seven, two intervention groups were recruited, one of which was the first for the AP and for 
the second the recordings were not available for analysis. At two sites (Sites five and six) there were 
very few recordings retrieved as the APs did not understand that all sessions needed to be recorded. 
There were 25 sessions in which the recording stopped part way through the session due to technical 
problems (e.g., the battery of the recorder being completely discharged). Overall there were some 
recordings from six of the nine sites. 
 
A selection of all recordings of complete sessions were analysed; seven recordings of complete 
sessions were not included because sufficient recordings from the site or the session had already 
been included in the analysis. In addition, as there were no complete recordings of session one, two 
that were almost complete were analysed for session one. The summary of the videos analysed is 
shown in Appendix 10, Table 36. Between two and five recordings of each session were analysed. A 
total of 31 sessions were included in the fidelity analysis; approximately 9% of the 350 memory 
rehabilitation sessions delivered during the trial. 
 
The frequency and percentage of each activity code were calculated per session and can be seen in 
Table 4 (APs) and Table 5 (participants). 
 
60 
 
Table 4: Frequency of AP skills and activities observed within a session 
 
Session 1 Session 2 Session 3 Session 4 Session 5 Session 6 Session 7 Session 8 Session 9 Session 10 Total 
Category n1 %2 n % n % n % N % n % n % n % n % n % n % 
Non-rehabilitation                       
Introductions 1 1.8 0 0 0 0 1 0.7 1 1.0 0 0 1 1.6 0 0 1 0.7 0 0 5 0.4 
Social chat 3 5.5 2 1.3 2 4.5 2 1.4 4 3.9 3 2.1 0 0 9 4.2 8 5.8 5 4.1 38 3.2 
Preparing materials, tasks 2 3.6 5 3.3 0 0 1 0.7 0 0 1 0.7 0 0 2 0.9 4 2.9 8 6.5 23 2.0 
Information about sessions, venue, 
group 20 36.4 3 2.0 2 4.5 4 2.9 6 5.8 2 1.4 1 1.6 4 1.9 1 0.7 13 10.6 56 4.8 
Hospital visit discussion 1 1.8 0 0 0 0 0 0 1 1.0 0 0 0 0 0 0 0 0 0 0 2 0.2 
Describing emotions and coping 
strategies 1 1.8 3 2.0 0 0 1 0.7 0 0 0 0 1 1.6 0 0 1 0.7 1 0.8 8 0.7 
Rehabilitation skills                       
Facilitating discussion (non-
specific prompts) 5 9.1 3 2.0 0 0 13 9.4 0 0 5 3.4 0 0 4 1.9 4 2.9 7 5.7 41 3.5 
Providing feedback not directly 
related to manual 1 1.8 5 3.3 0 0 3 2.2 5 4.9 0 0 0 0 5 2.3 5 3.6 4 3.3 28 2.4 
Providing 
encouragement/reassurance 4 7.3 6 3.9 0 0 6 4.3 4 3.9 4 2.7 1 1.6 6 2.8 3 2.2 3 2.4 37 3.2 
Summarising 0 0 1 0.7 0 0 0 0 0 0 0 0 0 0 1 0.5 1 0.7 0 0 3 0.3 
Paraphrasing 1 1.8 8 5.2 0 0 4 2.9 2 1.9 2 1.4 1 1.6 3 1.4 1 0.7 0 0 22 1.9 
Rehabilitation activities                       
Presenting/discussing educational 
material 13 23.6 81 52.9 21 47.7 41 29.7 24 23.3 48 32.9 12 19.7 57 26.8 31 22.6 41 33.3 369 31.5 
Presenting/discussing strategies 1 1.8 2 1.3 18 40.9 53 38.4 49 47.6 75 51.4 44 72.1 102 47.9 60 43.8 16 13.0 420 35.8 
Providing general information on 
memory not related to manual 2 3.6 25 16.3 1 2.3 2 1.4 2 1.9 2 1.4 0 0 3 1.4 2 1.5 3 2.4 42 3.6 
Recap of previous session 0 0 9 5.9 0 0 7 5.1 5 4.9 4 2.7 0 0 17 8.0 15 10.9 22 17.9 79 6.7 
Total 55 100 153 100 44 100 138 100 103 100 146 100 61 100 213 100 137 100 123 100 1173 100 
1 n= number of observations.  2 %= percentage of observation.
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Table 5: Activities observed in participants within a session 
 Session 1 Session 2 Session 3 Session 4 Session 5 Session 6 Session 7 Session 8 Session 9 Session 10 Total 
Category n1 %2 n % n % n % n % n % n % n % n % n % n % 
Non-rehabilitation                       
Introductions 5 6.2 0 0 0 0 3 2.0 0 0 0 0 0 0 0 0 1 0.6 0 0 9 0.8 
Social chat 14 17.3 6 8.7 5 21.7 13 8.8 22 14.8 10 8.1 2 5.9 40 22.7 46 26.1 27 13.8 185 15.8 
Preparing materials, tasks  2 2.5 2 2.9 0 0 0 0 0 0 0 0 0 0 1 0.6 0 0 1 0.5 6 0.5 
Information about sessions, 
venue, group 3 3.7 0 0 1 4.3 3 2.0 1 0.7 2 1.6 0 0 1 0.6 2 1.1 5 2.6 18 1.5 
Hospital visit discussion 8 9.9 0 0 0 0 2 1.4 1 0.7 0 0 0 0 0 0 0 0 0 0 11 0.9 
Describing emotions and 
coping strategies 13 16.0 10 14.5 0 0 6 4.1 2 1.3 0 0 1 2.9 4 2.3 10 5.7 28 14.4 74 6.3 
Rehabilitation activities                       
Discussing/ filling in 
educational material 13 16.0 17 24.6 11 47.8 63 42.9 51 34.2 32 26.0 19 55.9 12 6.8 11 6.3 53 27.2 282 24.0 
Discussing strategies 6 7.4 8 11.6 5 21.7 28 19.0 51 34.2 62 50.4 6 17.6 76 43.2 95 54.0 45 23.1 382 32.6 
Asking for information 0 0 6 8.7 1 4.3 4 2.7 2 1.3 0 0 2 5.9 3 1.7 0 0 3 1.5 21 1.8 
Feedback on home 
activities 0 0 5 7.2 0 0 4 2.7 13 8.7 4 3.3 3 8.8 14 8.0 6 3.4 20 10.3 69 5.9 
Describing problems 
related to memory 17 21.0 15 21.7 0 0 21 14.3 6 4.0 13 10.6 1 2.9 25 14.2 5 2.8 13 6.7 116 9.9 
Total 81 100 69 100 23 100 147 100 149 100 123 100 34 100 176 100 176 100 195 100 1173 100 
1 n= number of observations.  2 %= percentage of observation. 
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The main non-rehabilitation activity of APs was information about sessions, which occurred 
on just under 5% of AP observations. The main rehabilitation activities of APs were 
discussing the educational material (31.5%) and discussing memory strategies (35.8%). The 
main rehabilitation skills of APs were facilitating discussion and providing encouragement. 
Overall APs spent 88.9% of the time in rehabilitation skills and activities. The pattern across 
time showed that the initial session included more non-rehabilitation activities (50.9%), 
whereas all subsequent sessions included more rehabilitation activities (78.0% to 95.9%). 
 
For participants, the main non-rehabilitation activity comprised social chat which occurred on 
about 16% of observations. The main rehabilitation activities were discussing the educational 
material (24%) and discussing memory strategies (32.6%). Overall participants spent 74.2% 
of the sessions in rehabilitation activities. The pattern of activities across time showed that 
the initial session included more non-rehabilitation activities (55.6%), whereas all subsequent 
sessions included more rehabilitation activities (62.1% to 91.1%). 
 
Overall the results indicate that the APs followed the guidelines in the manual by providing 
and discussing rehabilitation strategies and this was mirrored by participants who also 
discussed the educational materials and strategies. Most sessions included summarising and 
paraphrasing by the AP and providing general information on memory not related to the 
manual. Most sessions included describing problems related to memory. 
 
In order to examine the consistency between sites, we compared the distribution of 
observations at each site. Results are shown in Appendix 10, Table 37 and Table 38. 
 
The distributions of AP activities were similar across sites. The AP at Site five spent more 
time in organising sessions e.g. discussing the venue and time of groups (20.9%) and more 
time facilitating discussion (16.4%) than the APs in other sites. Most variation between sites 
occurred in the time spent in presenting and discussing strategies which varied from 16.4% 
(Site five) to 65.6% (Site nine). Providing a recap of the previous session was more frequent 
in Site three (17.2%) than other sites. 
 
From the participants’ perspective, those at Site five spent more time discussing information 
about sessions (4.4%) and discussing hospital visits (11.1%). Participant rehabilitation 
activities were similar between sites. Site three participants spent the most time discussing the 
63 
 
educational material (35.6%) and participants at Sites five and nine spent the highest 
proportion of time discussing strategies (42.5% and 41.8%).  Site six participants spent the 
highest proportion of time describing problems related to memory (20.9%). 
 
Overall the results of the fidelity analysis indicate that the components of therapy described 
in the manual were delivered to participants. Each session included essential components of 
therapy. The distribution of time was as expected with session one being introductory and 
providing an opportunity for participants to get to know each other, whereas later sessions 
were more focussed on the rehabilitation content. This suggests that outcomes reflect the 
effect of the intervention as described in the manual. 
 
 
Follow-up  
Follow-up assessments were completed between October 2013 and December 2016. At 6-
month follow-up, 260 (79%) participants returned the questionnaire booklet and 276 (84%) 
participants completed the assessment visit (see Table 6). Questionnaire booklet return and 
visit completion were similar in the two arms. 
 
At 12-month follow-up, 238 (73%) of participants returned the questionnaire booklet and 256 
(78%) completed the assessment visit and completion rates were again similar in the two 
arms (see Table 6). 
 
Most visits (n=275, 84% at 6-months; n=256, 78% at 12-months) and questionnaires (n=254, 
77% at 6-months; n=237, 72% at 12-months) were completed within three months of the 
scheduled time point. 
 
A total of 64 (20%) participants did not have any 12-month follow-up, due to either 
withdrawing consent (8%) or being lost to follow-up (12%). Numbers lost to follow-up and 
withdrawing consent were similar in each arm. Twenty-six participants (8%) withdrew from 
the trial: 12 in the usual care arm and 14 in the memory rehabilitation arm (see Table 6). The 
main reasons for withdrawal were health problems, lack of time, personal and family issues. 
Three participants withdrew from the usual care arm due to not being randomised to group 
memory rehabilitation. Four participants from the memory rehabilitation arm withdrew, due 
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to not finding the sessions as they had expected or because they felt the sessions were having 
a negative impact on their mood.  
 
Of the 328 participants randomised, some follow-up data (e.g., questionnaire or visit at 6- or 
12-month follow-up) was collected for 290 (88%).  
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Table 6: Participant visit and questionnaire completion at 6- and 12-month follow-up  
 
 
Usual care 
 (n=157) 
Memory 
Rehabilitation 
 (n=171) 
 
Total 
 (n=328) 
 
Usual care 
 (n=157) 
Memory 
Rehabilitation 
 (n=171) 
 
Total 
 (n=328) 
 6 month follow-up 12 month follow-up 
  Face to face visit  n (%) n (%) n (%) n (%) n (%) n (%) 
     Attended 133 (85%) 143 (84%) 276 (84%) 124 (79%) 132 (77%) 256 (78%) 
     Not done1 7 (4%) 7 (4%) 14 (4%) 2 (1%) 6 (4%) 8 (2%) 
     Discontinued  17 (11%) 21 (12%) 38 (12%) 31 (20%) 33 (19%) 64 (20%) 
         Lost to follow-up 8  10  18  19  19  38  
         Death 0  0  0  0  0  0  
         Withdrawal of consent 9  11  20  12  14  26  
     Days to visit  
     from randomisation 
      
          Median [25th, 75th centile] 183 [180, 189] 184 [182, 189] 184 [180, 189] 364 [361, 368] 366 [362, 370] 364 [361, 370] 
          Min, Max 169, 251 153, 291 153, 291 351, 415 330, 440 330, 440 
 n (%) n (%) n (%) n (%) n (%) n (%) 
      Visit completed within 3  
      months of due date 133 (85%) 142 (83%) 275 (84%) 124 (79%) 132 (77%) 256 (78%) 
  Participant questionnaire booklet  n (%) n (%) n (%) n (%) n (%) n (%) 
      Returned 125 (80%) 135 (79%) 260 (79%) 112 (71%) 126 (74%) 238 (73%) 
      Not done1 15 (10%) 15 (9%) 30 (9%) 14 (9%) 12 (7%) 26 (8%) 
      Discontinued 17 (11%) 21 (12%) 38 (12%) 31 (20%) 33 (19%) 64 (20%) 
         Lost to follow-up 8  10  18  19  19  38  
         Withdrawal of consent 9  11  20  12  14  26  
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Usual care 
 (n=157) 
Memory 
Rehabilitation 
 (n=171) 
 
Total 
 (n=328) 
 
Usual care 
 (n=157) 
Memory 
Rehabilitation 
 (n=171) 
 
Total 
 (n=328) 
 6 month follow-up 12 month follow-up 
      Days to completion from  
      randomisation  
      
           Median [25th, 75th centile] 174 [167, 188] 174 [166, 185] 174 [166, 186] 356.5 [349.5, 364] 357 [349, 366] 357 [349, 364] 
           Min, Max 159, 278 159, 286 159, 286 340, 611 316, 438 316, 611 
 n (%) n (%) n (%) n (%) n (%) n (%) 
      Questionnaire completed within 
3  
      months of due date 123 (78%) 131 (77%) 254 (77%) 111 (71%) 126 (74%) 237 (72%) 
1 – Not done for participant visit/questionnaires indicates participant follow-up at later time point or completed only one of the visit or questionnaire at that follow-up time-point. 
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Inclusion in primary analysis of the primary outcome  
There were 122 (78%) participants in the usual care arm and 129 (75%) in the memory rehabilitation 
arm included in the primary analysis of the EMQ-p at 6-month follow-up. Three participants in the 
usual care arm and six in the memory rehabilitation arm who returned questionnaires were not 
included, due to either completing the questionnaire more than nine months from randomisation or 
not completing enough items on the EMQ-p for it to be scored (see Figure 1).  
 
Participants with no primary outcome tended to have a slightly lower level of educational attainment 
and slightly more memory problems at baseline based on both patient- and relative/friend-report. 
There were no important differences in other baseline characteristics (see Appendix 11). 
 
 
Unblinding at follow-up visits 
RAs reported being unblinded more often in the memory rehabilitation arm than in the usual care 
arm, both prior to and during the visits (see Appendix 12). The percentage of participants assessed 
correctly as ‘definitely’ in their allocated arm was higher in the memory rehabilitation arm than the 
usual care arm. The most frequent assessment of allocation at each time-point was ‘probably 
control’. 
 
The Kappa statistic was used to assess the agreement between a participant’s actual treatment 
allocation and the RA’s opinion of treatment allocation (collapsing probably and definitely into one 
category). Kappa values of ≤0.20 are considered to indicate no or poor agreement, 0.21 to 0.40 as 
fair agreement, 0.41 to 0.6 as moderate agreement, 0.61 to 0.8 substantial agreement, and ≥0.81 as 
near perfect agreement. Kappa values were fair before goal assessment and moderate after goal 
assessment (see Appendix 12) 
 
 
Relative/friend questionnaire follow-up  
Of the 210 relative/friends who agreed to participate in the trial, the questionnaire booklet was 
returned by 144 (68%) at the 6-month follow-up and 131 (62%) at the 12-month follow-up (see 
Appendix 13). A slightly higher percentage of relative/friends in the usual care arm returned the 
questionnaire booklet at the 6-month follow-up. However, the percentage returning the booklet at the 
12-month follow-up was similar in the two arms.  
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Primary outcome: EMQ-p at 6-month follow-up 
 
Primary analysis  
The mean EMQ-p score was lower in both arms at 6-month follow-up compared to baseline, 
however there was no clinically important difference between the two arms (see Table 7).  
 
Table 7: Everyday Memory Questionnaire – patient version (EMQ-p) at 6-month follow-up  
 Baseline 
Mean [sd] 
6-month follow-up 
Mean [sd] 
Adjusted 
difference in 
means (95% CI) 
 
p-value 
     
Usual care (n = 122) 48.9 [23.9] 44.1 [24.6]   
     
Memory Rehabilitation  
(n = 129)  
45.9 [21.0] 38.8 [26.1] -2.1 (-6.7 to 2.5) 0.37 
     
EMQ-p scores range from 0 to 112 with higher scores indicating more frequent memory problems. Difference in means at the 6-month 
follow-up (memory rehabilitation compared to usual care) estimated using a multi-level linear model with a random effect for cluster 
in the intervention arm, allowing the participant-level variance to vary between arms and baseline EMQ-p score and site included as 
covariates. 
 
The mean cluster size with EMQ-p at follow-up was 3.9 in the usual care arm and 3.7 in memory 
rehabilitation arm. Diagnostic plots were used to check the assumptions for the model with no strong 
evidence that these were not met. The estimated intracluster correlation coefficient for the participant 
EMQ-p was 0.05 in the memory rehabilitation arm.  
 
Sensitivity analyses for the primary outcome 
The estimates of the difference between the two arms in EMQ-p at the 6-month follow-up, after 
additional adjustment for baseline variables, multiple imputation (assuming missing outcomes 
missing at random) and the complier average causal effect estimate, were slightly greater than in the 
primary analysis (see Table 8 and Appendix 14, Figure 15). However, the lower limit of the 95% 
confidence interval for all of these sensitivity analyses were greater than -12, the minimum clinically 
relevant difference specified in the sample size calculation.    
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We conducted a further sensitivity analysis to explore the robustness of the results if missing EMQ-p 
data at the 6-month follow-up were not missing at random. Under the extreme assumption of scores 
in the usual care arm being 12 points worse than as imputed under the missing at random 
assumption, the lower limit of the 95% confidence interval was -9.8.  
 
The analysis after Rasch conversion of the EMQ-p gave similar results to using the standard EMQ-p 
total score (see Appendix 14). 
 
Table 8: Sensitivity analyses for primary outcome  
Analysis type n Adjusted difference in means 
(95% CI) 
   
Additional adjustment for educational attainment 
and time since TBI  (log-transformed) due to 
slight imbalance at baseline 
251 -2.8 (-7.2 to 1.7) 
   
Including participants completing the 6 month 
questionnaire booklet more than 9 months after 
randomisation 
257 -2.0 (-6.5 to 2.5) 
   
After multiple imputation of missing outcome 
data1 
328 -2.4 (-7.1 to 2.3) 
   
Complier average causal effect using observed 
data at 6 months 
251 -2.6 (-7.9 to 2.7) 
   
Complier average causal effect at 6 months after 
multiple imputation of missing outcome data 
328 -3.2 (-9.3 to 2.9) 
   
1 – Multiple imputation using chained equations separately for each arm and assumes missing data is missing at random.  The 
imputation model included age, site, gender, baseline EMQ-p, baseline GHQ-30, baseline RBMT-3 GMI, highest education attainment 
(predictive of dropout) and log-transformed time since TBI. The following outcomes were imputed: EMQ-p score at 6- and 12-month 
follow-up and RBMT-3 GMI at 6- and 12-month follow-up. In addition for the intervention arm, the number of sessions attended was 
included.  Forty datasets were imputed and estimates were combined using Rubin rules. 
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Sub-group analysis for the primary outcome 
We conducted a pre-specified sub-group analysis based on the baseline level of memory impairment, 
as assessed on the RBMT-3. The difference in mean EMQ-p score for those with 
borderline/moderate memory impairment favoured the memory rehabilitation arm but there was no 
evidence of a difference in the effect of the group memory rehabilitation sessions across the sub-
groups (p-value for interaction = 0.12) (see Table 9 and Appendix 15). 
 
Results of the post hoc sub-group analysis conducted on time since TBI are shown in Appendix 16. 
There was no evidence of a difference in the intervention effect according to the time since TBI 
based on this analysis (p-value for interaction effect 0.48). 
 
Table 9: Sub-group analysis for Everyday Memory Questionnaire according to memory 
impairment at baseline  
 
Baseline 
Mean [sd] 
6-month 
follow-up 
Mean [sd] 
Adjusted difference 
in means (95% CI) 
Adjusted 
interaction effect 
(95% CI) 
     
RBMT-3 GMI score ≥ 85 
(average and above average 
range) 
    
Usual care (n = 34) 43.4 [15.0] 36.0 [20.5]   
Memory Rehabilitation (n = 35)  42.7 [16.9] 34.4 [21.9] -0.1 (-8.3 to 8.1)  
     
RBMT-3 GMI score 70 to 84 
(borderline/moderate memory 
impairment) 
   
 
Usual care (n = 43) 45.7 [25.0] 43.9 [25.6]   
Memory Rehabilitation (n = 59)  43.5 [20.8] 34.0 [23.9] -7.1 (-13.9 to -0.3) -7.0 (-17.5 to 3.4) 
     
RBMT-3 GMI score ≤ 69 
(significant memory 
impairment) 
   
 
Usual care (n = 45) 56.3 [26.9] 50.4 [25.1]   
Memory Rehabilitation (n = 35)  53.2 [23.7] 51.3 [29.8] 3.3 (-4.4 to 11.0) 3.4 (-7.7 to 14.6) 
EMQ scores range from 0 to 112 with higher scores indicating more frequent/important memory problems. 
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Secondary outcomes 
 
EMQ-p at 12-month follow-up  
There was no clinically important difference between the two arms in EMQ-p score at the 12-month 
follow-up (seeTable 10). The EMQ-p importance scores at 6- and 12-month follow-up are reported 
in Appendix 17. The importance scale was originally added to be able to investigate the effect of 
memory rehabilitation on memory problems weighted for their importance. However analysis of data 
from a subsequent independent study 78 showed no effect of weighting items according to their 
importance and therefore this was not included in the main analyses. 
 
 
Objectively assessed memory ability 
The General Memory Index scores (GMI) from the RBMT-3 were slightly higher at the 6-month 
follow-up in the memory rehabilitation arm compared to the usual care arm. However by the 12-
month follow-up there was no evidence of a difference between the two arms (see Table 10).  
 
Table 10: Secondary outcomes for memory and mood at 6- and 12-month follow-up  
 
Baseline 
Mean [sd] 
Follow-up 
Mean [sd] 
Adjusted 
difference in 
means (95% CI) 
EMQ-p – frequency of problems     
12-month follow-up    
Usual care (n = 107) 47.5 [24.6] 43.0 [26.7]  
Memory Rehabilitation (n = 124) 46.7 [20.4] 38.0 [25.0] -4.8 (-9.6 to 0.0) 
General Memory Index scores from 
the Rivermead Behavioural Memory 
Test     
6-month follow-up1    
Usual care (n = 133) 77.1 [14.5] 79.1 [15]  
Memory Rehabilitation (n = 141) 78.9 [13.7] 82.7 [14] 2.5 (0.1 to 4.8) 
    
12-month follow-up2    
Usual care (n = 124) 76.2 [14.0] 84.0 [18.4]  
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Baseline 
Mean [sd] 
Follow-up 
Mean [sd] 
Adjusted 
difference in 
means (95% CI) 
Memory Rehabilitation (n = 131) 79.5 [12.8] 87.2 [15.7] 0.5 (-2.6 to 3.6) 
General Health Questionnaire 
Scores    
6-month follow-up    
Usual care (n = 110) 33.9 [15.7] 34.1 [16.8]  
Memory Rehabilitation (n = 124) 36.2 [15.4] 33.6 [16.3] -1.6 (-5.3 to 2.1) 
    
12-month follow-up    
Usual care (n = 103) 33.4 [15.8] 32.5 [18.8]  
Memory Rehabilitation (n = 119) 35.7 [15.3] 33.1 [18.5] -0.2 (-4.5 to 4.1) 
EMQ-r – frequency of problems     
6-month follow-up    
Usual care (n = 66) 43.2 [23.1] 40.9 [25.9]  
Memory Rehabilitation (n = 68) 39.4 [26.3] 31.8 [24.5] -4.2 (-10.1 to 1.7) 
    
12-month follow-up     
Usual care (n = 57) 42.9 [23.5] 37.6 [26.6]  
Memory Rehabilitation (n = 67) 40.0 [26.7] 32.2 [26.2] -5.3 (-12.0 to 1.4) 
    
The General Memory Index from the Rivermead Behavioural Memory Test ranges between 52 and 174 and has been standardised to 
have a mean of 100 and an SD of 15 on a demographically representative sample from the UK. 
GHQ-30 score ranges from 0 to 90 (Likert scoring) with higher scores indicating increased psychological distress. 
EMQ scores range from 0 to 112 with higher scores indicating more frequent/important memory problems. 
1- RBMT-3 not done for one participant who completed visit at the 6-month follow-up in the memory rehabilitation arm as visit done 
on phone as participant moved out of area.  
2- One participant in the memory rehabilitation arm refused to do the RBMT-3 at the 12-month follow-up visit. 
 
 
Goal attainment 
Participants set on average 2.5 (SD 1.2) short term goals and 2.4 (SD 1.2) long term goals at the 
second assessment. These included goals such as better recall of names and dates, remembering 
forthcoming tasks or appointments and improved memory of past events. We were unable to set 
goals for three participants (two randomised to the usual care arm, one randomised to the memory 
rehabilitation arm); two participants did not wish to set any goals and one participant was not able to 
as they were preoccupied with other non-memory issues. 
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For short- and long-term goals, the goal attainment scores favoured the memory rehabilitation arm at 
both 6- and 12-month follow-up (seeTable 11). There was no evidence of a difference in the effect 
according to the number of goals set, p-values for the interaction effect between treatment arm and 
one goal set or more than one goal set: 0.67 and 0.59 for short term goals and 0.07 and 0.67 for long 
term goals at 6 and 12 months respectively. 
 
Of the 819 short-term goals set, 692 (84%) were classified as SMART. Of the 775 long-term goals 
set, 679 (88%) were classified as SMART. Thirty participants (9%) had no SMART short term goals 
set and 35 participants (11%) had no SMART long term goals set. The results from the analysis for 
goal attainment including only SMART goals were similar to the results from the analysis including 
all goals (see Appendix 18). 
 
 
Mood 
GHQ-30 scores were similar in the two arms at both time-points (see Table 10). 
 
 
Cognitive, emotional, and social wellbeing 
Scores from all subscales of the EBIQ-p were similar in the two arms at both 6- and 12-month 
follow-up (see Table 11).  
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Table 11: Goal attainment and European Brain Injury Questionnaire – patient version (EBIQ-
p) subscale scores at 6 and 12 month follow-up 
 6-month follow-up 12-month follow-up 
 
 
n Mean [sd] 
Adjusted 
difference in 
means  
(95% CI) 
 
 
n Mean [sd] 
Adjusted 
difference in 
means  
(95% CI) 
       
Goal attainment        
Short term goal 
attainment average score  
 
  
   
Usual care  131 1.2 [1.0]  123 1.5 [1.1]  
Memory Rehabilitation  141 1.8 [1.0] 0.6 (0.3 to 0.9) 131 1.8 [0.9] 0.3 (0.0 to 0.5) 
       
Long term goal 
attainment average score  
 
  
   
Usual care  131 1.0 [0.9]  123 1.3 [1.0]  
Memory Rehabilitation  141 1.5 [1.0] 0.5 (0.2 to 0.7) 131 1.6 [1.0] 0.4 (0.1 to 0.6) 
EBIQ-p subscale scores       
Cognitive subscale       
Usual care 109 1.97 [0.43]  99 1.94 [0.47]  
Memory Rehabilitation 121 1.89 [0.45] -0.05  
(-0.17 to 0.06) 
117 
 
1.88 [0.46] -0.05  
(-0.17 to 0.08) 
Depression subscale       
Usual care 109 1.68 [0.62]  97 1.63 [0.63]  
Memory Rehabilitation  118 1.76 [0.62] 0.06  
(-0.10 to 0.23) 
118 1.77 [0.64] 0.16 
 (-0.01 to 0.34) 
Communication subscale       
Usual care  110 1.86 [0.53]  99 1.90 [0.57]  
Memory Rehabilitation 120 1.92 [0.57] 0.06 
 (-0.10 to 0.21) 
115 1.85 [0.57] -0.05 
 (-0.21 to 0.11) 
Difficulties in social 
interaction subscale 
 
  
 
  
Usual care 110 1.71 [0.48]  97 1.71 [0.45]  
Memory Rehabilitation 120 1.82 [0.50] 0.09  
(-0.04 to 0.22) 
118 1.77 [0.48] 0.05  
(-0.08 to 0.18) 
Impulsivity subscale       
Usual care  108 1.7 [0.50]  97 1.64 [0.48]  
Memory Rehabilitation 121 1.8 [0.51] N/A1 118 1.76 [0.50] N/A1 
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 6-month follow-up 12-month follow-up 
 
 
n Mean [sd] 
Adjusted 
difference in 
means  
(95% CI) 
 
 
n Mean [sd] 
Adjusted 
difference in 
means  
(95% CI) 
       
Somatic subscale       
Usual care 110 1.94 [0.52]  96 1.91 [0.51]  
Memory Rehabilitation 120 1.95 [0.52] N/A1 115 1.89 [0.50] N/A1 
       
Fatigue subscale       
Usual care 107 2.01 [0.47]  99 1.99 [0.55]  
Memory Rehabilitation 120 2.00 [0.50] N/A1 117 1.97 [0.51] N/A1 
Goals attainment was assessed on a 4-point Likert scale of not met (0), met a little (1), mostly met (2), and fully met (3). The average 
attainment score across the goals set was calculated for each participant. Number of goals set was included in the analysis model.  
Of those completing 6-month follow-up, two participants in the usual care arm and one participant in the memory rehabilitation arm 
had set any goals. 
Of those completing 12-month follow-up, one participant in the usual care arm and one participant in the memory rehabilitation arm 
had not set any goals. 
EBIQ-p sub-scale scores range between 1 and 3 with higher scores indicating increased difficulties. 
1 Impulsivity, somatic and fatigue subscales summarised using descriptive statistics only as per the SAP. 
 
Relative/friend secondary outcomes  
The differences between the two arms at follow-up based on the relative/friend assessment were 
consistent with the participant completed questionnaires (see  Table 10 for EMQ-rand Table 12 for 
EBIQ-r), indicating that there was no clinically important difference between the two arms, even 
though these outcomes were only completed for a sub-group of participants. The EMQ-r importance 
scores at 6- and 12-month follow-up are reported in Appendix 19. 
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Table 12: European Brain Injury Questionnaire – relative version (EBIQ-r) subscale scores  
 6-month follow-up 12-month follow-up 
 
 
n Mean [sd] 
Adjusted 
difference in 
means  
(95% CI) 
 
 
n Mean [sd] 
Adjusted 
difference in 
means  
(95% CI) 
       
Cognitive subscale       
Usual care 72 1.98 [0.50]  60 1.88 [0.52]  
Memory Rehabilitation 69 1.89 [0.52] -0.06  
(-0.23 to 0.12) 
68 1.91 [0.53] 0.00  
(-0.18 to 0.19) 
Depression subscale       
Usual care 67 1.67 [0.65]  59 1.64 [0.61]  
Memory Rehabilitation  68 1.71 [0.59] 0.10 
 (-0.11 to 0.31) 
69 1.77 [0.57] 0.13 
 (-0.08 to 0.34) 
Communication subscale       
Usual care  71 1.76 [0.65]  59 1.72 [0.59]  
Memory Rehabilitation 70 1.75 [0.58] 0.00 
 (-0.20 to 0.21) 
69 1.80 [0.59] 0.04 
 (-0.17 to 0.26) 
Difficulties in social 
interaction subscale 
 
  
 
  
Usual care 71 1.95 [0.57]  59 1.85 [0.52]  
Memory Rehabilitation 67 1.97 [0.51] 0.05  
(-0.13 to 0.23) 
63 1.97 [0.56] 0.11  
(-0.08 to 0.30) 
Impulsivity subscale       
Usual care  72 1.92 [0.61]  60 1.83 [0.56]  
Memory Rehabilitation 69 1.93 [0.55] N/A1 68 1.97 [0.59] N/A1 
       
Somatic subscale       
Usual care 69 1.95 [0.50]  56 1.79 [0.47]  
Memory Rehabilitation 68 1.97 [0.51] N/A1 66 1.92 [0.54] N/A1 
       
Fatigue subscale       
Usual care 70 2.01 [0.50]  59 1.92 [0.51]  
Memory Rehabilitation 68 1.97 [0.54] N/A1 66 2.02 [0.55] N/A1 
1 Impulsivity, somatic and fatigue subscales summarised using descriptive statistics only as per the SAP. 
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Notable events 
There were 11 notable events recorded during the trial; two occurred during contact with potential 
participants before consent, four occurred during memory rehabilitation groups and five were 
reported during follow-up visits. 
 
The events reported during memory rehabilitation included issues with group dynamics, such as 
disagreements between participants which were addressed within the group sessions.  The events 
reported during follow-up included inappropriate behaviour exhibited by some participants towards 
the RA. 
 
Protocol deviations 
All reported protocol deviations were reviewed by the TMG prior to data lock. None were 
considered to constitute violations of the protocol. 
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Chapter Four:  Health Economics 
 
Introduction and aim 
This chapter reports the methods and results of the economic evaluation conducted alongside the 
trial. The aim was to assess the cost-effectiveness of the group-based memory rehabilitation 
programme (the intervention) in addition to usual care compared to usual care alone. In line with 
NICE guidelines,79 a UK NHS and personal social services perspective was taken. 
 
Methods 
We took two approaches to the economic evaluation as follows: 
i. A within-trial evaluation to assess the cost-effectiveness of the group-based memory 
rehabilitation programme compared with usual care based on the time horizon of the trial (12 
months).  
ii. A decision analytic model to estimate the cost-effectiveness of the group-based memory 
rehabilitation programme compared with usual care over longer time periods. 
 
A summary of the health economic analyses was set out in the trial protocol with an agreed analysis 
plan in place prior to data lock and commencement of the analysis. 
 
Within-trial economic evaluation 
The primary economic analysis was a cost-utility analysis (incremental cost per Quality Adjusted 
Life Year [QALY] gained) at 12 months based on area under the curve analysis. In order to present a 
comparable time point of interest with the clinical analyses, we undertook additional analyses of the 
6-month follow-up data.  Secondary cost-effectiveness analyses were undertaken to assess the 
incremental cost per point improvement based on the primary clinical outcome (EMQ-p) and 
assessment of mood (GHQ-30) at 6-month follow-up in order to reflect the primary time point of 
interest, with additional consideration at 12-month follow-up to reflect a comparison of costs over 
potential maintenance of treatment gains over time. As the within-trial evaluation did not exceed 12 
months, costs and outcomes were not discounted. 
 
Resource use and costs 
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Resource use and associated costs were calculated across the following broad categories: 
• The implementation and delivery of the group-based memory rehabilitation programme, and; 
• Health and personal social care resource use. 
 
All resource data were valued in pound sterling (£) using published unit costs 80-82 at 2016 prices. If a 
current unit cost was not available, a unit cost from a previous version (e.g., earlier edition of the 
Personal Social Services Research Unit [PSSRU]) was used and inflated to 2016 costs using the 
Bank of England Inflation calculator.83 
 
Costs associated with the implementation and delivery of the group-based memory rehabilitation 
programme 
We estimated the cost of the implementation and delivery of the intervention during the trial using 
information from the trial team and data obtained within the trial (e.g., number of participants). The 
key resources and associated costs of delivering the intervention focused on the opportunity costs of: 
• Assistant psychologist (AP) training in the intervention 
• Delivery of the intervention by APs to trial participants. 
 
We assumed that in standard clinical practice, the intervention would be delivered in an NHS setting, 
thus the cost of travel, room hire or other capital costs were not included. Resources and associated 
costs related to research, and the management and administration of the trial were excluded. Costs of 
supplying course booklets, stationary and refreshments were included.  No provision for supervision 
was included in the intervention cost.  It is instead assumed that the costs and resources related to 
supervision are part of standard clinical practice for the delivery of any intervention by APs. 
 
The skill mix, time required, and grade of staff involved in delivering the intervention were obtained 
from information collated by the trial team. These costs were aggregated to give a total cost given the 
number of groups to which participants were allocated and the number of sessions offered. 
 
Individual-level resource use and associated cost within the group memory rehabilitation 
programme 
We assessed individual-level resource use using the SUQ, as previously described in Chapter Two. 
Resource use was initially summated across each time point for each individual into discrete 
categories (primary care, medication use within primary care, secondary care).  
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For primary care costs, we used published unit costs based on average contact times.80 We obtained 
NHS net prices for medications from the British National Formulary (BNF).81  Where the dosage and 
prescription length was recorded by the participant, the cost of the medication was calculated. Where 
the dosage or prescription length was either not recorded by the participant, or otherwise unclear, a 
cost of the standard adult dosage as per BNF dose advice was used. We calculated the use of 
secondary care attendances by applying unit costs from national published sources to the usage 
reported in the questionnaire.82 Where possible for in-patient admissions, the type of procedure and 
length of stay were matched and the National Average Unit Cost used. Where no length of stay was 
stated, the lowest National Average Unit Cost was used, based on the lowest casemix classification 
(CC) Score (i.e. 0-1).  As only a small number of participants did not report any length of stay, this 
approach was preferred to a weighted cost approach, which would have substantially over-estimated 
the cost of service use contacts. Where an unspecified or ambiguous visit to a hospital was indicated, 
but no length of stay was stated, an average General Surgery cost was used to ensure that these 
contacts were appropriately captured. 
 
Whilst the SUQ allowed participants to differentiate between resource use as a consequence of 
memory problems or for other reasons (e.g., other comorbidities), this information was not obtained 
for medication use. We decided, in consultation with the trial team, that it would be difficult for 
participants to classify resource use according to whether it was due to memory problems or other 
problems. Therefore, the decision was made to use total resource use (i.e., service use because of 
memory problems and because of other reasons) within the base case analysis. Appropriate 
sensitivity analysis was undertaken to assess the impact of including resource use attributed to 
memory problems only. 
 
Resource use and costs were summated to give an overall cost for the intervention arm (including 
intervention costs) and control arm over the trial period (12 months) with interim assessment at 6-
month follow-up also reported in order to reflect the time points of interest. The mean total cost and 
difference in mean total cost (with 95% confidence intervals) per participant between the 
intervention and control arms were compared using 2-tailed Student’s t-test, following the intention-
to-treat (ITT) principle. 
 
A description of unit costs associated with service resource and medication usage is presented in 
Appendix 20 and Appendix 21.  
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Health Utilities and Quality Adjusted Life Years 
Health-related quality of life (HRQoL) data were collated using the EQ-5D-5L questionnaire as 
described in Chapter Two. The reported EQ-5D-5L values were used to derive utilities based on the 
UK social tariff.84 Individual level utility scores across each assessment point were summated for the 
intervention and control arms with QALYs for each patient calculated based on the utility scores at 
different points using the area-under-the-curve approach (AUC). We assumed linear interpolation 
between the measurement points. 
 
Summary statistics across each time point were used to describe and compare QALYs between the 
two arms from baseline to 12 months for the primary analysis, with additional analysis to derive 
QALYs at baseline to 6-month follow-up. The impact of baseline imbalance in utilities was 
examined, with adjusted analyses on similar covariates (baseline score, treatment arm and site) 
undertaken commensurate with the statistical analysis methods of the clinical outcomes. Mean 
utilities and QALYs gained per participant were evaluated between the intervention and control arm 
using the difference-in-difference approach and compared using the Student’s t-test. 
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Clinical outcomes 
The primary outcome data (EMQ-p) and GHQ-30 scores were used to calculate a point improvement 
in score (as described in Chapter Two) at 6-month follow-up (as per the primary clinical analysis) 
and at 12 months (to assess whether an improvement is maintained over time). The analysis of the 
EMQ-p is commensurate with the clinical analysis, with a difference-in-difference approach adopted 
to determine the incremental effect of the intervention compared to usual care.  For the analysis of 
the GHQ-30, the GHQ (0-0-1-1) scoring methodology was applied.  This differs from the clinical 
analysis, which adopted the Likert (0-1-2-3) scoring methodology.  Higher scores on the EMQ-p are 
indicative of more frequent memory problems, and higher scores on the GHQ-30 are indicative of 
greater psychological distress. Therefore, ‘improvement’ over time would be characterised by a 
decreasing (-) score.  
 
Missing data 
The problems concerning missing data are particularly relevant to health economic analysis as 
missing items relating to healthcare service usage may undervalue the total costs, whilst missing 
outcome data may be correlated to effects as those individuals without information may be 
systematically different to those for whom all information is observed.85 A complete case analysis 
would therefore result in meaningful data being excluded.85 Therefore, we adopted appropriate 
techniques to provide a comprehensive investigation of the impact of missing data on our estimations 
of cost-effectiveness. 
 
For the questionnaires used within the economic analysis (i.e., EQ-5D-5L, EMQ-p, GHQ-30) we 
followed the same rules for missing data as applied to the analysis of clinical outcomes (see Chapter 
Two). In order to ensure comparable consideration was taken to missing data in relation to the SUQ, 
we devised similar rules with the trial team. 
 
For both costs and outcomes, two imputation methods were used for the health economic analysis. 
Simple imputation using the site specific treatment arm mean, and multiple imputation using chained 
equations (MICE) were undertaken on costs and outcomes for both 6- and 12-month follow-ups to 
impute missing items. Mean imputation provides a single estimate for each missing item. However, 
it is unable to account for the uncertainty inherent to missing data resulting in a smaller standard 
error and can result in biased estimates due to covariance and correlations being decreased in 
magnitude compared to alternative methods. The multiple imputation methods used were similar to 
the imputation of the primary outcome data performed, i.e., chained equations were undertaken 
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separately for each allocated arm under the assumption that data were missing at random (MAR) 
using similar predictor variable (with baseline EQ-5D-5L score used) with similar datasets included 
and results of imputed sets combined following Rubin’s rules.86 Due to the typically skewed 
distribution of cost data, predictive mean matching (PMM) was used. Missing outcome data were 
imputed using truncated regression to restrict imputations to the scores range. 
 
For the base-case cost-effectiveness analyses we used the multiply imputed data to construct 
incremental cost-effectiveness ratios (ICERs). The non-imputed and mean imputed data were 
presented to fully reflect the impact on the base-case ICERs when different scenarios for missing 
data are considered. 
 
Incremental-Cost Effectiveness Analysis 
As summarised in the description of the within-trial evaluation, a series of cost-effectiveness 
analyses were undertaken, with a cost-utility analysis undertaken as the primary analysis. This 
comparative analysis of incremental costs and effects can be summarised in terms of an ICER. 
 
The ICER can be represented as: 
𝐼𝐶𝐸𝑅 =
𝐶1 − 𝐶0
𝐸1 − 𝐸0
=
Δ𝐶
Δ𝐸
 
 
Where C1 and E1 are the costs and effects of the intervention arm and C0 and E0 are the cost and 
effects of the usual care arm; with ΔC and ΔE the incremental costs and effects of the intervention 
compared to usual care.   
 
The ICER is reported to determine the cost-effectiveness of the intervention compared to competing 
alternatives and aid decision-making. Whilst NICE reports a base cost-effectiveness threshold of 
£20,000 per QALY, cost-effectiveness is a spectrum rather than a dichotomy, with the maximum 
threshold increasing dependent upon the circumstances. The reported ICERs from our analysis are 
presented to assist the decision making process and are not an absolute statement on whether the 
intervention can be deemed cost-effective.  
 
We also calculated net monetary benefits (NMB) based on the following equation: 
𝑁𝑀𝐵 = Δ𝐸𝜆 − Δ𝐶 
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Net monetary benefit represents the value of the intervention in monetary terms given a willingness-
to-pay threshold λ.86 Where the incremental NMB, calculated as the difference in net monetary 
benefit between the intervention and usual care, is positive, the intervention is identified as cost-
effective at the given threshold relative to usual care.87 
 
For the cost-effectiveness analyses (i.e., incremental cost per point improvement in EMQ-p and 
GHQ-30 scores), no accepted willingness to pay (WTP) threshold could be identified. However, as 
these are based on important endpoints of relevance and importance to the assessment of the effect of 
memory problems, decision makers and clinicians can judge the results against different thresholds 
as part a full examination of cost-effectiveness. 
 
 
Sensitivity analysis 
A series of one-way sensitivity analyses (OWSAs) were undertaken to assess the impact of 
parameter and methodological uncertainty on the estimations of cost-effectiveness.  For primary and 
secondary outcomes, we assessed the impact of altering key parameters (i.e., costs, QALYs and 
outcomes scores) based on lower and upper 95% confidence intervals (CI) for incremental costs and 
outcomes on the base case ICER.  
 
We also assessed the extent of uncertainty based on imputation method as documented earlier. 
Scenario analysis was conducted to ascertain the potential impact over potential maintenance of 
treatment gains over time (as measured by the EMQ-p and GHQ-30) on the base-case ICER.  
Sensitivity analyses on the intervention cost were conducted on the available case analysis. 
 
Bootstrapping was undertaken to address the joint uncertainty and impact on the ICER; 1000 
simulations were undertaken using random sampling of the distributions of costs and outcomes, 
presented on a cost-effectiveness plane (CE) plane. The CE plane is presented as a scatter plot of the 
point estimates obtained as a result of the 1000 runs depicted in four quadrants (see Appendix 22) 
which can be summarised as follows:  
 
• North-west (upper-left) quadrant – The intervention is dominated by usual care. The intervention 
is more costly and less effective than usual care. 
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• North-east (upper-right) quadrant - Further evaluation required.  The intervention is more costly 
and more effective than usual care.  ICER computed to assess whether the net incremental health 
gain is worth the incremental cost. 
• South-west (lower-left) quadrant – Further evaluation required.  The intervention is less costly 
and less effective than usual care. ICER computed to assess whether the cost saving is worth the 
net incremental health loss. 
• South-east (lower-right) quadrant – Intervention is dominant compared to usual careand 
unambiguously preferred to usual care.  The intervention is less costly and more effective than 
usual care. 
 
For consistency with the CE plane for QALYs, the incremental effect for the EMQ-p and GHQ-30 
was reversed (i.e., multiplied by -1) such that a positive value was representative of an improvement 
in everyday memory or mood. Cost-effectiveness acceptability curves (CEACs) were produced to 
present the probability of the intervention being considered as cost-effective at alternative WTP 
thresholds. For the cost per QALY CEAC, the WTP threshold based on NICE guidance 79 was used. 
No similar WTP threshold exists for the clinical outcomes.  
 
Long Term Cost-Effectiveness 
We constructed a decision analytical model to extrapolate the findings from the trial to estimate cost-
effectiveness of the group-based memory rehabilitation programme compared to usual care beyond 
the trial horizon of 12 months. A cost-utility analysis was undertaken. We based the modelling 
exercise on extrapolating results from the within-trial analysis to longer-term cost per QALY 
estimates supplemented with data sources from the literature, and where necessary clinical opinion 
from the trial team. 
 
Modelling Approach 
We developed a Markov model given that TBIs are considered to have a disease and treatment 
pathway consistent with chronic health conditions, e.g., with evolving progression of the condition 
over time. The decision analytic Markov model was developed using Microsoft Excel with coding in 
Visual Basic for Applications (VBA). The Markov model simulated the costs and QALYs over a 
minimum 5-year time horizon using four mutually exclusive health states (low, moderate, high, and 
death). As the time-horizon exceeded 12 months we discounted all future costs and QALYs at the 
UK Treasury discount rate of 3.5% per year as recommended by NICE.79 
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The cost and utility data reported at 12-month follow-up within the trial were used alongside external 
data such as UK life tables and standard mortality ratios, to estimate longer-term costs and QALYs. 
Time horizons of 5- and 10-years were chosen for the analysis although the model was constructed to 
undertake a life-time horizon, should suitable data be available in the future. Whilst this was an 
amendment from the original protocol, where a lifetime horizon was proposed, we chose this 
approach based on a) the availability of plausible estimates of longer term effects from external 
literature sources and b) where necessary, appropriate clinical assumptions could be made by the trial 
team. 
 
We categorised psychological distress into three mutually exclusive states of no/mild distress, 
moderate distress, or severe distress, pro-rating the categories defined by Rai et al. 88 for the GHQ-12 
to the GHQ-30 as follows: 
• GHQ-30 scores less than 5.5 were classified as mild 
• GHQ-30 scores between 5.5 and 17.5 were classified as moderate 
• GHQ-30 scores of 17.5 or greater were classified as severe. 
 
Participants could also transition to a fourth state of death, which is an absorbing state with 
participants unable to transition out of this state. 
 
Model Structure 
The basic outline of the Markov model used to evaluate the longer-term cost-effectiveness of the 
intervention is illustrated in Appendix 23. For the intervention and usual care arms, separate Markov 
processes with different input parameters are obtained. The same structure, depicted in Appendix 23 
would, however apply. 
 
We assumed that the sample adhered to the trial protocol. For each 6-month cycle, individuals were 
categorised into one of three mood states based on their GHQ-30 score, or the absorbing death state. 
We assumed that psychological distress in individuals with TBI can either worsen or improve, i.e., 
the GHQ-30 score could either increase or decrease from the value observed at the previous time 
point. Moreover, transitions from the high mood state to the low mood state (or vice-versa) were 
permitted in addition to sequential transitions, i.e., high to moderate to low. Aside from death, we 
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assumed that there were no intervention-related adverse events that impacted upon an individual’s 
state of psychological distress. 
 
Model Inputs 
The base-case analysis was estimated using a cohort of 10,000 patients.  The population was 
consistent with the trial, i.e., men represented 72% of the model cohort with a mean age of entry of 
45 years. Base-case transition probabilities were defined by those observed in the trial between 
baseline and 6-month follow-up, and 6-month and 12-month follow-up. For intervals beyond the 12-
month within-trial horizon, we assumed that that the 6-month to 12-month transition probabilities 
would persist at intervals beyond 12-months. This assumption was made due to a lack of published 
data beyond 12-months follow-up. 
 
To account for missing items observed in the trial, mean imputed data were used, despite the 
limitations highlighted earlier, to provide a single transition for each individual and prevent scenarios 
of an individual occupying multiple states at a given time point. This provides a single set of 
transition probabilities at each time point. Sensitivity analysis was conducted to determine how 
changes in transition probabilities influenced the ICER to account for this potential bias.  
 
Details of the model parameters used are presented in Appendix 24. A summary is presented in Table 
13. 
 
Clinical/epidemiological inputs 
No deaths were reported in the trial. We therefore assumed that patients would not be at increased 
risk of death from the intervention. Additionally, the model did not include any provision for the 
occurrence of serious adverse events, as these were not assessed within the trial. In the model, all-
cause age-related mortality rates were based on the Office of National Statistics (ONS) National Life 
Tables: England and Wales 89 based on mid-year population estimates for 2013-2015. Considering 
that individuals with TBI are recognised to have a higher all-cause mortality rate and shorter life 
expectancy than those of the general population 88, 90 we adjusted general population mortality using 
the TBI standardized mortality ratio (SMR) presented by Brooks et al.91 
 
Costs 
All costs were based on the within-trial costs reported (see Appendix 25). Costs associated with each 
health state defined by the model included the costs relating to the delivery of the intervention and 
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any healthcare service usage recorded by participants over the preceding 6-month interval. For cycles 
beyond the in-trial 12-month horizon, costs are assumed to remain unchanged in relation to the 6-12 
month cycle. No provision was made in the model for any top-up sessions relating to the 
intervention. 
 
Utilities 
The model applied different utility values to each of the non-dead health states, differentiated by 
intervention or usual care arms. In accordance with the manner in which costs are handled, all 
utilities were based on those observed in the within-trial analysis reported. For cycles beyond the 
within-trial 12-month horizon, utilities were assumed to remain unchanged in relation to the 6-12 
month cycle. 
 
Incremental cost effectiveness ratio 
Similar to the within-trial analysis, ICERs were calculated based on a 5- and 10-year horizon. As this 
was a cost-utility analysis, we applied the same approach in relation to assessing the base case results 
against the WTP threshold set out by NICE.79 
 
Sensitivity analysis 
Similar sensitivity analyses were conducted as outlined in the within-trial evaluation methods. 
We conducted a series of one-way sensitivity analyses (OWSAs) by manipulating the values of the 
main parameters in the model (i.e., costs, QALYs, transition probabilities) and assessed the 
subsequent impact on the ICER. Table 13 presents a list of OWSAs conducted to the model. 
 
Table 13: Base-case Model Inputs and OWSAs 
Parameter Lower Base Case Upper 
Age 30 years 45 years 65 years 
Discount Rate 1.5% 3.5% 5.0% 
Intervention Cost £116.90 £167 £217.10 
Cost per Cycle in GHQ State -30% Various (State dependent) +30% 
Utility per Cycle in GHQ State -30% Various (State dependent) +30% 
Transition Probability to Lower GHQ State -20% Various (State dependent) +20% 
Transition Probability to. Higher GHQ States -20% Various (State dependent) +20% 
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In general, the upper and lower values of the input parameters were arbitrarily chosen, but were 
considered an appropriate estimate given the uncertainty inherent to the parameter values. The lower 
discount rate value of 1.5% is consistent with NICE guidelines.79 Costs and QALYs are discounted 
at the same rate under all scenarios. Changes to the transition probabilities to either higher or lower 
states also affect the probability that an individual remains within the state, but not to any other 
transitions including death. 
 
To account for the simultaneous uncertainty regarding the input parameters, a probabilistic 
sensitivity analysis (PSA) was conducted. CE planes and CEACs illustrating the probability that the 
intervention is cost-effective across a range of threshold values were produced. 
 
 
Results 
Intervention Cost 
The resource use and associated costs of delivering the intervention are summarised in Table 14 with 
a detailed account of each component presented in Appendix 25. The total cost of memory 
rehabilitation per patient was £167. 
 
Table 14: Resources and costs associated with the training and delivery of the intervention 
Resource 
Total 
(£) 
Training Costs (9 Sites) 1,818 
Admin Costs (35 Groups) 875 
Session Costs (350 Sessions) 24,500 
Participant Costs (171 participants) 1,402 
TOTAL COST 28,595 
Cost per Participant (171 participants) 167 
 
The first resource intensive component was AP training in the memory rehabilitation programme. 
One clinical psychologist (based on NHS Agenda for Change 8a grade) delivered the training across 
all sites. We did not include any travel costs as training would occur on-site in standard practice. In 
addition, the opportunity cost of each of the APs attending the training was included; with costs 
estimated using published unit costs.80 The training was a one-off session. Ongoing 
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monitoring/supervision of the APs during the trial (one-to-one supervision between the AP and 
clinical psychologist) was considered part of standard clinical practice. Sensitivity analysis was 
conducted to determine the impact of the addition of supervision on the intervention cost and the 
resulting ICERs. 
 
The second component was the delivery of the intervention by the APs across the trial sites. This was 
based on the 171 participants randomised to the intervention arm; each allocated to one of 35 groups 
of four to six individuals across the nine sites involved in the trial. Each group that received the 
intervention was invited to attend 10 sessions giving a total of 350 sessions. We made the 
assumption that the costs of delivery would be the same for each session, regardless of attendance, 
e.g., if participants withdrew or did not attend.  We assumed that the delivery of one 90-minute 
session required 2 hours from the AP, inclusive of the preparation. Administrative support was also 
included for 1 hour per group in total for the 10 sessions delivered. 
 
Resource use and costs 
The resource use and associated costs for available cases is summarised in Appendix 26 with 
summary of costs presented in Table 15. We observed that visits to primary care services and use of 
inpatient services are the primary cost drivers for both the intervention and usual care arms. The 
number of participants with inpatient appointments for either arm at each time point is small (<10%), 
yet costs attributed to these contacts are high with a maximum of £9,444. In contrast, a much higher 
proportion (>65%) report costs associated with visits to primary care or medication, however, these 
costs are typically much lower yet more frequent. The costs per patient associated with resource use 
in the intervention and control arms across the time points is summarised in Table 15. 
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Table 15: Non-Imputed (Available Cases) Cost Summary by Trial Arm 
  Mean (£) 
[SD] 
95% CI (£) Difference in 
Means (£) 
(95% CI)a 
p-value 
BASELINE 
    
Usual care (n = 155) 453.325 
(849.822) 
(318.480, 
588.171) 
45.990 
(-171.671, 
263.652) 
0.697 
Memory Rehabilitation (n = 170) 499.315 
(1112.967) 
(330.805, 
667.826) 
6-MONTHS 
Usual care (n = 111) 587.123 
(1543.587) 
(297.903, 
876.344) 
-255.336 
(-362.273, -
148.398) 
<0.001*** 
Memory Rehabilitation (n = 120) 328.078 
(687.450) 
(203.816, 
452.339) 
12-MONTHS 
Usual care (n = 101) 355.034 
(824.026) 
(195.565, 
514.504) 
18.353 
(-24.782, 
61.488) 
0.403 
Memory Rehabilitation (n = 121) 372.092 
(824.026) 
(211.335, 
532.848) 
TOTAL SERVICE RESOURCE USAGE COSTS UP TO 12-MONTHS 
(excluding intervention cost) 
Usual care (n = 93) 1184.905 
(1877.947) 
(811.303, 
1584.820) 
83.624 
(-302.345, 
469.593) 
0.670 
Memory Rehabilitation (n = 103) 1281.685 
(2001.812) 
(890.452, 
1672.919) 
TOTAL COSTS UP TO 12-MONTHS 
(including intervention cost) 
Usual care (n = 87) 1184.905 
(1877.947) 
(782.903, 
1586.908) 
250.624 
(-135.345, 
636.593) 
0.202 
Memory Rehabilitation (n = 102) 1449.329 
(2001.812) 
(1054.196, 
1844.461) 
TOTAL COSTS UP TO 6-MONTHS 
(including intervention cost) 
Usual care (n = 110) 1002.020 (610.984, 30.113 0.873 
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(1537.326) 1393.056) (-340.619, 
400.845) Memory Rehabilitation (n = 119) 1026.477 
(2052.678) 
(746.240, 
1306.714) 
a Controlling for baseline service usage costs as a covariate 
 
The total mean cost per participant was £1,449 (std. err. £199.19) and £1185 (std. err. £202.22) for 
the intervention and control arms respectively. The aggregate service use is £84 (CI £302.35, 
£469.59) higher for the intervention arm than for the usual care arm. Including the cost of the 
intervention, the intervention arm have higher total costs compared to usual care of £251 (CI -
£135.35, £636.59) at 12-months and £30 (CI -£340.62, £400.85).  
 
Impact of missing data on cost estimations 
SUQ data was obtained for 98.8% of participants at baseline (see Appendix 27). However, at 6- and 
12-month follow-up missing questionnaires were seen in approximately 20% and 29% respectively 
in each arm; with more missing data in the control arm (36%) compared to the intervention arm 
(29%) at 12-month follow-up. The planned approach to missing data was subsequently adopted. 
 
 
 
Whilst numerical differences were seen depending on the imputation method used, there was no 
statistically significant impact on the total costs, with the intervention arm showing higher total mean 
cost per participant at 12-month follow-up. With the inherent issues associated with skewed costs, 
imputed costs were subsequently bootstrapped to derive mean and 95% confidence intervals to be 
used in the base-case (see Table 16). 
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Table 16: Base-case (multiple imputed) cost used in the cost-effectiveness analyses 
  
Mean 
[std. err.] 
95% CI Difference 
[std. err.] 
p-value of 
difference 
  
  
 
BASELINE 
 
  
 
Usual Care (n = 157) 
456.152 
(70.206) 
(317.402, 594.902) 
44.447 
(111.880) 
0.691 
Memory Rehabilitation (n = 171) 
500.599 
(85.388) 
(332.019, 669.178) 
6-MONTHS 
Usual Care (n = 157) 
576.071 
(126.547) 
(325.267, 826.875) 
-247.060 
(138.067) 
0.075 
Memory Rehabilitation (n = 171) 
329.011 
(63.367) 
(203.293, 454.729) 
12-MONTHS 
Usual Care (n = 157) 
391.396 
(86.106) 
(220.008, 562.784) 
8.718 
(116.615) 
0.941 
Memory Rehabilitation (n = 171) 
400.115 
(80.789) 
(239.918, 560.311) 
TOTAL SERVICE RESOURCE USAGE COSTS UP TO 12-MONTHS 
(excluding intervention cost) 
Usual Care (n = 157) 
1423.619 
(197.761) 
(1031.972, 1815.265) 
-193.894 
(249.157) 
0.437 
Memory Rehabilitation (n = 171) 
1229.724 
(154.178) 
(924.911, 1534.538) 
TOTAL COSTS UP TO 12-MONTHS 
(including intervention cost) 
Usual Care (n = 157) 
1423.619 
(197.761) 
(1031.972, 1815.265) 
-26.894 
(249.157) 
0.914 
Memory Rehabilitation (n = 171) 
1396.724 
(154.178) 
(1091.910, 1701.538) 
TOTAL COSTS UP TO 6-MONTHS 
(including intervention cost) 
Usual Care (n = 157) 
1032.222 
(165.900) 
(703.941, 1360.504) 
-35.613 
(201.227) 
0.860 
Memory Rehabilitation (n = 171) 
996.610 
(119.018) 
(761.459, 1231.760) 
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Outcomes 
EQ-5D-5L utilities 
The EQ-5D-5L utility scores and QALY increments, based on area-under-the-curve analysis, across 
the trial assessment points based on the available cases for the intervention and usual care arms are 
presented in Table 17.
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Table 17: EQ-5D-5L utilities and QALY gained at 6- and 12-months (available cases) 
Control 
Memory Rehabilitation 
Adjusted Differencea 
Time period 
EQ-5D-5L 
mean score 
[SD] 
Change over 
time 
Time period 
EQ-5D-5L 
mean score 
[SD.] 
Change over 
time 
Baseline (𝒏 = 𝟏𝟓𝟕) 
0.581 
(0.275) 
 Baseline (𝒏 = 𝟏𝟕𝟏) 
0.637 
(0.266) 
 
 
6 Months (𝒏 = 𝟏𝟏𝟗) 
0.581 
(0.299) 
-0.020 
6 Months (𝒏 =128) 
0.642 
(0.269) 
-0.007 0.060*** 
(0.015, 0.105) (-0.063, 0.024) (-0.047, 0.033) 
12 Months (𝒏 = 𝟏𝟐𝟑) 
0.625 
(0.253) 
-0.001 
12 Month (𝒏 = 𝟏𝟎𝟔) 
0.644 
(0.264) 
-0.010 0.019 
(-0.026, 0.063) (-0.043, 0.041) (-0.047, 0.027) 
QALY gain at 6 
Months 
-0.005 
(-0.016, 0.006) 
QALY gain at 6 
Months 
-0.002 
(-0.012, 0.008) 
0.003 
(-0.002, 0.008) 
QALY gain at 12 
Months 
0.000 
(-0.011, 0.010) 
QALY gain at 12 
Months 
-0.002 
(-0.012, 0.007) 
-0.004 
(-0.016, 0.007) 
a Controlling for baseline utility as a covariate 
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At 6-months, small QALY losses were observed for both arms; incremental QALY gains between 
arms of 0.003 were not significant at the 5% level (𝑝 = 0.154).  At 12-months small QALY loses 
were observed with the small incremental QALY gains of 0.004, which were not significant at the 
5% level (𝑝 = 0.743). The incremental QALY gains calculated from the mean imputed and multiple 
imputed data are analogous to those from the available cases presented above, with a small gain for 
the intervention arm at 6-months and a small gain for usual care at 12-months. 
 
Impact of missing data 
There was 100% completion of the EQ-5D-5L questionnaire at baseline, with subsequent missing 
data increasing at 6- and 12-months across both arms. There was no clear pattern evident. Most 
participants who missed one follow-up assessment had another follow-up assessment available. A 
descriptive profile of EQ-5D-5L completion is presented in Appendix 28. 
 
When the EQ-5D-5L utility and subsequent QALY gains were examined using the imputation 
methods, there were no statistically significant differences in within group utility scores or between 
group QALY gains at either 6- or 12-month follow-ups. Table 18 presents the results based on 
multiple imputation, and the results of the mean imputation are presented in Appendix 29. 
 
Table 18: EQ-5D-5L scores and QALY gains over time (6- and 12-month) based on multiple 
imputation. 
Control 
(𝒏 = 𝟏𝟓𝟕) 
Intervention 
(𝒏 = 𝟏𝟕𝟏) 
Time period 
EQ-5D-5L 
mean score 
Change over 
time 
Time period 
EQ-5D-5L 
mean score 
Change over 
time 
Baseline 0.581  Baseline 0.637  
6 Months 0.553 
-0.028 
6 Months 0.625 
-0.012 
(-0.071, 0.015) (-0.050, 0.027) 
12 Months 0.589 
0.008 
12 Months 0.624 
-0.013 
(-0.034, 0.051) (-0.050, 0.023) 
QALY gain at 6 
Months 
-0.007 
(-0.018, 0.004) 
QALY gain at 6 
Months 
-0.003 
(-0.013, 0.007) 
QALY gain at 
12 Months 
0.004 
(-0.017, 0.025) 
QALY gain at 
12 Months 
-0.007 
(-0.025, 0.012) 
97 
 
  
Similar to the results presented in Table 17, there was a small QALY loss in both arms at 6-month 
follow-up (-0.003, 95% CI -0.013, 0.007 versus -0.007 95% CI -0.0018, 0.004) in the intervention 
and control arms respectively. At 12-month follow-up, this translated into small QALY gains in the 
control arm (0.004 95% CI -0.017, 0.025) compared to a small QALY loss (-0.007 95% CI -0.025, 
0.012). These differences did not reach statistical significance with 𝑝 = 0.536 and 𝑝 = 0.442 for 6-
months and 12-months respectively. 
 
Clinical outcomes 
The EMQ-p scores used for the health economic analyses are presented in Table 7 and Table 10 in 
Chapter 3, and the per point improvements at 6- and 12-month follow-up for the GHQ-30 are 
presented in Table 19.  There was an improvement in everyday memory compared to baseline for 
both intervention and control arms at both 6- and 12-month follow-up, but the difference between 
arms was not statistically significant at the 5% level. 
 
Table 19: GHQ-30 scores at 6- and 12-month follow-up 
Usual Care 
Memory Rehabilitation 
 
Time 
period 
GHQ-30 
score 
[SD] 
Change over 
time 
Time 
period 
GHQ-30 
Score 
[SD] 
Change over 
time 
Adjusted 
Differencea 
Baseline 
(𝒏
= 𝟏𝟓𝟕) 
9.6 
(8.1) 
 
Baseline 
(𝒏 = 𝟏𝟕𝟏) 
9.7 
(8.0) 
 
 
6 Months 
(𝒏
= 𝟏𝟏𝟎) 
9.1 
(8.4) 
0.0 
6 Months 
(𝒏 =124) 
8.6 
(8.1) 
-1.2 
-1.2 
(-2.1, -0.3) (-1.3, 1.4) 
(-2.7, 0.2) 
12 Months 
(𝒏
= 𝟏𝟎𝟑) 
8.2 
(8.1) 
-0.4 
12 Month 
(𝒏 = 𝟏𝟏𝟗) 
8.4 
(8.8) 
-1.1 
-0.7 
(-1.7, 0.4) 
(-2.1, 1.3) (-2.7, 0.5) 
a Controlling for baseline covariates 
 
Whilst there was a significant difference between arms in the GHQ-30 at 6-months with the 
intervention arm having a greater reduction in mood score, there was no significant difference for the 
EMQ-p at either follow-up, or for the GHQ-30 score at 12-months. The finding of a significant 
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difference at 6-months in the GHQ differs from the findings of the statistical analysis of clinical 
outcomes. This is due to the use of GHQ scoring in the health economic analysis, rather than Likert 
scoring of the GHQ-30 used in the analysis of clinical outcomes. 
 
Impact of missing data 
There were missing data within the questionnaires at each of the follow-up assessments. When the 
imputation methods were examined, numerical differences were seen but these did not demonstrate 
any statistically significant differences. The results of the multiple imputed data are presented in 
Table 20 and mean imputations are reported in Appendix 30 and Appendix 31. 
 
Table 20: EMQ-p and GHQ-30 Score – Multiple Imputation 
Multiply Imputed 
Usual Care 
(𝒏 = 𝟏𝟓𝟕) 
Memory Rehabilitation 
(𝒏 = 𝟏𝟕𝟏) 
Time 
period 
EMQ-p 
score 
Change over time 
Time 
period 
EMQ-p 
Score 
Change over 
time 
Difference 
p-value 
Baseline 
50.075 
(1.953) 
 Baseline 
47.363 
(1.606) 
 
 
6 
Months 
45.622 
(2.165) 
-4.453 6 
Months 
40.589 
(2.061) 
-6.774 0.297 
(-7.756, -1.149) (-9.732, -3.817)  
12 
Months 
44.370 
(2.248) 
-5.705 12 
Months 
40.248 
(2.112) 
-7.115 0.560 
(-9.118, -2.292) (-10.442, -3.788)  
Time 
period 
GHQ-30 
score 
Change over time 
Time 
period 
GHQ-30 
Score 
Change over 
time 
Difference 
p-value 
Baseline 
9.601 
(0.646) 
 Baseline 
9.670 
(0.613) 
 
 
6 
Months 
9.901 
(0.771) 
0.300 6 
Months 
8.972 
(0.683) 
-0.698 0.320 
(-1.127, 1.727) (-2.065, 0.669)  
12 
Months 
10.143 
(0.944) 
0.542 12 
Months 
9.474 
(0.771) 
-0.195 0.551 
(-1.324, 2.409) (-1.763, 1.372)  
 
Reductions in the multiple imputed EMQ-p were observed for both the intervention and usual care 
arms at 6- and 12-month follow-up. These results are commensurate with those presented in the 
analysis of clinical outcomes. The difference is not statistically significant for either 6-month (𝑝 =
0.297) or 12-month follow-up (𝑝 = 0.560). 
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For the GHQ-30 score, whilst a reduction was observed for the intervention arm for both 6- and 12-
month follow-up relative to baseline, an increase was observed relative to baseline for the usual care 
arm at both follow-ups. This indicates an improvement in mood for the intervention arm compared to 
a worsening in mood for the control arm. There is a worsening in mood for both intervention and 
control arms between the 6- and 12-month follow-ups. Despite using the GHQ (0-0-1-1) scoring 
rather than the Likert (0-1-2-3) scoring, these results are broadly comparable to the clinical outcomes 
with no statistically significant difference in GHQ score within or between arms at either 6-month or 
12-month follow-up.  
 
Incremental Cost-Effectiveness Analyses 
The results for the cost-utility analysis (CUA) are presented in Table 21. This presents the ICER 
when calculated on the available cases and multiple imputed approaches. 
 
Table 21: Incremental cost per QALY gain at 6- and 12-month follow-up 
  
Incremental 
Cost 
Incremental 
Effect 
ICER (£) 
NMB1 
(£) 
NMB2 
(£) 
 12-Months 
Q
A
L
Y
 
Multiple 
Imputed 
-26.895 -0.011 2,445 
SW Quadrant 
Further Investigation 
Required 
-193.10 -303.10 
Available 
Cases 
250.62 -0.004 -62,656 
NW Quadrant 
Usual Care Dominant 
-330.62 -370.62 
Mean 
Imputed 
-26.197 -0.023 1,139 
SW Quadrant 
Further Investigation 
Required 
-443.80 -663.80 
 6-Months 
Q
A
L
Y
 
Multiple 
Imputed 
-35.612 0.004 -8,903 
SE Quadrant 
Intervention Dominant 
115.61 155.61 
Available 
Cases 
30.11 0.003 10,038 
NE Quadrant 
Further Investigation 
Required 
29.89 59.89 
Mean 
Imputed 
-38.146 0.001 -38,146 
SE Quadrant 
Intervention Dominant 
58.15 68.15 
1 NMB at WTP threshold of £20,000 
2 NMB at WTP threshold of £30,000 
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The base case analysis (incremental cost per QALY gained at 12-months, based on multiple 
imputation) showed the intervention to be slightly less effective but less costly than usual care, with 
a reported ICER of £2,445. At 6 months the intervention was found to dominate usual care with 
small numerical incremental lower costs and QALY gain, but these were not statistically significant. 
Uncertainty was seen in these findings as the results changed at 12 and 6 months, depending on the 
imputation method used. 
 
Incremental cost per point improvement in EMQ-p and GHQ-30 scores at 6- and 12-months 
Table 22 presents the ICERs for the EMQ-p and GHQ-30, respectively. As higher scores in the 
EMQ-p represent more frequent forgetting in daily life, and higher scores in the GHQ-30 indicate 
more psychological distress, negative incremental effects will be observed where the intervention is 
more effective than usual care. To calculate appropriate ICERs consistent with those for the EQ-5D-
5L presented above, the denominator of the equation presented earlier is multiplied by −1. 
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Table 22: Incremental Cost-Effectiveness – EMQ-p and GHQ-30 at 6 and 12 months 
  Incremental 
Cost 
Incremental 
Effect 
ICER (£) 
 12-Months 
E
M
Q
-p
 
Multiply 
Imputed 
-26.895 -1.4 -19.07 
SE Quadrant 
Intervention Dominant 
Available 
Cases 
250.62 -4.8 52.21 
NE Quadrant 
Further Investigation Required 
Mean 
Imputed 
-26.197 -2.5 -10.58 SE Quadrant 
Intervention Dominant 
G
H
Q
-3
0
 
Multiply 
Imputed 
-26.895 -0.7 -36.49 
SE Quadrant 
Intervention Dominant 
Available 
Cases 
250.62 -0.2 1,253.10 
NE Quadrant 
Further Investigation Required 
Mean 
Imputed 
-26.197 0.4 70.23 SW Quadrant 
Further Investigation Required 
 6-Months 
E
M
Q
-p
 
Multiply 
Imputed 
-35.61 -2.3 -15.34 
SE Quadrant 
Intervention Dominant 
Available 
Cases 
30.11 -2.1 14.34 
NE Quadrant 
Further Investigation Required 
Mean 
Imputed 
-38.146 -1.4 -27.36 
SE Quadrant 
Intervention Dominant 
G
H
Q
-3
0
 
Multiply 
Imputed 
-35.61 -1.0 -35.68 
SE Quadrant 
Intervention Dominant 
Available 
Cases 
30.11 -1.6 18.82 
NE Quadrant 
Further Investigation Required 
Mean 
Imputed 
-38.146 -0.2 -205.09 
SE Quadrant 
Intervention Dominant 
 
 
For both the EMQ-p and GHQ-30, the primary analysis based on multiple imputed data at 12 and 6 
months, the intervention dominates usual care due to non-statistically lower costs and improved 
EMQ-p and GHQ-30 scores.  Again, uncertainty arises with the results varying based on the 
imputation method used. 
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Sensitivity analysis 
Sensitivity analysis using the upper and lower 95% confidence interval bounds for the primary cost 
per QALY gained analysis is presented in Appendix 32. For two of the four scenarios, the 
intervention is found to be dominated by usual care (higher costs and smaller effects for the 
intervention), namely where the upper 95% CI for both costs and outcomes is used and when the 
upper bound for costs is compared to the lower bound for QALYs. 
In summary, the results suggest the findings are not robust to changes in these parameters. 
 
A further sensitivity analysis (based on available cases) was conducted on the intervention cost by 
including the costs of AP supervision by a clinical psychologist.  Based on the recommendations of 
good practice presented by The British Psychological Society,92 we assumed that a minimum of three 
one-to-one supervision sessions of one hour were required at each site for the 10-weekly sessions.  
For a band 8a clinical psychologist at £66 per hour, and mid-band 5 AP at £35 per hour 80 a total of 
£2,727 is incurred in addition to the total cost of rehabilitation presented in Table 14.  The effect on 
total cost and the ICER is presented in Table 23. 
 
Table 23:   Cost Summary with inclusion of supervision in intervention cost 
  Mean (£) 
[SD] 
95% CI (£) Difference in 
Means (£) 
(95% CI)a 
p-value 
TOTAL COSTS UP TO 12-MONTHS 
(including intervention cost) 
Usual care 
(n = 88) 
1184.905 
(857.282) 
(782.903, 
1586.908) 
275.539 
(-70.275, 678.959) 
0.111 
Memory 
Rehabilitation 
(n = 102) 
1460.444 
(1678.229) 
(1130.808, 
1790.079) 
TOTAL COSTS UP TO 6-MONTHS 
(including intervention cost) 
Usual care 
(n = 110) 
1002.020 
(1190.572) 
(610.984, 
1393.056) 
56.313 
(-314.273, 
426.898) 
0.765 
Memory 
Rehabilitation 
(n = 119) 
1040.160 
(1634.991) 
(743.358, 
1336.962 
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a Controlling for baseline service usage costs as a covariate 
 
Table 24:   Incremental cost-effectiveness with inclusion of supervision in intervention cost 
 
Incremental 
Cost 
Incremental 
Effect 
ICER (£) 
NMB1 
(£) 
NMB2 
(£) 
12-Months 
Available 
Cases 
275.54 -0.004 -68,885 
NW Quadrant 
Usual Care Dominant -355.54 -395.54 
6-Months 
Available 
Cases 
56.313 0.003 18,771 
NE Quadrant 
Further Investigation 
Required 3.687 33.687 
 
Taking into account these changes to the intervention costs, the intervention is found to be dominated 
by usual care at 12 months, and an ICER of £18,771 per QALY gain at 6 months is calculated (Table 
24). 
 
The results of the bootstrapped replications are presented as a cost-effectiveness (CE) plane and 
corresponding cost-effectiveness acceptability curve (CEAC) for the primary cost-utility analysis 
(cost per QALY). As the multiple imputed base-case for the EMQ-p and GHQ-30 at both 6-months 
and 12-months presented in Table 22 indicate dominance of the intervention (lower cost and higher 
effects than usual care), CE planes and CEACs are not presented for the secondary cost-effectiveness 
analyses. The CE plane for cost per QALY gained is presented as a scatter plot of the point estimates 
obtained as a result of the 5,000 runs; depicted as quadrants (NE, SE, SW, NW), as illustrated in 
Appendix 22. The CEAC graph shows the probability of the intervention being considered as cost-
effective at different monetary thresholds.  
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Figure 2 and Figure 3 present the CE plane and CEAC for the incremental cost per QALY gain at 12 
months. 
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Figure 2: Cost-Utility plane for the bootstrapped incremental cost per QALY at 12-months 
 
 
 
Figure 3: CEAC for the bootstrapped incremental cost per QALY at 12-months 
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Figure 2 characterises the uncertainty in the cost-effectiveness analysis with point estimates 
distributed across all four quadrants. The largest proportion of estimates are located in the SW 
quadrant consistent with the intervention being less costly and less effective than usual care. The 
associated CEAC in Figure 3 shows that at threshold values of £30,000 per QALY gained or less, the 
probability that the intervention is cost-effective is 24.5%%. At a threshold of £20,000 per QALY 
gained, the probability of cost-effectiveness is 29.0%. The CE plane and corresponding CEAC for 
the additional 6 months analysis is presented in Figure 4 and Figure 5. 
 
Figure 4: Cost-Utility plane for the bootstrapped incremental cost per QALY at 6-months 
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Figure 5: Utility Cost-Effectiveness Acceptability Curve – 6-Months 
 
 
In accordance with the 12-month results presented in  
 
 
  
109 
 
Figure 2, at 6-months the CE plane presented in Figure 4 further demonstrates the uncertainty 
inherent in the cost-effectiveness results with all four quadrants populated. In contrast to the 12-
month analysis, the largest proportion of estimates is located in the SE quadrant consistent with the 
intervention being less costly and more effective than usual care; the intervention dominates usual 
care. The incremental effect is however small.  The associated CEAC presented in Figure 5 
illustrates that at a WTP threshold of <£20,000 per QALY gained the intervention has a68.1% 
probability of being cost-effective. For a higher WTP threshold of <£30,000 per QALY gained the 
intervention a 70.6% probability of being cost-effective. 
 
It is however noted that bootstrapped replications of the cost per point improvement ICERs for the 
EMQ-p and GHQ-30 based on mean imputed data produced CE planes somewhat analogous to those 
presented in Figure 3 and Figure 4 for the cost-utility analysis.  Estimates are spread across all four 
quadrants further demonstrating the uncertainty observed within the results. For both secondary 
outcomes at 12-months and 6-months, the largest proportion of point estimates are located in the NE 
and SE quadrants associated with the intervention being more effective than usual care. 
 
In Table 22 the base case cost-effectiveness analyses, based on multiple imputed data, of the EMQ-p 
and GHQ found the intervention to dominate usual care at both 6- and 12-months. The resulting CE 
planes for these outcomes show the largest proportion of bootstrapped estimates in the SE quadrant, 
consistent with the intervention being less costly and more effective than usual care The probability 
of intervention dominance  based on the proportion of bootstrapped estimates in the SE quadrant of 
the CE plane was 43.9% and 50.1% for the EMQ-p and 43.5% and 50.8% for the GHQ-30 at 6- and 
12-month follow-up respectively. 
 
For both secondary health economic outcomes, the probability of dominance at 6-months is larger 
than that at 12-months consistent with the larger effect observed for the shorter time horizon.  
Similar levels of dominance are however observed for the EMQ-p and GHQ. 
 
Results of the model-based analysis to estimate longer-term cost-effectiveness   
For a longer-term perspective, the cost-effectiveness estimates were extrapolated over horizons of 5- 
and 10-years using the Markov model presented in Appendix 23. The deterministic cost-effectiveness 
results obtained from the model for both horizons are presented in Appendix 33 and Appendix 34. 
The base-case analysis is estimated using a cohort of 10,000 patients aged 45 years, corresponding to 
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the average age of participants in the ReMemBrIn trial. The base-case results are presented in Table 
25. 
 
 
Table 25: Longer-Term Cost per QALY estimations of the memory rehabilitation programme 
versus usual care 
 Intervention Control Incremental  
Horizon Cost (£) QALY Cost (£) QALY Cost (£) QALY ICER (£) 
5-Year 3,599.08 2.952 3,404.27 2.651 194.81 0.301 646.36  
10-Year 6,451.25 5.340 5976.51 4.806 474.73 0.535 887.76  
 
The results indicate that for a 5-year horizon the intervention is cost-effective with an incremental 
cost of £194.81 and incremental QALY of 0.301, resulting in an ICER of £646.36 per QALY.  For 
the 10-year horizon, the intervention is again shown to result in larger costs and larger QALYs with 
an ICER of £887.76. These results suggest that for longer horizons, the intervention is cost-effective. 
 
One-way sensitivity analyses (OWSA) were conducted on the base-case results presented in Table 
25 using a variety of parameter inputs including the age at which individuals enter the model, the 
discount rate applied to costs and outcomes, the value of the intervention cost, costs and outcomes 
related to each health state, and transition probabilities. A summary of the results is presented in 
Appendix 33 and Appendix 34. 
  
In general, the ICER results for both 5-year and 10-year horizons appear robust to OWSA changes in 
the input parameters, with positive incremental costs and QALYs. However, by reducing the cost 
associated with one-cycle in each health state by 30%, for both the 5-year and 10-year horizons, the 
intervention becomes less costly compared to usual care, with incremental QALYs remaining 
positive.  This represents a shift from the base-case where the intervention was more effective and 
more costly than usual care, generating a positive ICER (NE quadrant of CE plane), to a scenario 
where the intervention is dominant, being less costly but more effective than usual care (SE quadrant 
of CE plane). 
 
The OWSAs presented above, suggest that the base-case scenario is generally insensitive to a range 
of model inputs. The results of the probabilistic sensitivity analyses, which consider uncertainty 
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regarding a variety of input parameters simultaneously, are illustrated in CE planes and 
corresponding CEACs (see Figure 6 to Figure 9).  
 
Figure 6: Probabilistic Cost-Effectiveness Plane -5 Year Horizon 
 
Figure 7: Probabilistic Cost-Effectiveness Acceptability Curve-5 Year Horizon 
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Figure 8: Probabilistic Cost-Effectiveness Plane -10 Year Horizon 
 
Figure 9: Probabilistic Cost-Effectiveness Acceptability Curve-10 Year Horizon 
 
 
Consistent with the CE planes for the within-trial analysis (incremental cost per QALY gain at 12-
month and 6-month follow-up), the 5-year and 10-year horizons illustrate substantial uncertainty 
with all four quadrants populated. The CEACs presented in Figure 7 and Figure 9 indicate that the 
probability that the intervention is cost effective is around 45% for both 5- and 10-year time horizons 
irrespective of the threshold value, 𝜆. 
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Discussion 
Overall, the findings from the health economic evaluation show that there was an ambiguity in the 
findings, with results not remaining robust when different imputation approaches and time-points 
were taken into account and when the impact of variation of costs and outcomes were examined, 
given the small (statistically non-significant) differences between treatment arms and wide 
confidence intervals seen. 
 
The CE planes for all outcomes and time horizons in the analyses showed that dispersion of point 
estimations of incremental costs and effects across all four quadrants and illustrates the uncertainty in 
our findings.  
  
 
It is important to consider our results from not just the technical assessment of cost-effectiveness. 
Memory rehabilitation was estimated to cost £167 per participant (based on the multiple imputed 
data), this resulted in small cost differences between treatment arms. We also based our comparator 
on usual care and given the pragmatic nature of the trial, this could have reflected different models of 
care within the arm and associated resources (and costs) in delivery. However, the interpretation of 
small effect sizes are also important in the health economic analysis; the small, numerical QALY 
gains seen are not statistically significant and are unlikely to be considered clinically meaningful. 
The analysis of our findings based on a ‘point per improvement’ basis also should be fully 
considered in light that no statistically significant or clinical meaningful differences are seen, as 
reported in Chapter Three.  
 
There are limitations to our health economic analyses. The methods used to collect resource use 
within this population should be carefully considered, e.g., whether recall bias was a potential issue 
(albeit this applying to both arms). The SUQ used and data derived were not sufficiently clear to 
enable us to fully examine resource use specifically attributed to memory problems, thus we took all 
resource use and costs into account. Whilst this may have over-estimated costs, this applied to both 
arms. We undertook a thorough investigation of our data, given the scenario that in the non-imputed 
analysis, costs were higher for the memory rehabilitation arm at baseline and 6-12 months.  Whilst 
there was evidence of a reduction in service usage costs between baseline and 6-months for the 
intervention arm, after including the cost of the intervention the difference in costs between the 
intervention and usual care arms was not statistically significant. 
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One potential limitation with the analysis of service usage data is that we only considered a health 
and personal social services perspective; by the nature of rehabilitation, there could be potential 
downstream effects on the patient, carer and family and wider impact in terms such as employment, 
which have not been evaluated by this study. Instead, the health economic analysis used the EQ-5D-
5L as its primary outcome measure. This provided a more ‘general’ assessment of patient outcomes 
and could (in theory) capture those broader aspects of HRQoL rather than a single dimension of 
mood or function as captured in the other trial outcomes. However, the trade-off is often that the use 
of such a generic measure can result in a lack of precision in estimation of health effect.  
 
We fully considered whether or not it was feasible and plausible to undertake a model-based analysis 
to explore the longer-term cost-effectiveness of the intervention that had been set out in the protocol 
and health economics analysis plan. In light of the trial findings, we chose to do so to ensure we 
conducted a comprehensive analysis as originally set out. We have placed appropriate caution on any 
interpretation of the longer-term effects based on our model-based evaluation, although it does give a 
useful indicator of expected benefits. We have created a de-novo model (as far as the data and 
external evidence allowed us) using the results of a robustly conducted trial alongside reasonable, 
albeit basic, assumptions to examine the longer-term cost-effectiveness. This may provide a basis for 
future health economic analyses to be conducted. 
 
We argue that decisions to amend the original protocol to not undertake a life time horizon but base 
it on mid-term horizons (5- and 10-year) were a sensible compromise. There is not sufficient 
available evidence to precisely determine the costs and outcomes associated with longer-term 
horizons. Therefore, extrapolating the trial results in the model to a lifetime horizon would likely 
lead to misleading or erroneous conclusions. 
 
One potential area for consideration is how future analyses could capture some of the ‘wider’ 
benefits of such interventions, given the qualitative findings indicate potential for benefit across 
broader outcomes. This raises potential questions including further examination for patient 
preferences for interventions to support memory rehabilitation and the inclusion of other outcomes of 
interest to fully consider the impact of group memory rehabilitation in terms of value for money. 
 
The trial has raised important questions in its discussion on how future trials should be developed in 
this area. Similar questions should also be tested in the development of any future health economic 
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evaluations. Whilst the conclusions from our health economic analyses are appropriately cautious as 
they must be made ‘on the evidence’ as presented, the need for high quality methodically driven but 
‘real-world’ led economic evaluations must be part of any future agenda in deriving the evidence on 
whether to invest in this area of patient care. 
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Chapter Five:  Qualitative Feedback Interviews 
 
Rationale 
Mixed methods designs are increasingly being used in evidence-based practice research.93, 94 
Qualitative research can explore and explain the real-world complexities involved in participating in 
a trial or being a recipient of healthcare interventions. This nested qualitative study provided a 
separate evaluation of memory rehabilitation, which served as an adjunct to the primary trial. We 
believed insights from this qualitative data and analysis would serve to inform developments of the 
intervention programme in the future and to generate user-oriented proposals about areas for further 
investigations. 
 
Aims 
While there is an overlap in terms of the broad aims of the trial and this study, the specific focus of 
this study was an experiential and phenomenological one, with a view to provide a nuanced account 
of participant experiences. The aims of this sub-study were therefore linked to the main aim of the 
trial (i.e., to evaluate the effectiveness of memory rehabilitation in TBI), but specifically, we wanted 
to explore patient-participant experiences of: 
- being involved in the trial, 
- receiving group memory rehabilitation,  
- using strategies to cope with their memory, and 
- usual care. 
 
Methods 
We conducted one-to-one feedback interviews with participants enrolled in the trial within two 
months of completion of the 6-month follow-up assessment.  
 
Sampling 
Participants were purposefully selected from a sub-group of trial participants who had originally 
consented to being invited for these interviews. We used a maximum variation sampling strategy, a 
purposive sampling technique used to identify and select participants who have important shared 
experiences that cuts across different sub-groups based on demographic, clinical, or other variables 
(see 95 for a review of purposive sampling techniques). Maximum variation sampling was used to 
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achieve multiple perspectives that demonstrate real-world complexities.96 The selection strategy was 
designed to include participants with varying demographic features (age, gender, ethnicity) and 
levels of memory impairments (based on the patient version of the Everyday Memory Questionnaire 
[EMQ-p] conducted at baseline) and sites. Once the first few people were interviewed, we then 
selected others who were different from the first interviewees (in terms of demographics and 
memory impairments). This iterative process continued until we recruited the required number of 
participants.   
 
Sample size 
In determining the sample size for the feedback interviews, we followed Onwuegbuzie and Leech’s 
97 recommendation of identifying a corpus of studies that use the same design and wherein data 
saturation was reached, and examining the sample sizes in these studies. Data saturation (the point at 
which further data collection is unlikely to lead to new insights) has been described as an ‘elastic’ 
concept, and the desirable degree of saturation depends, in part, on the nature and breadth of the 
research question.98 Indeed, the concept of saturation is a contested one, and there is no one-size-fits-
all method to reach data saturation.99, 100 
 
Our meta-synthesis of published qualitative studies of group-based memory rehabilitation 101 
revealed sample sizes of 10 to 38 participants. We therefore opted to recruit 32 participants, aiming 
for 16 from the control arm and 16 from the intervention arm. We believed that data saturation would 
be achieved with this number of interviews. Furthermore, this would allow us to sample four people 
each from the intervention and control arm from four sites. However, as we increased the number of 
sites as the trial progressed, we altered the sampling frame to recruit at least two people from each 
site where possible. 
 
Procedure 
Consent to be interviewed was checked with the participants selected for this study, and where 
participants were willing to participate, the interview was arranged. To reduce social desirability 
response bias, a researcher who was not involved with the participants’ assessment or treatment 
conducted the interviews. This researcher was not blind to the treatment allocation, as they needed to 
follow a semi-structured interview schedule (see Appendix 35), which included general questions for 
all participants, and specific questions to those who had received the intervention and those who 
were in the control arm. 
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The interviews took place face-to-face in participants’ homes. At the interview, the researcher 
reiterated the purpose of the interview and informed the participants that the interview was being 
audio recorded on a dictaphone. During the interviews, participants were invited to discuss their 
thoughts as freely as possible, although the researcher used the interview schedule to guide the 
interview agenda, and to create some comparability across interviews.102 Participants were assured 
confidentiality and had the option to pause, stop the interview or skip questions if they chose to. The 
audio recordings were transcribed verbatim by a professional transcription service.  
 
Analysis 
The transcripts were analysed using framework analysis.103 Framework analysis is a specific type of 
thematic analysis 104 that is atheoretical, and allows researchers to collapse large datasets of 
qualitative data along broad areas of research interest determined a priori. It is more deductive and 
structured than other forms of thematic analysis, and usually yields a matrix of cases and codes, with 
data in cells that contain chunks of the interview data. Through a constant-comparison method (both 
within and across cases), the data are then reduced to the key themes. Themes can be broken down to 
subthemes and further subsidiary themes. This method is useful in multidisciplinary research teams 
with more than one researcher analysing the data.104 
  
Two researchers (SC and HC) read and re-read the interview transcripts a number of times to 
familiarise themselves with the data. Each separately conducted a line-by-line coding of half the 
transcripts before swapping over to check the codes. Disagreements were resolved by discussion 
with another researcher (RdN). Thereafter, we created a ‘master map’ based on the aims of this sub-
study, which served as the framework to map the data onto. Mind-maps for each transcript based on 
their coding, which were discussed with the third researcher (RdN), were then created. Use of mind-
maps is not common in framework analysis, but we included this step because mind-maps allow us 
to see how the various themes, sub-themes and codes connect with each other, thereby suggesting 
possible relations between them. We then populated the framework matrix, and four themes (and 
sub-themes) were extracted from the condensed data. 
 
Below, we discuss each theme and subtheme. For each theme and sub theme we provide relevant 
quotes from participant feedback interviews, with quotes attributed to participants (demarcated by a 
unique participant identification number, gender, age, and treatment allocation). We describe our 
results using quantity measures such as “all participants”, “most”, “half”, “almost half” and “a few” 
with this order representing decreasing values. 
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Quality considerations 
To ensure the quality of the study, we adopted the criteria by Mays and Pope 105 by providing a clear 
exposition of methods of data collection, sampling and analysis; our reflexive position; attending to 
negative cases; the context; and ‘fair dealing’ with respect to providing different perspectives so as to 
not privilege one group over another. 
 
We approached this sub-study from a critical realist epistemological perspective. Critical realism, 
where language is assumed to be used to construct our social realities but these constructions are 
limited to that which is grounded in the material world,106 functions as a “general methodological 
framework for research but is not associated with any particular set of methods” (p. 182).107 This 
perspective helps researchers explain social events or issues and suggest ways to address these.107 
 
Results 
Thirty-two participants were interviewed. Interviews were conducted in two tranches, lasting 
between 13 and 69 minutes. The participants were 10 women and 22 men, who were between the 
ages of 24 and 68 at randomisation; all were white. The time since TBI ranged from approximately 9 
months to more than 34 years. We recruited participants from eight of the nine sites. We did not 
recruit from one site because the site was closed to recruitment before participants reached the 6-
month follow-up. Details of the sites we recruited from and the composition of the participants in 
terms of whether they were intervention or usual care participants are shown in Appendix 36.  
 
Feedback on the trial 
The first theme relates to how people felt about taking part of the trial. Participants described their 
motivation for taking part, experiences of specific trial procedures, experiences of the assessment 
procedures, preferences for the group format, and reactions to the allocation. Participants also 
provided their overall impressions of the trial (see Figure 10). 
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Figure 10: Thematic map of ‘Feedback on trial’ theme. 
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Motivation for taking part 
Most participants appeared to be driven to take part in the study by altruism. Many spoke of wanting 
to help others. 
 
"I’m just helping you guys out so that, so that what you can get can help somebody else out, 
you know, in the future." (01003, male, 58 years, usual care) 
 
"So to go onto this [study] was good because I thought if this gets other people out of a 
situation that I was in then that’s why I wanted to do it." (06049, male, 68 years, usual care) 
 
Participants also thought that by taking part in the study, they would get some information about 
their memory problems and some help to deal with these problems. 
 
"It was a matter of floundering around thereafter [after discharge from hospital], er that’s 
why when this [study] came up we jumped at the opportunity to take part." (04005, male, 56 
years, intervention) 
 
"I wanted to get as much information as I could really about how it [brain injury] affects me 
and how I can deal with it. So that was my idea of going along with it [the study] in the first 
place." (05042, male, 51 years, intervention) 
 
Trial procedures 
Participants had positive feedback regarding the organisation of the trial. In addition, the qualitative 
study was praised for providing an opportunity to raise more attention about TBI and memory 
rehabilitation, including the need for increased funding for such services. 
 
"From the practical viewpoint I thought the study was done well. You’re kept informed 
people, errm, kept appointments, etc. it was all organised, kept to there’s no issues there." 
(04010, male, 55 years, usual care) 
 
"I’m very pleased that I’ve been part of this feedback… I think it [trial] is a very good thing 
to do I think more emphasis, more pressure on the powers that be to allocate more funding to 
this [TBI memory rehabilitation] because it’s very important and it does not receive 
anywhere near the amount of attention that it deserves." (07012, male, 37 years, usual care) 
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The trial also helped control arm participants understand that they were not alone with their TBI, 
despite not receiving the memory rehabilitation groups as part of the intervention. 
 
"It’s [taking part in the trial] opened my eyes an awful lot, of how thing are, and how I’ve got 
to accept my life is now and it’s not just me, there’s god knows how many out there are in the 
same position." (01005, male, 43 years, usual care) 
 
"It [taking part in the trial] was good, it, it was informative, it helped me understand I’m not 
the only one with the problems." (01017, female, 30 years, usual care) 
 
Experience of assessments 
Overall participants were positive about the assessments they had as part of the trial. The fact that 
they were conducted at home or at other convenient locations (e.g., local hospital) was highlighted as 
ideal in terms of travel arrangements and as a way of allowing participants to remain in their comfort 
zone. Additionally, participants found the assessments helpful with regards to highlighting their 
specific memory impairments and strengths. 
 
"The assessments have been done; it was either at [names location] when we were first 
looking at enrolling in the course, not exactly far to travel and then all the assessments and 
discussions afterwards have been here at the home - so that’s ideal for us." (03004, female, 
39 years, intervention) 
 
“Well my psychologist comes here [home]... I prefer it, it’s awful, it’s terrible… but this is my 
comfort zone… I feel better in my own home... I feel safe. I don't know why, it’s weird isn't it." 
(09018, female, 51 years, usual care) 
 
"It was helpful that they [researchers] got back to me and showed me where the deficits were, 
with where I was lacking sort of thing." (03022, male, 25 years, usual care) 
 
However, one participant reported that she did not like the assessments highlighting her specific 
memory weaknesses. 
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"I’m not sure if it [assessment] wasn't useful but I didn’t really like the faces when she 
[researcher] showed me the faces [from an assessment]... which is probably because I 
needed more help with that, do you know what I mean? ...But I knew that was a weakness and 
I don’t like weakness.” (08007, female, 41 years, intervention) 
 
Whilst most participants were positive about the assessments, some felt they were challenging and 
not necessarily reflective of real-life memory concerns. Additionally, one participant did not 
understand the need for repeated assessments throughout the trial. 
 
"I found it [the assessments] taxing in a way... some of the tests were OK, others because of 
problems with my memory and that was a bit taxing, do you know what I mean, but overall it 
was good to do, if that makes sense, yeah." (09018, female, 51 years, usual care) 
 
“It’s [assessments] either focused on stuff I’m not very good at anyway, so like remembering 
names and faces, you’ve got so many faces and they all look similar and they all have like are 
relatively the same... they’re people I don’t really know or care about, I’m not going to 
remember them.” (08002, male, 31 years usual care) 
 
"You start thinking, why are you doing this [the assessment]... and then I had a reassessment 
and we had to do it all again which I thought was quite, well we’ve been here before haven’t 
we, do we need to do it again kind of thing." (03005, female, 56 years, intervention) 
 
Preference of rehabilitation format 
The majority of participants stated that they would rather experience memory rehabilitation as part of 
a group than on a one-to-one basis, with the reason often being the benefit of sharing ideas with other 
participants who have first-hand knowledge of having a TBI. 
 
"In a group it’s much better cause then you can get the impact of someone else and they can 
give you an idea or vice versa so, erm but individual, no disrespect, but it’s like, yeah well 
I’m telling you all these things and you’ll try tell me, but they [group members] know what 
it’s like, but the actual person [assistant psychologist] doesn’t." (01010, female, 24 years, 
intervention) 
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"It would probably be helpful to have a group-based thing... because one-on-one you don’t 
necessarily know what you, what you currently want help with... if you’re in a group you kind 
of hear other people’s struggles and you kind of come out and go ‘yeah, I have some 
problems with that.’” (08002, male, 31 years, usual care) 
 
However, a few participants would have preferred one-to-one memory rehabilitation. They felt that 
one-to-one sessions would allow only their relevant concerns to be addressed, allowing discussion of 
personal issues, and because of difficulty concentrating in group situations. 
 
"One-to-one probably because I have had, I’ve been to other group sessions where I’ve found 
it’s not necessarily been very relevant which might sound a bit stupid... but I’ve definitely 
found, from my experiences, one-to-one sort of treatment and rehabs have been more useful. 
Because you can talk about your personal issues." (04008, female, 25 years, usual care) 
 
"I would probably prefer one-to-one... I tell you why because in [rehabilitation centre] 
sometimes I cannot concentrate because there’s so much rambling, because there’s people 
with different levels of head injury, right, and some of them really ramble on and on and on 
and on and arrgghh! So sometimes I have to sit right at the back." (09018, female, 51 years, 
usual care) 
 
A few participants were unsure as to their preference, due to being able to see the benefits of both 
one-to-one and group rehabilitation formats. 
 
"I don’t know. I think you could cover the same things more tailored to individuals faster [in] 
one-to-one, but then obviously, you know, other patients… have got contributions to make 
that the person that’s running it [groups] don’t have, as well, and… it is quite nice to see 
other people with the same issues." (07002, female, 29 years, intervention) 
 
"I think given my character I’m a very vivacious person I probably would have been good in 
a group but as you might have seen today I can go off on a tangent and I’m probably better 
with someone focusing on me... I don’t think a group would have been the wrong thing but 
better might have been I should try both." (07012, male, 37 years, usual care) 
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Reaction to ‘control’ allocation 
Half of the participants randomised to the control group stated that they had no problem with their 
allocation. This was often due to an understanding of the need for a control arm, whilst one 
participant expressed relief at not having to fit the weekly memory rehabilitation groups into his busy 
working schedule. 
 
"Which I don’t have a problem with [being in a control group] because I do understand the 
concept of how you need to have a baseline and I’d said that I was quite happy to participate 
in the study and, yes you’ve got to have willing baseline otherwise a study’s meaningless." 
(04010, male, 55 years, usual care) 
 
"Kind of a bit relieved... a bit of me was worrying, thinking ‘how am I going to squeeze that 
[rehabilitation sessions] in with everything else?’" (08002, male, 31 years, usual care) 
 
However, a few participants were disappointed with being allocated to the control arm because they 
had hoped to receive the intervention, which they believed would improve their memory. 
 
"It would have been nice to have been in the other [i.e., treatment] group… Just to see what 
you were doing and if it worked and made a difference." (04008, female, 25 years, usual 
care) 
 
"I was a little disappointed actually I was hoping that I might erm, experience something new 
that would help my memory." (04009, male, 46 years, usual care) 
 
A few participants misunderstood the randomisation process, and believed that it was their 
performance on the baseline assessments that decided their allocation. 
 
"I didn’t really mind which, which group I’d, I‘d end up in er cause obviously we went 
through the various er questions and, that determine over time which group you went into." 
(03014, male, 27 years, usual care) 
 
"It [the study test] was to see whether I’d be allocated into the, a group to go on to other tests 
or another different group, which obviously, which wouldn’t go onto the tests." (03022, male, 
25 years, usual care) 
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Overall impressions of trial 
When asked for their overall impressions of the trial, a few participants mentioned the personal 
characteristics of the trial staff. 
 
"All the assistants that have been involved in the study with me have been you know very easy 
going and explained everything to me." (03014, male, 37 years, usual care) 
 
"I would like to say that erm all the people I’ve met and talked to have been very happy and 
very polite and very pleasant." (04009, male, 46 years, usual care) 
 
Overall, participants expressed satisfaction with taking part in the trial, but when asked specifically 
for suggestions for improvement they recommended: control arm participants being sent the 
intervention manual at the end of the trial, a crossover study design (so everyone got the 
intervention), a wider variety of assessments, more frequent assessments, more detailed feedback on 
assessments, and a written timescale of key study dates (e.g., assessments). 
 
"Maybe the number maybe there could be more assessments, that would have been more 
helpful and give me a better idea between one and the next." (07012, male, 37 years, usual 
care) 
 
Experience of the rehabilitation group 
The second theme related to how participants randomised to receive the intervention experienced the 
memory rehabilitation groups. Participants described the timing of the intervention in relation to their 
TBI, the format of the group, the content of the intervention manual, their experience of the group 
facilitator and the perceived effects of the group (see Figure 11). 
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Figure 11: Thematic map of ‘Experience of group’ theme. 
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Timing of intervention 
Participants randomised to the intervention group stated that they would have preferred to receive the 
memory rehabilitation sooner after their TBI; however, “not too soon” due to difficulty processing 
information immediately after their injury. 
 
"Yes, earlier would have been good… But not right at the beginning, because right at the 
beginning, it would have just gone in one ear and out the other, effectively." (07002, female, 
29 years, intervention) 
 
"Personally, from my point of view, it [memory rehabilitation] would have helped me if it 
was like 6-12 months after the accident rather than four years later." (03004, female, 39 
years, intervention) 
 
Although, participants in the control arm were not asked specifically about timing of the memory 
rehabilitation, one control arm participant’s feedback is valuable here. This participant felt that there 
was a need for memory rehabilitation at the optimal time after TBI. She described a lack of 
engagement with a neurorehabilitation centre in the year after her TBI. 
 
"They [clinical staff] were quite keen to do different courses and different things with me but 
at the time I was very reluctant, I just wasn't in the right frame of mind I think, but had it 
been further down the line, because I was still quite unwell and not myself after the accident 
and I just wasn't interested." (04008, female, 25 years, usual care) 
 
The extended length of time between participants’ TBI and the intervention meant that some 
participants found it challenging to adopt the new strategies being taught in the memory 
rehabilitation group. 
 
"So trying to learn, it's like with a head injury and that you, you're learning stuff like, it's like 
you're learning from new kind of thing, but trying to learn new strategies like, oh what was 
the one she [assistant psychologist] said, like a dictaphone for instance, see that wouldn't 
work for me, so I wouldn't have tried it." (01010, female, 24 years, intervention) 
 
"I'd muddled through and found strategies that worked for me and then to be thrown into a 
group, that's the wrong term to use but to attend that group, and I'd be thrown 101 other 
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strategies it's like, hang on a minute I'm doing the, I'm using these strategies and it works for 
me and I can forget all those strategies and look at applying new ones and that takes effort 
and it takes energy and it takes thinking whereas had I not been going into a routine and 
using some of my own strategies I might have been a bit more susceptible to taking some of 
those on board." (03004, female, 39 years, intervention) 
 
This was linked to participants having already developed their own strategies. Almost half of the 
participants in the intervention arm already knew some of the strategies taught in the memory 
rehabilitation group due to either working them out themselves or attending other rehabilitation 
sessions.  
 
"Er yeah the, these strategies er, the strategies er I used most, I found at least half of them I 
use anyway." (01012, male, 59 years, intervention) 
 
"I was doing quite a lot of it anyway from my own work but there were some extra tips that I 
picked up." (08007, female, 41 years, intervention) 
 
Format 
The majority of participants described benefits gained from the group format of the memory 
rehabilitation. This included a feeling of not being alone with their TBI, sharing experiences with 
people in a similar situation, conversing with people who understand (as opposed to a lack of 
understanding outside of the group), social interaction and sharing ideas or strategies. 
 
"We both [participant and other group member] found that talking to other people who'd had 
brain injury made you feel more normal, made you feel like it wasn't just you." (05053, male, 
32 years, intervention) 
 
"… the good thing about it [group] was the problems that the other people at the group were 
having which were the same as mine with the memory and everything, very, very similar." 
(06045, male, 56 years, intervention) 
 
"I liked meeting others who've had brain injury and how they go about their day to day life 
and conversing really erm on how… other people you know in the, in the work, in their day-
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to-day life do not always understand you, maybe you're a bit slower or a bit, you know." 
(03001, female, 54 years, intervention) 
 
"The benefit of the group was to erm [pause] to realise that er, [pause] that, that I could get 
out and about and, and interact with these people socially." (01012, male, 59 years, 
intervention) 
 
"It was really good to see us like, not only me giving 'em ideas but them, them throwing ideas 
back at me, maybe that they haven't tried yet." (01010, female, 24 years, intervention) 
 
Participants also commented on the composition of the group in relation to group attendance, the 
benefits of seeing other people with TBI looking well, feeling like a “fraud” due to self-comparison 
of ability compared to those with more severe disabilities in the group, and conflicts within the 
group. 
 
"The other thing as I say, sadly er a, a couple of the guys erm didn't turn up, I mean one was 
working… I just thought it was a shame that erm people didn't turn up." (04005, male, 56 
years, intervention) 
 
"The hopes and dreams of these people [participants] have been er have been shattered you 
know, where, and er because of their circumstances but still they were, still they were happy 
within themselves and that to me was, that was important." (01012, male, 59 years, 
intervention) 
 
"When you listen to the other people [participants] and especially two of the other people 
and you think oh my god it happened so long ago and they're still really struggling. And it 
was really, it used to upset me, I felt like a fraud." (03005, female, 56 years, intervention) 
 
"I'd had enough of it and I just said 'will you shut up, you're putting me off' [to another group 
member] and it was like, even though everyone else was thinking it, I was the only one that 
had to say it but I thought no, it’s no use for me, you're spoiling it [attending the group] for 
me, because I even thought of not going because the thought of seeing her [participant] again 
I thought oh, here we go." (05042, male, 51 years, intervention) 
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Most participants were satisfied with the format of the memory rehabilitation group. However, the 
following suggestions were made when participants were specifically asked for ways we could 
improve the intervention: have more group sessions, longer sessions so that the information could be 
taught at a slower pace, the use of social events before and after the intervention, and a follow-up 
group to check maintenance of memory strategy use. 
 
"Apart from being able to erm [pause] do the course for a longer period of time to be able to 
actually utilise things, [pause] but what I, what I want and what is really achievable, I don’t 
know if it’s feasible." (01015, male, 33 years, intervention) 
 
"Instead of having I don't know how many hours in a session I, I thought that if you could get 
an afternoon session, now maybe you classify it as too long, to go through things, I'd say a 
little bit slower." (04005, male, 56 years, intervention) 
 
"I think the group was such a nice group I think we should be a good thing to organise like at 
the end of it was sit down and have a night out or go to the pub or something." (04002, male, 
24 years, intervention) 
 
"Well whether it was between the sessions or, erm if the sessions continues say, if they 
continued like, you know say you meet once every three months or once every, whatever and 
you, you met up with those people and you, and you know perhaps the lady [assistant 
psychologist] or, or somebody from the memory place said you know have you, how've you 
been getting on with your er, your diaries, have you got all your diaries, have you been filling 
them out regularly." (03003, male, 55 years, intervention) 
 
Content of the manual 
Almost half of the participants reported positive feedback on the content of the manual used in the 
memory rehabilitation groups. This included an appreciation of the group tasks, the belief that the 
structure of the sessions was good and stating that the language used in the manual was clear. 
 
"You have activities toward the end of each week, that's good, because sometimes it is the 
practical experience of doing something that actually kind of consolidates the learning of it." 
(09008, male, 33 years, intervention) 
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"But I think the way it was set out was good, the way the leaflets - well, like a booklet 
explaining everything, which you followed where they explained what they were trying to do." 
(05042, male, 51 years, intervention) 
 
"So the material was clear and concise and targeted so I don't think er, I don't think anything 
could be [improved]." (01012, male, 59 years, intervention) 
 
However, one participant felt that the manual was written in a way that was difficult to understand. 
 
“I think there are elements of it which are written in PhD language." (09008, male, 33 years, 
intervention) 
 
In terms of negative feedback, a few participants stated that each session contained too much 
information. Additionally, one participant reported that the content was repetitive, whilst another 
expressed a strong dislike for a particular relaxation exercise. 
 
"If I had to be really picky it was just that some of the sessions were very intense and there 
was a lot of information in that." (03004, female, 39 years, intervention) 
 
"I think some of the stuff was repetitive. Because I'd never come across these sort of 
strategies they were using for improving memory, I found it a bit confusing, Some sort of 
overlapped with each other. I'm trying to think, what am I trying to do with it? It's just like 
the last bit or something else." (05042, male, 51 years, intervention) 
 
"There were certain points where it was - there was one page, I remember exactly what page 
it was, it really, it just pressed my button of ‘I don't like this!’ It was page, I think it was 74, 
and it talked about relaxing…. and I remember thinking I'm not going to relax. I'm not being 
told to relax. What made me totally not relax was being told to relax." (09008, male, 33 
years, intervention) 
 
Group facilitator 
Half of the participants spoke positively about the facilitator (assistant psychologist) who led the 
memory rehabilitation groups. In particular, participants praised the facilitators’ knowledge, skill and 
positive personality traits. 
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"[Facilitator] was very good and she listened to, we'd get into our own little debates and you 
know sort of, you sit there for a minute and she was very good at explaining things and she'd 
go over things at the beginning of the next session." (03005, female, 56 years, intervention) 
 
"I thought [facilitator] was she was a nice person. I mean she was very, she was like, she 
obviously, you could tell she obviously cared by what she was doing it wasn't just pay check. 
So that was nice." (04002, male, 24 years, intervention) 
 
However, one participant felt that the group facilitator treated him differently compared to other 
group members. This was particularly in relation to how the facilitator was perceived to spend more 
time and attention on some individuals and not others.  
 
"He [other group member] could see there was a – I don’t want to say ‘favouritism’, but it 
was like – it was like he would get…60% of attention, if you like. And the other one would get 
30% and I’d get 10% [Laughing]. It wasn’t equal.” (09006, male, 53 years, intervention) 
 
Effects of the group 
All participants reported positive effects of attending the memory rehabilitation group. Besides the 
general positive comments ("I found it all helpful" [05053, male, 32 years, intervention]), 
participants commented on learning new strategies, the reinforcement of existing strategies, 
increased external strategy use, improvement in memory, increased understanding of how memory 
works, improvement in mood, increased confidence, reduced frustration/increased acceptance, and 
improved contact with group members outside of the group. 
 
 "But now you guys have given me more techniques like how to use them, my phone, my 
 laptop, my iPad, so ermm and erm I'm erm my card in my wallet, just check and they're all 
 there and I texted me my card in my wallet."  (04002, male, 24 years, intervention) 
 
"I'm going to say reiterated, er what, what we'd found that we were doing the right things." 
(04005, male, 56 years, intervention) 
 
"Memory wise, well I write a hell of a lot more down now so, I don’t forget half of much on 
that sense of things." (01015, male, 33 years, intervention) 
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"My wife says it [memory] has [improved], yes it has [pause and sighs]… I think it's 
improved." (04005, male, 56 years, intervention) 
 
"I suppose I'm more understanding, I've got more understanding of how brain injuries affect 
you, especially your memory, day-to-day things." (05042, male, 51 years, intervention) 
 
 
"It's given me confidence for a start to be able to travel outside of me little bubble, before it 
came to that point I never could quite get on a bus." (01015, male, 33 years, intervention) 
 
"I mean it's got better since I've been going to the group especially, has got better I'm not 
getting, I'm not getting as frustrated when people move things." (01010, female, 24 years, 
intervention) 
 
"One of the girls there [name], I mean, we met a couple of times, yeah for coffee and it was 
nice, really nice." (03001, female, 54 years, intervention) 
 
However, two participants reported that the groups had a negative impact on their mood. One 
participant found it very upsetting to hear the other group members talk about their struggles with 
their TBI (see quote from participant 03005 under Format of group sub theme), whilst another 
occasionally worried about her use of strategies. 
 
"It's just err a reminder to be me to try and be, as you know, as more on the ball or more, 
more, but that gives me, that aches, how, how can I put it, that gives me a headaches when I 
worry or con-concern or not so concern, when I am thinking about that too much." (03001, 
female, 54 years, intervention) 
 
Strategy use 
Participants from the intervention group spoke about the strategies that they were taught in the group, 
and which ones they found helpful or unhelpful. We covered this in some of the quotes related to 
effects of the group in the theme above. This theme therefore relates to the participants’ use of 
strategies to improve their memory that were learnt outside the group. Participants described 
strategies that they learned and were using prior to their TBI, strategies that they generated 
135 
 
themselves, strategies that were offered by other sources, and the significance of their strategy use 
(see Figure 12). 
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Figure 12: Thematic map of “Strategy use” theme. 
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Learned pre-TBI 
A minority of participants reported developing memory rehabilitation strategies before their TBI as 
part of their employment. 
 
"Several years before the accident I’d done some, I’d learnt some memory techniques for use 
in work when, when I was a consultant, erm and for use around presentations so I’ve learnt 
like pegging and erm you know sort of weaving in a story." (03015, male, 36 years, usual 
care) 
 
"Well a lot of the strategies I had... er a lot of the strategies [at the group] was stuff that er 
we used in the police... for er evidence gathering, erm investigations etc, erm so a lot of the 
strategies I already knew but not with this context, if that makes sense." (04005, male, 56 
years intervention) 
 
Self-generated strategies 
Linked to the preceding subtheme, almost half of participants had generated their own memory 
rehabilitation strategies. For some participants these were internal strategies, including name 
association and attempting to remember specific aspects of an event. 
 
"I mean I try to do association, so name association, erm, I’m, I’m terrible, I mean [name] 
I’ve got, but only because you’re, you’re here on your own, erm if there was two or three of 
you I probably wouldn’t get who was who." (04009, male, 46 years, usual care) 
 
"I try and make something memorable happen... even if it’s talking to a new person and 
talking to them and erm, in that situation I think oh yeah I remember him, he had the bright 
yellow jacket on, I spoke to him, that was a day, it was a Thursday." (01017, female, 30 
years, usual care) 
 
The majority of self-generated strategies were external memory aids. Writing things down was the 
most frequently used self-generated strategy, followed by inputting notes into a mobile phone. The 
use of a calendar, wall planner or a diary was the least frequently used strategies. 
 
"You find your own way of doing things and getting around and doing stuff which for me is 
writing a lot of things down." (03004, female, 39 years, intervention) 
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"So I kind of always have my phone with me, so I've got lots of notes and things in there, 
written down." (07002, female, 29 years, intervention) 
 
"Well, the main thing really is mainly with this, a calendar… Everything’s on there." (05042, 
male, 51 years, intervention) 
 
"Yeah over the years I’ve found having a, a diary to hand, always, I can always keep track of 
my main events during the day." (03014, male, 37 years, usual care) 
 
Almost a quarter of participants reported use of other self-generated strategies. This was 
predominantly relying on routines, and one participant used word substitution and another used 
relaxation techniques. 
 
"I try and think, ok I’ll do things at certain times and put things, I try and put things in places 
which I usually forget to do but I try and look in certain places first and see if I’ve put it 
there." (04008, female, 28 years, usual care) 
 
"If it happens in a sentence or something like that I can kind of er slide my way around it, the 
word that I can’t remember, so that people know what I’m talking about." (01003, male, 58 
years, usual care) 
 
Almost a quarter of participants specifically stated that they had had to generate their own strategies 
due to a lack of memory rehabilitation or support from other sources. For one participant this was 
cause for considerable distress. 
 
"I just give up and work it out myself.  ’Cause I guess, in a way, I’m lucky in that I do – I’m, 
you know, clever enough or whatever to have that own resources to try and do that.  So, yeah 
– so I know that I looked up things online and I got things from memory charities and stuff 
like booklets myself, to try to help myself... it would be better for them [doctors] to be giving 
me information, rather than not even telling me to go away, look it up and for me to have 
done something like this [intervention] group or – you know, just anything rather than just 
the feeling of, like – you know, as if it’s then your fault because it’s not been acknowledged 
that it’s actually an issue. [Crying]" (07002, female, 29 years, intervention) 
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"I’ve done a lot of things just myself… I had to do a lot of recovery on my own" (01017, 
female, 30 years, usual care) 
 
This lack of memory rehabilitation or support is described further in the fourth theme, “Usual care.” 
 
Offered by other sources 
Just under half of the participants had received advice or support regarding keeping a routine from 
other sources.  
 
"I have a routine, that’s another thing that I learnt in either the TBI team there and that or 
maybe is it [name of occupational therapist]." (01010, female, 24 years, intervention) 
 
"We [Acquired Brain Injury team] did do some strategy stuff, sort of around making, er you 
know sort of substituting routine for memory if you like... making sure you always put things 
in the, in the same place and, and that sort of thing." (03015, male, 36 years, usual care) 
 
In terms of external memory strategies offered by other sources, writing things down was the most 
frequently used strategy, followed by the use of a calendar or diary. 
 
"That [in-patient rehab] was one of the places that we, you know started to... say that it 
would be a good idea if you are not sure... where you want to go, what you want to wear or 
what you want to do, you know, write it down." (03001, female, 54 years, intervention) 
 
"I put them all up there, like phone numbers and stuff like that on the calendar. I’ve got one 
next to me when I sit down if I’m in there.  I write down on me calendar, like, ‘got to see me 
home Friday at 1 o’clock’, or whatever [suggested by Brain Injury Trust]." (05067, male, 53 
years, usual care) 
 
"She [from TBI team] told me that it was the right thing to do, get a diary and that it would 
help." (01005, male, 43 years, usual care) 
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Significance of strategies 
A few participants felt an initial resistance to adopting memory strategies after their TBI. However, 
these participants did persevere with the strategies and were then able to experience the benefits. 
 
"I do remember my opinion at the time was I’ve never had a diary, don’t need a diary… I 
gave in and got one and now it’s got to the point, that, yeah again she was right, I was wrong 
cause I live by it." (01005, male, 43 years, usual care) 
 
"I find them quite tedious and patronising and really you know, saying ‘Ohhh’, you know like 
sort of getting a pad out or whatever and writing things down and you know… But it does 
help." (03022, male, 25 years, usual care) 
 
Almost a third of participants heavily relied on their strategies (particularly external memory 
strategies) in their daily activities. 
 
"I had to have an alarm to pick my children up from school, because otherwise I would 
forget." (07002, female, 29 years, intervention) 
 
"I use, erm like my memory as my diary and my phone, this is like my lifeline, without them 
I’m you know, I’m just not, I, I’m useless." (01010, female, 24 years, intervention) 
 
Usual care 
The fourth theme related to the participants’ experience of rehabilitation external to the trial. 
Participants described a lack of memory rehabilitation, the types of memory rehabilitation that they 
did access and rehabilitation offered for non-memory issues (see Figure 13). 
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Figure 13: Thematic map of “Usual care” theme. 
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Lack of memory rehabilitation 
The level of memory rehabilitation received by the participants following their TBI varied 
greatly, with the majority reporting that they had no memory rehabilitation at all external to 
the trial. 
 
"I do think that there is a massive gap in between there’s a massive gap I think for me 
I mean this is my personal experience after the accident hospital you’re discharged 
goodbye, good luck" (07012, male, 37 years, usual care) 
 
"He [group member] got the care package, if you like, from day one... mine has been 
a DIY job... learning how to cope and – with not understanding other people – you 
know, people think you’re taking the micky by forgetting to do that task or doing – 
you know, etcetera." (09006, male, 53 years, intervention) 
 
One participant felt that she did not receive memory rehabilitation due to performing 
adequately on memory tests shortly after her TBI, whereas for her, her score represented a 
deterioration compared to before her injury. 
 
"So what I then found really difficult was they’re like, ‘Oh, well, you’re middle of the 
range on these tests. You’re fine.’ And I’m like, ‘Yes, but I wouldn’t have been middle 
of the range so, actually, I’m not fine'...And I think that I wasn’t able to articulate that 
at the time, because I wasn’t able to explain my thoughts properly then. So I think I 
just kind of got dismissed... I felt a huge amount of frustration and powerlessness, 
because I didn’t get any help, because I wasn’t able to explain that I needed it." 
(07002, female, 29 years, intervention) 
 
Perhaps not surprisingly, many participants stated that they wanted more support and 
rehabilitation to help with their memory. 
 
"It would be nice if there was access to errm memory techniques or a programme." 
(04010, male, 55 years, usual care) 
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"I would like more support, or – and certainly ideas and what I could do, not 
necessarily, well and probably also techniques of helping myself, but also stuff I could 
do to improve it [memory] as opposed to just working around, because I don’t want 
to just take notes all the time." (08002, male, 31 years, usual care) 
 
Memory rehabilitation received outside the trial 
Almost half of participants discussed the types of memory rehabilitation they had accessed 
through sources other than the trial. The most common sources were Brain Injury Teams and 
Neuropsychologists, but other professionals varied widely including in-patient rehabilitation, 
charities, work, private companies and social workers. 
 
"The way I see it is what I’ve had with rehab and the TBI team and everything else 
they’ve, they’ve just been amazing" (01010, female, 24 years, intervention) 
 
"Obviously I’ve gone through a few things with [neuropsychologist], and you know... 
sort of how, you know how I can help with writing things down and certain 
strategies” (03022, male, 25 years, usual care) 
 
"Well when I was in hospital, when I was like an inpatient I think I did have errm I 
did have some memory but wasn’t very common” (04002, male, 24 years, 
intervention) 
 
"That’s the Brain Injury Trust did that to me [suggested strategies], yeah" (05067, 
male, 53 years, usual care) 
 
"I’ve had like coaching, like kind of business kind of coaching and various different 
things to try and put strategies in place so I, I’ll try anything" (03015, male, 36 years, 
usual care) 
 
"I saw the rehab assistant from... July 2015 to December then got discharged 
officially in January this year, so the length of time that [private rehabilitation 
company] had been around for is a kind of, sort of, story of what… like cognitive 
rehab and all daily independent living" (09008, male, 33 years, intervention) 
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"Yeah, yeah, yeah, the social worker from the brain injury unit, I think she’s from 
[place], she was brilliant, she was good, she was very, very good... and she, you 
know, obviously because she works with the brain injury department, they knew a lot 
of the pitfalls of having this accident and a lot of the problems that you will have in 
the future, so she sort of pre-empted and tried to prevent a lot of them as well, which 
did work." (06045, male, 56 years, intervention) 
 
Other (non-memory) rehabilitation received 
As could be expected, participants experienced a range of other health issues comorbid to 
their TBI for which they also attended rehabilitation. The most common “other” 
rehabilitation was for mood issues, and a few spoke about fatigue management groups and 
courses, physiotherapy and balance rehabilitation. 
 
"Well now they [Brain Injury Trust] come round and just check me mood swings 
because I used to get in bad moods and that like, but I’m not scared of nothing… they 
come round and check me pills and they put me on these anti-depressant pills even 
though I don’t feel depressed.  But then they put me dose up and it has calmed me 
down a bit.” (05067, male, 53 years, usual care) 
 
"I’ve been to [place name, fatigue management group] and they showed me what 
happens because that’s why I sleep all the time" (05067, male, 53 years, usual care) 
 
“But I got seen by the Physios a bit longer than, than I should have done.  I got seen 
by the intermediate Community Team longer than I should have been and they tried to 
have more of a smooth transition, that’s why they looked after me a bit longer, they 
wanted to just hand over as they see it, me being ready for life” (08002, male, 31 
years, usual care) 
 
“After my head injury yes, because I couldn’t balance, I lost my sense of balance… So 
through [neuro rehabilitation unit]… erm I was under the care of a couple of people 
there erm there was actually one who I can speak really highly of, [staff member], she 
put in place coping mechanisms” (04010, male, 55 years, usual care) 
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Discussion 
One of the challenges of an interview study requiring people with memory problems to recall 
specific events that happened over the six months previously is that some people tend to 
forget some details. Indeed, this was the case with five participants who could not remember 
the study. Four participants who had received the intervention also had limited memory of the 
groups, but did recall that they were taught to use some ‘strategies’ to cope with their 
memory problems, and that some of these strategies were useful. Five people could not recall 
whether they had had any memory rehabilitation outside of the trial. However, the majority of 
the interviewees provided detailed and rich accounts of their experiences of being involved in 
the trial, and also before the trial. Therefore, these results should be seen in light of the 
difficulties that some participants faced. 
 
Some participants were motivated to participate in the trial by altruism, feeling that their 
participation, even if it did not help them, would help others in the future. The other major 
reason for participation was because they needed help with their memory problems. 
Participants were clear that there was a lack of provision of memory rehabilitation as part of 
their usual care. Some participants received rehabilitation for other non-memory issues (for 
problems with mood, fatigue, and balance), and only a few received help for their memory 
problems from their TBI teams, neuropsychologists, and other allied health professionals. 
This support was often felt to be insufficient.  
 
Although most participants reported that they preferred the group to one-to-one interventions, 
there were some who were ambivalent and some who would have preferred one-to-one 
sessions. The reasons for this are that participants felt there would have been greater focus on 
them as individuals and their problems in individual sessions and intervention material that 
was not seen as ‘relevant’ for them would be left out. Although the majority felt that groups 
were beneficial, there are aspects related to the composition of the group, timing of the group, 
the materials used in the group, and the group’s facilitator, that need to be carefully 
considered when delivering group interventions. 
 
Diversity in a group can be a strength but also a problem for some. Having people with 
different levels of severity was frustrating for those with milder levels of memory problems, 
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and one person even felt like a ‘fraud’ because their memory problems were not as severe as 
some other group members. Participants also felt that their preference for a group format was 
based on their own personalities (e.g., being ‘vivacious’). Most, however, felt that being with 
others with a similar condition made them feel ‘not alone’ and learning from peers was a 
beneficial aspect of the intervention. While some people felt good about seeing others who 
appeared to be coping well after their TBI, others felt bad about seeing people, even years 
after their TBI, not cope.  
 
Another aspect of the delivery of the group was in terms of the time since their TBI. 
Participants described an ‘optimal’ time (not too early but not too late) after TBI they thought 
they would have benefitted the most from memory rehabilitation. Although some people felt 
that they already had strategies in place, because they had been living with the TBI for some 
time before the trial, we had hoped that the memory rehabilitation groups would enable them 
to fine tune the use of these strategies. However, for some, because of the length of time since 
their TBI, they felt that incorporating new strategies with their old ones was a challenge. 
Where people had strategies in place, often these were self-generated, having been learned 
and used successfully before the TBI. However, some participants were taught these 
strategies (e.g., keeping a routine, using external memory aids) by rehabilitation professionals 
after their TBI. Most attested to the positive benefits of using such strategies.  
 
All participants reported benefits from having attended the intervention groups. The aspects 
they felt improved as a result of the intervention have also been reported in previous 
studies.23, 101, 108 Improvements related to learning new strategies, reinforcing the use of 
existing ones, increased use of external strategies, all related to improved memory. 
Furthermore, participants also felt they understood how memory worked. Concomitant 
improvements to confidence and acceptance, and reduced frustrations (with themselves) were 
also reported. While most reported improved mood as a result of attending the group 
sessions, a few participants felt that being in a group with severely memory impaired people 
affected them adversely.  
 
For some participants the group served an important social function. Participants enjoyed 
meeting others ‘like them’, who ‘understood them’ (because of their shared condition). In 
fact, some participants wanted to extend the relatively formal group meeting to more informal 
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social outings. Some participants did not want the groups to end. The social aspect of being 
part of a group of people with TBIs helped people not feel isolated. Indeed, people with TBIs 
often report that their social networks have markedly declined following their injury 109 and 
the groups may serve to establish new networks. 
 
Most participants had found the manual useful. They thought the content was useful and it 
was easy to understand. There were a few, however, who thought the language was too 
academic, and too much information was covered in too little time. However, others thought 
that there was too much repetition. We had structured the manual to provide a summary at the 
end of each session, and at the beginning of the next session there was a reminder of what 
they had done the previous week. Some participants found this helpful, but this is perhaps 
what others felt was repetition. This again may point towards the challenges of running a 
group with participants of very different cognitive abilities. 
 
The group’s facilitator played a key role in the success of the groups. Most participants found 
our facilitators were knowledgeable and competent to manage the group. Others spoke about 
the importance of the facilitators’ listening skills, making participants feel understood. There 
were a few people who did have interpersonal issues with the facilitator. This may have been 
due to the facilitator’s inability to deal effectively with a problem within the group or may 
have arisen due to the participant’s interpersonal communication style,110 difficulties in 
personal relationships,111 and neurobehavioural problems (such as impulsive behaviour and 
reduced frustration tolerance), which are documented psychosocial sequelae of TBI.112 
Further training and support for facilitators may help in this regard.  
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Chapter Six:  Discussion 
 
Context 
This pragmatic trial was designed and conducted in response to a commissioned call for 
‘proposals concerning people needing physical or psychological rehabilitation following 
trauma in a military or civilian context’ from the Health Technology Assessment (HTA) 
Programme.38 This call recognised the need for further research to develop services that 
support those who live with the disabilities that are sequelae of trauma, which includes TBI. 
Cognitive problems, especially memory problems, are common amongst those with TBIs and 
negatively affect personal, social and professional lives. Indeed, cognitive impairments are 
the leading cause of TBI-related disability and affect approximately 43% of those with 
moderate to severe injuries.113 The intervention in the ReMemBrIn trial included memory 
retraining and both internal and external strategies (thereby making it a comprehensive 
memory rehabilitation intervention), and the trial addressed most of the limitations identified 
in previous memory rehabilitation trials, in that it was an adequately powered pragmatic 
observer-blinded Phase III RCT that assessed both clinical and cost-effectiveness, and that 
included outcomes at an activity and participation level.  
 
Summary of findings 
Clinical effectiveness 
Our results indicate there was no benefit of this memory rehabilitation programme for this 
group of people with TBI, with no clinically important difference on the EMQ-p (the primary 
outcome) between the two arms at the 6-month follow-up. Although the difference in mean 
EMQ-p score for those with borderline/moderate memory impairment favoured the memory 
rehabilitation arm, there was no statistical evidence of any overall sub-group effect. There 
were also no important differences between the arms on memory ability, mood, quality of life 
and cognitive, emotional and social wellbeing at the 6- or 12-month follow-up. Goal 
attainment scores, however, favoured the memory rehabilitation arm at both 6- and 12-month 
follow-up. No safety concerns were raised and no deaths were reported. 
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Cost-effectiveness 
There was ambiguity in our cost-effectiveness findings, which was driven by methodological 
uncertainty (based on the impact of different imputation methods) and parameter uncertainty 
(based on different time-points, outcomes and costs). Whilst some of the findings suggest 
memory rehabilitation could be seen as cost-effective, with lower costs and lower effects 
observed for the cost per QALY gained at 12-months, this was  based on small, imprecise 
differences in costs and outcomes. When we take into account all the uncertainty in our 
results, memory rehabilitation is unlikely to be considered cost-effective.  The results of the 
cost-effectiveness analyses on the two clinical outcomes (EMQ-p and GHQ-30) showed 
consistent results, with the intervention seen as dominant for the base case MI data (i.e., less 
cost, more effect). Again, these are based on small, non-significant differences in costs and 
effects and uncertainty in our findings was seen when these results were further examined. It 
should be noted that any technical finding of cost-effectiveness does not overwrite that there 
was no clinical benefit of memory rehabilitation for this group of participants. 
 
Qualitative analysis 
Despite having memory problems, most people could recall their experience of being 
involved in the trial, and those who had received the intervention could recall what they felt 
about the group sessions. Most participants’ experience of being involved in the trial was 
positive. Most participants preferred a group format rather than one-to-one memory 
rehabilitation, but this finding may have been due to a selection bias (i.e., people agreed to 
take part knowing that they may receive a group intervention). Many participants reported the 
benefits of being in a group in terms of their improved use of strategies, and improved levels 
of confidence, acceptance, and mood. For many, the group also served a social function. The 
composition of the group (in terms of severity of people’s disabilities) affected participants’ 
experiences of the sessions. There appears to be an ‘optimal’ time since injury where people 
felt they would have benefited most from the sessions, which was not too early but not too 
late either. Participants found the intervention manual helpful. The success of the group also 
depended on the knowledge and skills of the group facilitator. 
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Interpretation 
There are several reasons why this intervention may not have been effective overall. The 
following factors may have had an impact on the overall outcome of the trial. 
 
Time since TBI 
One consideration is that the participants were recruited relatively late after TBI. We had a 
high proportion who were recruited late after injury, with a median time since injury of just 
over four years. Hoofien et al.114 found that even a decade post-injury, people with TBI had 
cognitive problems and needed professional assistance to maintain a reasonable quality of 
life. Therefore, we expected rehabilitation at this late stage to be useful because people’s 
lifestyle and expectations change after discharge from rehabilitation and new demands may 
require the use of different strategies. Also, Tsaousides and Gordon 115 suggested that 
cognitive rehabilitation is effective at any time post-injury.  
 
It may be that people had already learned many of the strategies taught or had established 
ways of coping that suited them and they were unlikely to adopt new methods of coping. Our 
qualitative study provided some support for this assumption (see subtheme ‘Timing of 
intervention’ in Chapter Five). Indeed, other studies116, 117 have found that there are various 
factors related to the use of strategies (particularly external memory aids). From their survey 
of people with ABIs, Evans et al.116 observed that many people were using memory aids, with 
many more aids being used after the ABI than pre-morbidly. They also found no relationship 
between rehabilitation and the level of memory aid use. Interestingly, they also found that the 
longer the time since the injury, the less memory aids were used. This again calls into 
question the impact of time since injury in strategy use and benefit finding from the 
rehabilitation programme. 
 
However, our results suggest this is not the case and that additional rehabilitation at this late 
stage conferred no benefits over usual care alone. Post hoc sub-group analysis in relation to 
time since injury (categorised into 2 years or less, 2 to 10 years, and more than 10 years) 
found no differences in outcomes. Therefore this is an aspect that needs to be investigated 
further in future studies. 
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Severity of memory impairment 
As this was a pragmatic trial, we recruited people with a wide range of severity of memory 
problems, which reflects the range of patients seen in clinical practice. There were some who 
reported memory problems in daily life but were within the average range or above on the 
RBMT-3. Although this may be an impairment relative to their premorbid level, it could also 
reflect mood problems. It is well-recognised that there is a strong relationship between 
reported memory problems in daily life and mood in people with neurological conditions.118-
121 Therefore, some of those recruited may have reported memory problems associated with 
low mood and therefore would be unlikely to benefit from memory rehabilitation. However, 
despite some previous studies demonstrating better mood in those who had cognitive 
rehabilitation compared to those who did not,122, 123 and previous meta-syntheses of 
qualitative studies demonstrating this,101, 124 our quantitative data suggested no significant 
differences between the treatment and control arms at the 6- or 12-month follow-up in 
relation to mood. Interestingly, our qualitative study (see ‘Effects of the group’ subtheme in 
Chapter Five) found mixed results, with some people finding benefits in relation to mood as a 
consequence of attending the group sessions, but others finding the groups distressing. 
Furthermore, there were some participants with very severe problems who may have been too 
impaired to cope with the demands of the intervention. This is supported by the finding that, 
although we found no benefit overall, those in the moderate range of impairment on the 
RBMT-3 showed the greatest benefit from rehabilitation. This is also consistent with 
recommendations 37 that suggest teaching memory rehabilitation strategies based on severity 
of memory impairment. 
 
Format of memory rehabilitation delivery 
The intervention was provided on a group basis because we felt this was more likely to be 
cost-effective and resource efficient than individual sessions, and based on previous 
research,23, 101 we also felt that participants may benefit from the interaction with others in a 
similar situation. The latter point was supported by the qualitative feedback in which the 
group aspect was seen to be useful by most participants (see ‘Preference of rehabilitation 
format’ and ‘Format’ subthemes in Chapter Five). Furthermore, Cicerone et al.,24 on the 
basis of their systematic review, recommended that “Group-based interventions may be 
considered for remediation of memory deficits after TBI” as a “Practice Option” (defined as 
evidence based on Class II or III studies). However, groups do not suit all (again evident from 
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our qualitative findings) and selecting only those who prefer group to individual treatment 
may have enhanced any benefits. Perhaps providing a few individual sessions before 
participants are allocated to a group or alongside group sessions may enable therapists to 
better prepare patients for group sessions to deal with issues such as being with others with 
severe disabilities and to improve attendance at groups.125 
 
The treatment was structured to be delivered as weekly sessions for ten weeks. Perhaps 
greater spacing between sessions would have allowed participants to practice their between-
session tasks and to get more familiar with one strategy before learning about another. In 
addition, the provision of top-up sessions over a longer period of time may have helped 
participants retain information that had been learned. Indeed, our qualitative study 
documented the perceived need for longer sessions and top-up sessions (see ‘Format’ 
subtheme in Chapter Five). However additional sessions may incur additional costs. 
 
Attendance and dose of memory rehabilitation 
Given that our sample had memory problems, attendance at the memory rehabilitation groups 
was good, with 77% attending four or more sessions. We assumed, based on our previous 
studies,22, 23 that given the modular structure of the programme, people would find some 
benefit from attending at least four sessions. This is also consistent with our clinical practice. 
Furthermore, in this study, the reasons for non-attendance were also mainly reasons that are 
encountered in clinical practice, such as clashing appointments, rather than due to 
withdrawing or not wanting to continue in the group. In the Rohling et al.12 meta-analysis the 
mean treatment duration was 13.3 weeks (SD=14.2) which is similar to ten weekly sessions 
in our trial. 
 
However, one challenge that clinicians and researchers face is determining the optimum 
‘dose’ of the intervention. There are very few rehabilitation studies that have investigated the 
optimum dose and format of the memory rehabilitation in detail. Even the large systematic 
reviews 12, 24 have not been able to consider the dose-response effect in memory 
rehabilitation. One reason for this is that primary studies do not always specify details of the 
intervention in sufficient detail.126 We expect that reporting guidelines such as the Template 
for Intervention Description and Replication (TIDieR) checklist and guide 127 and other more 
specific guidelines for reporting group memory rehabilitation programmes 126 will improve 
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the reporting of these interventions. Therefore, it seems that more Phase II studies are needed 
to optimise the recruitment of suitable participants and to provide the optimum format of the 
intervention before progressing to a Phase III trial. Indeed, Cicerone et al.24 stated that “future 
research should move beyond the simple question of whether cognitive rehabilitation is 
effective, and examine the therapy factors and patient characteristics that optimize the clinical 
outcomes of cognitive rehabilitation” (p. 1681). Thus, attendance rates may have affected 
outcomes. 
 
Choice of outcomes 
We included a variety of outcomes tapping memory (subjective and objective, patient and 
relative reports), mood, cognitive, social and emotional wellbeing, goal attainment, and 
health economic outcomes.  
 
There is debate amongst researchers and clinicians working in neuropsychological 
rehabilitation about the most appropriate outcome measures.128 When the trial was designed, 
we felt that a subjective report should be the primary end point because this assesses the 
effect of memory problem in everyday life and provides a patient-centred outcome rather 
than the views of healthcare professionals. This is also suitable for independent completion 
and return by post, which helped to ensure blind assessment of outcome. Other studies have 
considered goal attainment as a primary outcome.64, 129 While we consider this as a valid and 
useful measure, we felt that it would be more suited as a secondary outcome measure because 
the goals set are strongly influenced by the expectation of the treatment and the goals are 
likely to change over the course of the year when follow-up assessments are conducted.  
 
While Goal Attainment Scaling (GAS) is considered very much a part of rehabilitation in 
clinical practice where goals are set and assessed in collaboration between patients and 
clinicians, its application as an outcome measure in rehabilitation studies poses certain 
challenges.130 Indeed, Bovend’Eerdt et al.131 documented the challenges of using GAS as a 
blinded outcome measure by an independent assessor (who has not been part of the patient’s 
clinical team). One previous cross-over trial 132 that used goal attainment as a primary 
outcome had to modify their randomisation protocol to accommodate patient-relevant goals 
that would fit with the timing of the intervention. For instance, participants originally 
allocated to the intervention phase were moved to the control phase during school holidays if 
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the goal was to remind them to pick up their children from school. This therefore potentially 
biased the study. 
 
When we compare the findings from the quantitative and qualitative parts of this study, we 
find a discrepancy, with the qualitative study finding benefits of memory rehabilitation. 
Rohling et al. noted “It is not uncommon for patients and providers to report improvements in 
the real-world task of compensating for memory impairment, while the psychometric 
measures show little or no change” (p. 34).12 Goal attainment may be one way in which to 
accurately capture individual patient targets in a systematic and quantitative way, without 
having to resort to general pre-formatted questions that may not be applicable to all. The use 
of GAS may also help bridge the gap between what we find in qualitative and quantitative 
studies of memory rehabilitation, because it has the ability to identify what matters most to 
patients. For instance, in our trial the qualitative findings suggested that participants found 
improvements in levels of confidence and acceptance, aspects of improvement that may not 
have been identified in standardised questionnaires. Indeed, in our trial, participants’ 
individually set goals were better met in the intervention arm compared to control at both 6- 
and 12-month follow-up. Therefore, if some of the concerns raised about the use of GAS can 
be allayed, GAS may be a useful outcome to consider in future trials. 
 
 
Strengths and Limitations 
The findings from this trial should be viewed in light of its strengths and limitations. They 
key limitations are discussed below. 
 
Heterogeneity  
As a pragmatic trial, our inclusion criteria were necessarily broad, which replicates how 
memory rehabilitation is delivered in clinical practice and contributes to the generalisability 
of the findings. However, this also meant that the sample was heterogeneous, but our trial 
was not designed to detect differences in the effect of the group memory rehabilitation (i.e. 
sub-group effects) according to baseline factors. Therefore, we intend to further analyse the 
data in this respect, but the findings will only provide us with some indications of which 
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groups of people may benefit most from memory rehabilitation, which will need to be tested 
out in future trials. 
 
Generalisability  
It was necessary to screen a large number of potential participants to recruit the required 
sample size, and a large proportion of those screened were not enrolled. This is largely due to 
the methods of recruitment, which relied on postal invitations, which are known to suffer 
from poor response rates;133 indeed non-response to the postal invitation accounts for 43% 
people screened but not consented in the current trial. By comparison only 28% of people 
were excluded on the grounds of eligibility, lending support to the representativeness of the 
current sample. 
 
As a pragmatic trial, to reduce selection bias, we had multiple recruitment sources and 
strategies, including self-referrals. Unfortunately, this meant that we do not have 
demographic data on all those who were approached and invited, or those who chose to self-
refer as a result of the study publicity material. Furthermore, we were unable to collect this 
information at the recruitment stage because those interested had not given consent for us to 
collect this data for research purposes. Therefore, we cannot be certain whether there were 
differences in the characteristics of those who wanted to take part in the study and those who 
did not.  
 
Research suggests that white, middle-class, highly educated men tend to be overrepresented 
in healthcare research in most Western countries.134 Indeed, in our trial 96% of our sample 
identified as White. Surprisingly, the literature is sparse regarding racial and ethnic variations 
in the epidemiology of TBI in the UK. One older study,135 however found substantial 
differences based on ethnic groups in relation to seasonal variations and differences in length 
of hospital stay following TBI. In relation to gender, typically men are overrepresented by 3:1 
in all subgroups of TBI.136 Men formed more than a third of our sample.   
 
Comparability with other trials 
Rather than reviewing individual studies, we have opted to compare our findings with that of 
published reviews. More men than women sustain brain injuries, with estimates between 2:1 
and 3:1.137 This is consistent with our findings wherein 73% of participants were male. In the 
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Rohling et al.12 systematic review of cognitive rehabilitation following ABI, the authors 
identified eight studies that considered rehabilitation of memory difficulties in TBI. In this 
review, the mean age of TBI participants was 29.1y (SD=15.9) while our participants were 
older (mean 45.4, SD 12). The mean treatment duration was 13.3 weeks (SD=14.2), which is 
similar to our ten weekly sessions. 
 
The Cicerone review 24 discusses the various treatment strategies covered in memory 
rehabilitation in ABI. Study they included in the review used internal memory aids (e.g., 
visual imagery techniques), memory retraining, and external memory aids (e.g., diaries, 
pagers and other compensatory strategies). This suggests that the content of our intervention 
programme was comprehensive, elements of which were investigated in other trials. Most of 
these trials suggested that participants benefited from using these strategies. 
 
Fidelity of the intervention 
It was a strength of the study that we were able to assess the fidelity of the intervention. The 
video analysis suggested that the therapists were delivering the intervention as planned and in 
accordance with the manual. However, the main limitation of the video analysis is that 
recordings were incomplete and did not include all sites. There were additional sessions that 
were only partially recorded. These stopped part way through the session, probably due to the 
camera battery running low, or did not continue after the break, possibly due to the AP 
forgetting to turn the camera on again. Some recordings were lost and not transferred to the 
main site. This limited the recordings that could be included in the analysis and meant that 
not all sessions were observed at each site. Therefore, we cannot be certain that all sessions at 
all sites were delivered consistently in accordance with the manual. However, based on 
feedback obtained during our monthly peer and supervisor meetings with the APs we do not 
expect that the unrecorded sessions were markedly different from the recorded ones.  
 
Lack of an ‘active’ control arm 
One of the challenges of conducting complex intervention trials, particularly in rehabilitation 
contexts, is having an ‘active’ control arm. In our pilot trial,22 we had an attention placebo 
self-help group as the control arm. In this group, participants met to discuss their health and 
memory problems and were taught relaxation exercises. The group facilitator did not initiate 
any memory talk. Our fidelity analysis of these sessions compared to the treatment sessions 
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138 demonstrated that the self-help group did have very little discussion around ‘memory’ and 
was significantly less than our treatment groups. However, our qualitative research 23 
suggested that even people in this group were reporting some benefits in attending the 
sessions. Therefore, in ReMemBrIn, we opted to have a treatment as usual control arm. 
However, based on the qualitative data (see Chapter Five, ‘Usual care’ theme) it would 
appear that most people did not get much by way of usual care. This is a challenge that has 
been recognised in evaluating complex intervention and rehabilitation trials.139 
 
Despite these limitations, we believe this study has several strengths and has avoided many of 
the methodological weaknesses identified in previous trials of memory rehabilitation in TBI. 
 
Methodological quality 
ReMemBrIn was a randomised controlled trial. We took care to ensure allocation 
concealment and blinding of outcome assessors. Our Statistical Analysis Plan was agreed in 
advance of the data-lock stage. We have reported the trial in line with the Consolidated 
Standards of Reporting Trials (CONSORT) guidelines 140 and the content, format and 
delivery of the intervention in line with the TIDieR and other relevant guidelines.126, 127 This 
should enable other researchers who wish to replicate this study to deliver the intervention as 
we have. 
 
Sample size 
Most previous studies of memory rehabilitation have been small and underpowered. This is 
an issue within the wider field of cognitive rehabilitation studies. Rohling’s systematic 
review 12 identified controlled studies of TBI with sample sizes ranging from 4 to 22. The 
ReMemBrIn Trial was powered to detect a minimum clinically significant difference in mean 
EMQ-p score of 12 between the memory intervention arm and the usual care arm, taking into 
account between site variations and clustering due to the intervention being delivered in a 
group.  The target sample size of 312 was exceeded, with a total of 328 randomised 
participants making this, to our knowledge, the largest trial of its kind to date. 
 
Standardised manualised treatment  
We were able standardise the treatment by having a manual and facilitator notes for 
facilitators at each site and a workbook for all participants in the intervention arm. Facilitator 
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training happened centrally, and monthly peer supervision and one-to-one supervision with 
one supervisor for all APs who delivered the intervention enabled sharing of experiences 
which we hoped would encourage APs to adhere to the manual and facilitator notes. In the 
training programme and through supervision, we also taught the APs how they could adhere 
to the manual but also adapt the contents of each session to the needs of individuals within 
the group and the group as a whole.  
 
Assessment of treatment fidelity 
Our videos of the rehabilitation sessions from the various sites were coded and rated by two 
independent raters also enabled us to determine consistency of delivery of the intervention. 
There was some variation between sites, but part of this may have been due to variations in 
sessions available for analysis. Site five recordings were mainly from early sessions whereas 
recordings from sites three, eight and nine were mainly from later sessions. This may account 
for the high proportion of time spent discussing the venue and organisational issues rather 
than discussing strategies in the recordings from Site five. This site also had more facilitation 
of discussion, probably because this was needed more in early sessions than later ones. 
 
Time sampling has been used mainly for ward-based observations of behavioural problems, 
where behaviours are observed and recorded for a specific period of time,141 but we have 
found it useful to adapt this method to assess the ‘content fidelity’ of group-based 
rehabilitation interventions delivered in a research context with participants with neurological 
conditions.138, 142  
 
Content fidelity has been defined as “the extent to which each intervention component was 
effectively delivered to the participants in terms of required content” (p42).143 The recording 
of activities indicated that appropriate content was covered. ‘Process fidelity’ was evident 
from the therapist skills observed, such as facilitating discussion, summarising and 
paraphrasing. However, process fidelity also involves the interpersonal skills of the therapist 
143 and there was no attempt to rate the quality of the interactions. 
 
The fidelity to the intervention manual and consistency between therapists could have been 
improved if we had analysed the first group conducted by all APs, and provided them with 
detailed feedback. This could have then been done routinely to ensure that there was no 
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‘drift’ in terms of intervention delivery for the rest of the trial. This of course has resource 
implications. Therefore, in this trial, we only analysed the video data at the end of the trial.  
 
In the delivery of complex interventions, we cannot be certain what the key ingredients are 
that would contribute to a positive outcome. In this study, we decided on the coding frame 
based on the activities and skills described in the manual. However there may be other 
important aspects of the group sessions, such as group cohesiveness and therapist experience, 
which were not monitored. 
 
Follow-up completion rates 
Although 84% of the sample completed their assessment visits at 6-month follow-up, only 
75% and 78% of the participants’ questionnaires from the intervention and control arms 
respectively could be included in the primary analysis. This is slightly below our 80% 
response rate target, however sensitivity analyses using multiple imputation to impute 
missing outcome data gave very similar results to the analysis using the available data.   
 
Activity and participation level outcomes 
Outcomes related to activity and participation levels of the ICF framework.30 Frontera et 
al.,139 in their summary of the Rehabilitation Research at National Institutes of Health: 
Moving the Field Forward conference, stated “In rehabilitation research, outcomes are often 
complex, occur across the domains of the International Classification of Function, and 
include patient-reported as well as performance-based and instrumented outcomes”. Many of 
the previous studies used impairment level measures to assess the outcome of memory 
rehabilitation. While impairment level measures are useful in understanding the potential 
mechanisms that underlie changes effected by rehabilitation, as an outcome, it may not 
generalise to a meaningful functional outcomes for patients.144 Many of these impairment 
level measures are ‘objective’ measures (i.e., based on cognitive tests). However, studies 
have also shown discrepancies between perceived and objective cognitive functioning,145, 146 
with subjective ratings being influenced by mood and self-efficacy. We acknowledge that the 
EMQ-p would have been influenced by these factors, but felt that it was the appropriate 
primary outcome because we expected participants who received the intervention to report a 
reduction in forgetting and improvements in coping with memory problems, which is in 
keeping with the spirit of cognitive rehabilitation.69 Furthermore, we also included an 
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objective measure of memory and relatives’ assessment of participants’ memory failures as 
secondary outcomes. Goal attainment was also a secondary outcome. 
 
Another strength related to outcomes is that we assessed participants at both 6- and 12-month 
follow-up. Most previous studies have only assessed outcomes proximal to the end of the 
intervention; therefore, in this study we were able to evaluate the longevity of treatment 
effect, if any. 
 
Economic analysis 
Past studies have only considered the clinical effectiveness of memory rehabilitation. To our 
knowledge, this is the first trial to have determined the costs of delivering memory 
rehabilitation and the cost-effectiveness of this.   
 
Lessons Learned 
Throughout the trial we experienced some delays. These were largely due to unforeseen 
circumstances beyond our control. At one site, the AP was not allowed access to the patient 
database after there was disagreement between the Trust’s Caldicott Guardian and their R&D 
department (after all approvals were granted) in relation to data access. This resulted in us 
having to raise this with the Head of R&D at that Trust, and required us to recruit a new AP 
at their Trust (instead of a secondment from the sponsoring Trust). One site changed its 
organisational structure from being an NHS Trust to a social enterprise without an R&D 
department. We therefore had to subcontract a research consortium to act as that site’s R&D 
approvers. At one site, we had a delay in recruiting the AP for that site because of an impasse 
between the CLRN and the NHS Trust regarding finances. This took five months to resolve. 
In these instances, considerable amount of time was spent in escalating the issue to Trust 
R&D directors and chief executives, with a view to have the issues resolved.  
 
In addition to these problems, we did have one recurrent problem: keeping APs in post. We 
chose to appoint APs to deliver the intervention because they have the qualification and skills 
to deliver low-intensity manualised interventions under the supervision of a clinical 
psychologist. They often deliver such interventions in the NHS, and are seen as a safe, cost-
efficient way of providing psychological therapies for some, circumscribed, problems.   
161 
 
 
APs are graduates who work in NHS Trusts, typically for one year, before they move on to 
work in another area (seeing a different patient group) or they are successful in obtaining a 
place on a doctorate in clinical psychology programme. Therefore, by appointing the best and 
most experienced APs, we could only retain them for a year, needing to re-advertise and 
recruit to each post a number of times at each sites. To mitigate delays, we developed and 
shared draft advertisements, job descriptions and person specifications for the job to the 
principal investigators at all the sites. We also had a log of when APs’ contracts were coming 
to an end, and worked closely with the APs to ensure that they would give us sufficient notice 
to allow us to recruit someone to their post, preferably before they left. Knowing the patterns 
of when APs were scheduled to leave the ReMemBrIn team to start on their doctoral courses 
(if successful in obtaining a place) allowed us to factor this in to our recruitment projections 
with a slowing down of participant recruitment around this time. This, therefore, provided us 
with a more realistic monthly recruitment target.  
 
These delays caused an overall delay in participant recruitment. However, as can be seen in , 
when we did have staff available in active sites, participant recruitment was not a problem.  
We attempted to recruit military personnel into the trial. We obtained the necessary research 
ethical approval from the Ministry of Defence, had a TSC member who had experience of 
working with military charities, and recruited a PIC to identify potential participants. Despite 
various attempts to identify potential participants with this PIC and relevant military 
charities, we did not succeed in recruiting many participants from the military. Future studies 
may benefit from having a military co-applicant within the research team, and may need to 
have confirmed support from military command.   
Another source of delay was between assessing and randomising participants. Participants 
waited a median of 18 days between the second assessment and randomisation. This is 
inevitable in studies where the intervention is delivered in a group format. We needed to 
gather sufficient numbers of participants who were eligible to take part in the study and could 
attend at a particular time and place. We did learn, however, that targeting a specific 
geographical area (e.g., postcodes within a small area) with our recruitment mail outs in small 
batches as opposed to one large mail out to a large area enabled us to form clusters faster, as 
participants were able to travel to the venue where the groups were held. Interestingly, the 
delay did not deter people from wanting to participate. However, in conditions where 
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people’s cognitive functions can fluctuate or deteriorate, such as in multiple sclerosis, this 
may mean people’s baseline assessments may not reflect their cognitive ability at the start of 
the intervention.  
 
We experienced problems in collecting postal outcome questionnaires with our participants 
who had memory problems, who forgot to complete them or send them back to us. This 
resulted in a lower than expected initial response rate for outcome questionnaires. However, 
we were able to identify this problem quite early on and institute a recovery plan. This plan 
necessitated the outcome assessor checking with the participant at the time of their 6-month 
outcome visit whether they had completed the questionnaires. If they had not, a new 
questionnaire pack was provided for them to complete and for the outcome assessor to return 
to the NCTU. This change to our procedure resulted in an increase in our response rates 
(from 73% for 6 month questionnaires before we instituted this plan to 81.5% after).  
 
We trust that the lessons we have learned serve to inform future researchers when they 
develop their research protocols. 
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Chapter Seven:  Conclusions 
 
Implications for practice 
This trial has not shown any benefit of this group memory rehabilitation for people with TBI 
late after their injury. However, people continue to report memory problems later after injury 
and the qualitative feedback from the participants who received the intervention was positive, 
therefore clinicians need to identify what interventions may be useful at this late stage after 
TBI. 
 
 
Recommendations for research 
The results of this study highlight the need for more adequately powered studies of memory 
rehabilitation in patients with traumatic brain injury. We found that despite extensive 
development work and early studies suggesting the intervention was potentially effective, the 
findings suggest that our group-based memory rehabilitation conferred no benefit over usual 
care in the NHS. 
 
• There is a range of other memory rehabilitation strategies, such as computer games, 
mnemonics training, visual imagery, and these all need full-scale evaluation. 
Interventions can be delivered in individual or group formats, or delivered face-to face or 
on a computer. Future research may consider the usefulness of online and internet-based 
memory rehabilitation. The effect of the format of delivery on outcomes needs to be 
established. In addition, the question of what works best for whom requires further 
consideration of participant selection in order to ensure that people receive the treatment 
that is most appropriate to their needs. All these issues require more randomised 
controlled trials of high methodological quality. 
 
• We used a usual care control arm in order to determine whether the memory rehabilitation 
programme conferred any benefits over and above what was provided in the NHS. 
However, usual care is difficult to document and varies between sites. Future studies 
would benefit from developing appropriate attention control interventions to assess the 
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specific effects of the intervention. Although we have previously used an attention control 
group for memory rehabilitation 22 this proved difficult to deliver as a plausible control 
activity of equivalent duration and intensity. Utilising other support services, such a 
Headway groups, as a control intervention may enable better identification of the 
essential components of treatment. 
 
• Future research will need to consider more small scale efficacy studies to establish 
appropriate selection criteria for group memory rehabilitation programmes, so that the 
intervention is tailored to those who can benefit. Research will also need to offer more 
information on usual care for people with memory problems following TBI so that group 
memory rehabilitation can be evaluated in those who have not already been taught the 
strategies covered in the group programme. 
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Appendices 
Appendix 1. Participating Sites 
 
Table 26: Sites 
Lead NHS Trust 
Date opened to 
recruitment 
Months 
open 
Cheshire and Wirral Partnership NHS Foundation Trust 06 February 2013 23 
Nottingham University Hospitals NHS Trust 07 February 2013 31 
Birmingham Community Healthcare NHS Trust 18 April 2013 5 
Central Surrey Health 30 April 2013 7 
The Walton Centre NHS Foundation Trust 12 March 2014 21 
Sheffield Health and Social Care NHS Foundation 03 November 2014 13 
St. George's Healthcare NHS Trust 18 March 2015 9 
North Bristol NHS Trust 01 May 2015 7 
South Tees Hospitals NHS Foundation Trust 12 June 2015 6 
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Appendix 2. Plan of study procedures and data collection 
Table 27: Data Collection 
Assessments 
Initial 
screening 
assessment 
Second 
assessment 
visit 
R
A
N
D
O
M
IS
A
T
IO
N
 
Intervention 
period 
6-month 
follow-up 
12-month 
follow-up 
Initial eligibility screening X1   
 
Intervention arm 
receives Memory 
Rehabilitation (1.5 
hour group 
sessions, once a 
week for ten weeks) 
in addition to usual 
care. 
 
 
 
Control arm 
receives usual care 
only. 
  
Informed consent X1    
Demographic information X1    
Everyday Memory Questionnaire – patient version (EMQ-p) X1  X2 X2 
Rivermead Behavioural Memory Test – third edition (RBMT-3) X1  X1 X1 
Sheffield Screening Test for Acquired Language Disorders (SST) X1    
National Adult Reading Test (NART) X1    
General Health Questionnaire (GHQ-30) X1  X2 X2 
Setting of short and long term goals  X1   
EuroQol Quality of Life – five dimensions, five levels questionnaire (EQ-5D-5L)  X1 X2 X2 
Service use questionnaire (SUQ)  X1 X2 X2 
Everyday Memory Questionnaire – relative version (EMQ-r)  X2 X2 X2 
Check availability for treatment group  X1   
European Brain Injury Questionnaire – patient version (EBIQ-p)   X2 X2 
European Brain Injury Questionnaire – relative version (EBIQ-r)   X2 X2 
RA opinion on participant’s treatment group before and after assessment of goals   X1 X1 
Assessment of individual goal attainment   X1 X1 
Qualitative feedback interviews with a sample of participants   X3  
Clinical data collected from medical notes where available X   
1 Completed during visit.  2 Included in the questionnaire pack.  3 Completed within two months of the 6-month follow-up visit. 
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Appendix 3. Treatment fidelity coding schedule 
Table 28: Coding schedule for analysis of video recordings 
Non-rehabilitation activities Rehabilitation activities 
AP (T) Participant (P) Code AP Skills Code AP Activities Code Participant Code 
Introductions T1, P1 Facilitating discussion 
(Non-specific prompts) 
T7 Presenting/ discussing educational 
material 
T10 Discussing/filling in 
educational material 
P10 
Social chat T2, P2 Providing feedback not 
directly related to content of 
manual  
T8 Presenting/ discussing strategies T11 Discussing strategies  P11 
Preparing materials, tasks 
etc.  
T3, P3 Providing encouragement/ 
reassurance 
T9 Providing general information related 
to memory which is not covered in 
educational material 
 
T15 Asking for information P12 
Information about 
sessions, venue, group 
etc. 
T4, P4 Summarizing T16 Recap of previous session T18 Feedback on home 
activities 
P13 
Hospital visit discussion T5, P5 Paraphrasing T17   Describing problems 
related to memory 
P14 
Describing emotions and 
coping strategies 
T6, P6       
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Appendix 4. Estimates of the intracluster correlation coefficient in 
the intervention arm for each outcome calculated from the multi-
level models 
 
Table 29. Estimates of the instracluster correlation coefficient in the intervention arm 
 6 months 12 months 
   
EMQ– p – frequency of problems 0.05 0.00 
   
EMQ– p – importance of 
problems  
0.00 0.00 
   
GHQ 30 0.07 0.00 
   
RBMT-3 (GMI) 0.00 0.00 
   
Short term goal achievement 
average score 
0.13 0.00 
   
Long term goal achievement 
average score 
0.06 0.00 
   
EBIQ – p - cognitive  0.00 0.00 
EBIQ – p - depression 0.00 0.00 
EBIQ – p - communication 0.09 0.03 
EBIQ – p - difficulties in social 
interactions 
0.00 0.00 
   
EMQ– r– frequency of problems 0.00 0.00 
   
EMQ– r– importance of problems  0.00 0.01 
   
EBIQ – r - cognitive  0.08 0.00 
EBIQ – r - depression 0.00 0.00 
EBIQ – r - communication 0.04 0.09 
EBIQ – r - difficulties in social 
interactions 
0.00 0.00 
   
ICC calculated using multi-level linear model used for the analysis of each outcome. 
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Appendix 5. Cumulative recruitment against target 
Figure 14: Cumulative recruitment 
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Appendix 6. Further details for non-enrolment in the trial 
Table 30: Reasons participants were not eligible for the trial  
Reason  Number Percentage of Screened 
Unsuitable for group 236 6% 
Involved in other studies 1 0% 
Impairment of language 26 1% 
Traumatic brain injury  < 3 months previously 8 0% 
Under 18 years of age 33 1% 
Over 69 years of age 622 15% 
Unable to travel 196 5% 
Unable to consent 7 0% 
Total 1129 28% 
 
Table 31: Other reasons for non-enrolment in the trial  
Other reasons for non-enrolment Number Percentage of Screened 
Deceased 119 3% 
Not traumatic brain injury 167 4% 
No memory difficulties 105 3% 
Declined 75 2% 
Unable to contact 66 2% 
English language difficulties 36 1% 
Working or no time 24 1% 
Out of area 23 1% 
Other illness 16 0% 
Not accepted/did not engage 12 0% 
Cause of brain injury unknown 10 0% 
Did not attend 9 0% 
Clinician's advice 9 0% 
Other rehabilitation 7 0% 
Recruitment closed at site 5 0% 
Student so unable to attend 2 0% 
Not known 33 1% 
Total 718 18% 
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Appendix 7. Randomisation by arm and site 
Table 32: Cluster and participant randomisation by arm and site 
  
Usual care 
Memory 
Rehabilitation 
 
Total 
 n n n 
Number of clusters randomised    
Site 1 8 8 16 
Site 2 0 1 1 
Site 3 4 6 10 
Site 4 2 1 3 
Site 5 7 7 14 
Site 6 6 6 12 
Site 7 1 2 3 
Site 8 1 2 3 
Site 9 2 2 4 
Number of participants randomised    
Site 1 38 39 77 
Site 2 0 5 5 
Site 3 19 27 46 
Site 4 10 4 14 
Site 5 36 33 69 
Site 6 33 33 66 
Site 7 5 8 13 
Site 8 4 11 15 
Site 9 12 11 23 
Size of cluster randomised     
4 10 12 22 
5 9 15 24 
6 12 8 20 
Days between initial screening and 
randomisation 
   
  Median [25th, 75th centile] 39 [20, 110] 29 [21, 62] 33 [21, 78.5] 
  Min, Max 6, 455 5, 317 5, 455 
Days between second assessment and 
randomisation 
   
  Median [25th, 75th centile] 22 [7, 90] 15 [8, 42] 18 [8, 54.5] 
  Min, Max 0, 444 0, 282 0, 444 
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Appendix 8. Other clinical data collected at baseline 
 
Table 33. Other clinical data collected at baseline 
  
Usual care 
 (n = 157) 
Memory 
Rehabilitation 
 (n = 171) 
 
Total 
(n = 328) 
    
Clinical notes available  58 (37%) 42 (25%) 100 (30%) 
Clinical notes not available  99 (63%) 129 (75%) 228 (70%) 
    
Type of head injury    
Open 5 (9%) 4 (10%) 9 (9%) 
Closed 39 (67%) 31 (74%) 70 (70%) 
Unknown 14 (24%) 7 (17%) 21 (21%) 
    
Severity of the head injury (GCS1)    
Closest to admission    
Median [25th, 75th centile] 10 [6, 14] 12 [6, 15] 11.5 [6, 14] 
Min, max 3, 15 3, 15 3, 15 
n 25 21 46 
Unknown 33 (57%) 21 (50%) 54 (54%) 
    
Worst total score    
Median [25th, 75th centile] 8.5 [4, 14] 9 [4, 14] 8.5 [4, 14] 
Min, max 3, 15 3, 15 3, 15 
n 22 18 40 
Unknown 36 (62%) 24 (57%) 60 (60%) 
    
Other neurological conditions2    
None 35 (60%) 31 (74%) 66 (66%) 
Stroke 0  2 (5%) 2 (2%) 
Subarachnoid Haemorrhage 3 (5%) 5 (12%) 8 (8%) 
Epilepsy 8 (14%) 4 (10%) 12 (12%) 
Multiple Sclerosis 0  0 0  
Parkinson’s 0  0  0  
Other3 4 (7%) 0  4 (4%) 
Unknown 8 (14%) 1 (2%) 9 (9%) 
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Percentages for type of head injury and other neurological conditions use the number of participants with 
clinical notes available as the denominator.  
1 – Glasgow Coma Scale scores range from 3 to 15 with lower scores indicating more severe brain injury 
2 – Not mutually exclusive, 2 conditions ticked for one participant.  
3 – Other neurological conditions reported were: Paraplygic T9/T10 Spinal cord severed, Attention deficit 
disorder, seizures undiagnosed - under investigation and TIA.  
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Appendix 9. Attendance at group memory rehabilitation 
Table 34: Attendance at each session of group memory rehabilitation  
 
Attendance  Duration (mins) Size of group in attendance 
 n % Median [min, max] Median [min, max] 
Session 1 124 73% 90 [60, 110] 4 [1, 6] 
Session 2 124 73% 90 [60, 110] 4 [1, 6] 
Session 3 114 67% 90 [75, 185] 3 [1, 6] 
Session 4 108 63% 90 [70, 110] 3 [1, 5] 
Session 5 108 63% 90 [60, 100] 3 [1, 5] 
Session 6 101 59% 90 [60, 95] 3 [1, 5] 
Session 7 103 60% 90 [60, 105] 3 [0, 6] 
Session 8 106 62% 90 [60, 110] 3 [0, 6] 
Session 9 94 55% 90 [50, 110] 3 [0, 5] 
Session 10 101 59% 90 [60, 120] 3 [0, 5] 
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Appendix 10. Additional details of treatment fidelity analysis 
Table 35: Video recordings available for inclusion in the analysis 
Site Group Videos Available Videos included in analysis 
Site 1 003 Sessions 4,5,6,7,8,9,10 Sessions 4,5,6,8,9,10 
 011 Sessions 5,7,8,9 Sessions 8,9 
 012 Sessions 9,10 Sessions 9,10 
 020 Sessions 1,2,4,6,7 Sessions 1,2,4,6 
 023 Sessions 2,3,4,5,8 Sessions 2,5 
 024 Sessions 2,3,4 Sessions 3,4 
 031 Sessions 1,3,4,5,8,9,10  
 036 Sessions 1,3,4,5,6,7,8  
Site 2 008 First group  
Site 3 001 First group  
 017 Session 4,5,9,10 Sessions 9,10 
 018 Sessions 8,9 Session 8 
 021 Sessions 3,8  
 029 No recordings  
 032 No recordings  
Site 4 004 First group  
Site 5 016 Sessions 1,2,3,4,5 Sessions 1,4 
 028 No recordings  
 041 No recordings  
 042 No recordings  
 044 No recordings  
 061 No recordings  
 066 No recordings  
Site 6 038 First group  
 039 No recordings  
 045 Session 6 Session 6 
 047 Sessions 2,9 Session 2 
 050 No recordings  
 055 No recordings  
Site 7 048 First group  
 062 Camera missing  
Site 8 053 First group  
 057 Sessions 8,9,10 Sessions 8,10 
Site 9 056 First group  
 058 Sessions 5,6,7,8,9 Sessions 5,6,7,8 
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Table 36: Summary of number of recorded sessions included in the analysis 
 
Session 1 Session 2 Session 3 Session 4 Session 5 Session 6 Session 7 Session 8 Session 9 Session 10 Total 
Site 1 1 2 1 3 2 2 0 2 3 2 18 
Site 3 0 0 0 0 0 0 0 1 1 1 3 
Site 5 1 0 0 1 0 0 0 0 0 0 2 
Site 6 0 1 0 0 0 1 0 0 0 0 2 
Site 8 0 0 0 0 0 0 0 1 0 1 2 
Site 9 0 0 0 0 1 1 1 1 0 0 4 
Total  2 3 1 4 3 4 1 5 4 4 31 
 
  
195 
 
Table 37: Frequency of AP activity observations for each site 
  Site 1 Site 3 Site 5 Site 6 Site 8 Site 9 Total 
Category n1 %2 n % n % n % n % N % n % 
Non-rehabilitation activities               
Introductions 3 0.5 0 0 0 0 0 0 0 0 2 1.1 5 0.4 
Social chat 24 3.7 4 3.4 3 4.5 1 1.3 2 3.0 4 2.2 38 3.2 
Preparing materials, tasks etc 17 2.6 2 1.7 1 1.5 0 0 3 4.5 0 0 23 2.0 
Information about sessions, venue, group etc 32 4.9 4 3.4 14 20.9 1 1.3 1 1.5 4 2.2 56 4.8 
Hospital visit discussion 0 0 0 0 1 1.5 0 0 0 0 1 0.5 2 0.2 
Describing emotions and coping strategies 6 0.9 1 0.9 0 0 0 0 0 0 1 0.5 8 0.7 
Rehabilitation skills               
Facilitating discussion (non-specific prompts) 18 2.7 1 0.9 11 16.4 2 2.5 6 9.0 3 1.6 41 3.5 
Providing feedback not directly related to manual 19 2.9 0 0 2 3.0 2 2.5 5 7.5 0 0 28 2.4 
Providing encouragement/reassurance 24 3.7 1 0.9 3 4.5 3 3.8 0 0 6 3.2 37 3.2 
Summarising 3 0.5 0 0 0 0 0 0 0 0 0 0 3 0.3 
Paraphrasing 13 2.0 1 0.9 1 1.5 6 7.5 0 0 1 0.5 22 1.9 
Rehabilitation activities               
Presenting/discussing educational material 200 30.4 40 34.5 19 28.4 43 53.8 28 41.8 39 21.0 369 31.5 
Presenting/discussing strategies 216 32.9 42 36.2 11 16.4 11 13.8 18 26.9 122 65.6 420 35.8 
Providing general information on memory not related to manual 35 5.36 0 0 1 1.5 3 3.8 1 1.5 2 1.1 42 3.6 
Recap of previous session 47 7.2 20 17.2 0 0 8 10.0 3 4.5 1 0.5 79 6.7 
Total 657 100 116 100 67 100 80 100 67 100 186 100 1173 100 
1 n= number of observations.  2 %= percentage of observation. 
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Table 38: Frequency of participant activity observations for each site 
  Site 1 Site 3 Site 5 Site 6 Site 8 Site 9 Total 
Category n1 %2 n % n % n % n % n % n % 
Non-rehabilitation               
Introductions 7 1.1 0 0 2 2.2 0 0 0 0 0 0 9 0.8 
Social chat 109 16.4 25 17.1 9 10.0 2 4.4 14 20.0 26 16.5 185 15.8 
Preparing materials, tasks etc 6 0.9 0 0 0 0 0 0 0 0 0 0 6 0.5 
Information about sessions, venue, group etc 11 1.7 1 0.7 4 4.4 0 0 1 1.4 1 0.6 18 1.5 
Hospital visit discussion 1 0.2 0 0 10 11.1 0 0 0 0 0 0 11 0.9 
Describing emotions and coping strategies 50 7.5 9 6.2 3 3.3 1 2.2 10 14.3 1 0.6 74 6.3 
Rehabilitation               
Discussing/ filling in educational material 147 22.1 31 21.2 32 35.6 8 17.8 16 22.9 48 30.4 282 24.0 
Discussing strategies 216 32.5 62 42.5 15 16.7 12 26.7 11 15.7 66 41.8 382 32.6 
Asking for information 10 1.5 4 2.7 0 0 5 11.1 0 0 2 1.3 21 1.8 
Feedback on home activities 32 4.8 9 6.2 0 0 4 8.9 13 18.6 11 7.0 69 5.9 
Describing problems related to memory 75 11.3 5 3.4 15 16.7 13 28.9 5 7.1 3 1.9 116 9.9 
Total 664 100 146 100 90 100 45 100 70 100 158 100 1173 100 
1 n= number of observations.  2 %= percentage of observation. 
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Appendix 11. Baseline characteristics and assessments according 
to primary outcome completion and allocated arm 
 
Table 39: Baseline characteristics and assessments completed prior to randomisation 
according to EMQ-p completion at 6-months and allocated arm 
 Usual care – 
no primary 
outcome1 
(n=35) 
Usual care – 
primary 
outcome 
(n=122) 
Intervention – 
no primary 
outcome1 
(n=42) 
Intervention – 
primary 
outcome  
(n=129) 
Age (years)     
Mean [sd] 45.4 [11.1] 45 [12.9] 44.1 [11.6] 46.3 [11.5] 
Median [25th, 75th centile] 46 [38, 54] 44.5 [35, 55] 45 [35, 53] 48 [39, 54] 
Min, max 25, 63 19, 69 20, 65 21, 68 
 n (%) n (%) n (%) n (%) 
Gender     
Men 28 (80%) 88 (72%) 30 (71%) 93 (72%) 
Women 7 (20%) 34 (28%) 12 (29%) 36 (28%) 
     
Ethnicity     
White 30 (86%) 117 (96%) 42 (100%) 125 (97%) 
Black 4 (11%) 2 (2%) 0 2 (2%) 
Mixed Race 0  3 (2%) 0  1 (1%) 
Other 1 (3%) 0  0  1 (1%) 
     
Residential status     
Lives alone 8 (23%) 36 (30%) 11 (26%) 32 (25%) 
Lives with others 25 (71%) 81 (66%) 28 (67%) 92 (71%) 
Living with informal care 1 (3%) 1 (1%) 0  1 (1%) 
Living with formal care 0  2 (2%) 0  0  
Living in care home 1 (3%) 2 (2%) 3 (7%) 4 (3%) 
     
Highest educational attainment     
Below GCSE 7 (20%) 19 (16%) 10 (24%) 19 (15%) 
GCSE 17 (49%) 37 (30%) 16 (38%) 33 (26%) 
A-Level 4 (11%) 38 (31%) 8 (19%) 26 (20%) 
Degree 6 (17%) 18 (15%) 5 (12%) 36 (28%) 
Higher Degree 0  10 (8%) 3 (7%) 14 (11%) 
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 Usual care – 
no primary 
outcome1 
(n=35) 
Usual care – 
primary 
outcome 
(n=122) 
Intervention – 
no primary 
outcome1 
(n=42) 
Intervention – 
primary 
outcome  
(n=129) 
Not known 1 (3%) 0  0  1 (1%) 
     
Current military service     
Military 3 (9%) 1 (1%) 0  0  
TA/reservist 0  0 0 2 (2%) 
Non-military 32 (91%) 121 (99%) 42 (100%) 127 (98%) 
     
Previous military service     
Military 4 (11%) 10 (8%) 3 (7%) 8 (6%) 
TA/reservist 1 (3%) 1 (1%) 2 (5%) 2 (2%) 
Non-military 30 (86%) 111 (91%) 37 (88%) 119 (92%) 
     
TBI during service 2 (6%) 1 (1%) 0  1 (1%) 
     
Time since TBI (months)     
Mean [sd] 103.9 [139.3] 97.6 [107.4] 102.4 [106.5] 102.7 [116] 
Median [25th, 75th centile] 44 [21, 101] 49 [24, 119] 68 [24, 151] 55 [27, 139] 
Min, max 4, 491 4, 520 4, 410 3, 587 
     
Length of initial hospital stay for 
TBI (days)     
Mean [sd] 61.2 [95.5] 87.7 [111.7] 97.4 [200.5] 83 [120.5] 
Median [25th, 75th centile] 21 [7, 63] 36 [7, 122] 35 [9, 84] 38 [11, 120] 
Min, max 1, 468 0, 465 0, 999 0, 999 
n 33 115 39 121 
Length of hospital stay unknown 2  7  3  8  
     
EMQ-p – frequency of problems     
Mean [sd] 54.1 [26.5] 48.9 [23.9] 51.9 [20.5] 45.9 [21] 
Median [25th, 75th centile] 53 [33, 75.4] 48 [32, 64] 56 [43, 68] 44 [30, 60] 
Min, max 12, 105 0, 105 8, 93 5, 102 
n 35 121 42 129 
     
EMQ-p – importance of problems     
Mean [sd] 76.7 [18.3] 68.8 [23.2] 66.7 [19.8] 65.4 [24.6] 
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 Usual care – 
no primary 
outcome1 
(n=35) 
Usual care – 
primary 
outcome 
(n=122) 
Intervention – 
no primary 
outcome1 
(n=42) 
Intervention – 
primary 
outcome  
(n=129) 
Median [25th, 75th centile] 80.9 [67, 89] 70.5 [54, 85] 69.5 [51, 81.9] 69 [51.5, 84] 
Min, max 27, 108 2, 112 5, 101 0, 112 
n 34 118 42 128 
     
RBMT-3 GMI     
Mean [sd] 73.5 [13.8] 77.2 [14.6] 74 [12] 78.8 [13.9] 
Median [25th, 75th centile] 71 [63, 84] 76 [66, 86] 74.5 [65, 83] 78 [68, 85] 
Min, max 53, 106 53, 114 53, 98 56, 127 
n 35 122 42 129 
     
GHQ-30     
Mean [sd] 39.4 [17.7] 34.2 [15.8] 34.7 [14.5] 36.6 [15.7] 
Median [25th, 75th centile] 36.5 [27, 52] 32.5 [21, 45] 32.5 [24, 39] 34.5 [25, 45.3] 
Min, max 10, 90 6, 82 6, 70 10, 84 
n 34 120 42 128 
     
Estimated premorbid IQ (NART)     
Mean [sd] 105.4 [9.5] 106.9 [10.1] 106 [10.2] 108.8 [10.1] 
Median [25th, 75th centile] 102 [100, 116] 103 [99, 117] 103 [100, 114] 112 [100, 117] 
Min, max 89, 121 86, 126 88, 124 87, 128 
n 33 122 42 128 
     
SST      
Mean [sd] 19.4 [0.9] 19.3 [0.9] 19.1 [1.0] 19.5 [0.8] 
Median [25th, 75th centile] 20 [19, 20] 20 [19, 20] 19 [19, 20] 20 [19, 20] 
Min, max 17, 20 17, 20 17, 20 17, 20 
n 35 122 42 129 
Level of memory impairment 
based on RBMT-3 n (%) n (%) n (%) n (%) 
significant memory impairment 
(≤ 69) 
16 (46%) 45 (37%) 15 (36%) 35 (27%) 
borderline/moderate memory 
impairment (70 to 84) 
11 (31%) 43 (35%) 18 (43%) 59 (46%) 
average range or above average 
range (≥85) 
8 (23%) 34 (28%) 9 (21%) 35 (27%) 
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 Usual care – 
no primary 
outcome1 
(n=35) 
Usual care – 
primary 
outcome 
(n=122) 
Intervention – 
no primary 
outcome1 
(n=42) 
Intervention – 
primary 
outcome  
(n=129) 
 n (%) n (%) n (%) n (%) 
Relative/friend agreed to 
participate in trial 17 (49%) 83 (68%) 27 (64%) 83 (64%) 
     
EMQ-r – frequency of problems     
Mean [sd] 53 [28] 45.2 [23.7] 56.8 [29.7] 37.4 [26.6] 
Median [25th, 75th centile] 55.5 [24, 77.6] 41 [27, 58.2] 62 [30, 83] 32.3 [17, 58.5] 
Min, max 10, 98 0, 107 6.2, 108 0, 104 
n 14 81 25 80 
     
EMQ-r – importance of problems     
Mean [sd] 78.3 [14.6] 70.2 [25.9] 74.5 [19.5] 70.8 [21.6] 
Median [25th, 75th centile] 80.8 [67.4, 88] 76 [58, 87] 71 [63, 88.4] 72.6 [60, 87] 
Min, max 52.7, 104 0, 112 33, 112 4, 112 
n 15 75 27 74 
1 No primary outcome group includes participants who did not complete the questionnaire, participants who completed the 
questionnaire more than 9 months after randomisation and participants who completed the questionnaire but missed more 
than 3 items on the EMQ. 
EMQ scores range from 0 to 112 with higher scores indicating more frequent/important memory problems. 
RBMT-3 GMI scores range between 52 and 174 and has been standardised to have a mean of 100 and an SD of 15 on a 
demographically representative sample from the UK. 
GHQ-30 score ranges from 0 to 90 with higher scores indicating increased psychological distress. 
A total SST score of 17 or more was required to participate in the trial. Maximum score 20.   
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Appendix 12. Unblinding of outcome assessors 
Table 40: Unblinding of outcome assessors at 6- and 12-month follow-up visits and opinion of treatment allocation 
 6-month follow-up 12-month follow-up 
  
Usual care 
 (n = 133) 
Memory 
Rehabilitation  
(n = 143) 
 
Kappa 
statistic 
 
Usual care 
 (n = 124) 
Memory 
Rehabilitation  
(n = 132) 
 
Kappa 
statistic 
 n (%) n (%)  n (%) n (%)  
Unblinded prior to the visit 9 (7%) 35 (24%)  9 (7%) 28 (21%)  
Unblinded during the visit 16 (12%) 52 (36%)  7 (6%) 36 (27%)  
Unblinded prior to and/or during the visit 21 (16%) 64 (45%)  13 (10%) 42 (32%)  
       
  Opinion of treatment allocation prior  
  to goal assessment 
   
0.24 
  
0.26 
Definitely control 9 (7%) 0   7 (6%) 1 (1%)  
Probably control 109 (82%) 92 (64%)  111 (90%) 90 (68%)  
Probably intervention 15 (11%) 19 (13%)  4 (3%) 14 (11%)  
Definitely intervention 0  32 (22%)  2 (2%) 27 (20%)  
       
  Opinion of treatment allocation after  
  goal assessment 
   
0.42 
  
0.46 
Definitely control 21 (16%) 2 (1%)  9 (7%) 2 (2%)  
Probably control 97 (73%) 64 (45%)  108 (87%) 61 (46%)  
Probably intervention 14 (11%) 17 (12%)  6 (5%) 28 (21%)  
Definitely intervention 1 (1%) 60 (42%)  1 (1%) 41 (31%)  
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Appendix 13. Relative/friend questionnaire return 
Table 41: Rates of return of relative/friend questionnaire at follow-up 
 6-month questionnaire booklet1 12-month questionnaire booklet1 
 
Relative/friend agreed to 
participate in trial 
 
Usual care 
 (n=100) 
Memory 
Rehabilitation  
(n=110) 
 
Total 
(n=210) 
 
Usual care 
 (n=100) 
Memory 
Rehabilitation  
(n=110) 
 
Total 
(n=210) 
 n (%) n (%) n (%) n (%) n (%) n (%) 
Questionnaire booklet1       
      Returned 73 (73%) 71 (65%) 144 (68%) 61 (61%) 70 (64%) 131 (62%) 
      Not done 21 (21%) 27 (25%) 48 (22%) 24 (24%) 22 (20%) 46 (22%) 
      Participant discontinued 6 (6%) 12 (11%) 18 (8%) 15 (15%) 18 (16%) 33 (16%) 
       
      Days to  completion from  
      randomisation  
      
           Median [25th, 75th centile] 171 [167, 179] 174 [168, 184] 173 [167, 181] 352 [349, 360] 358 [353, 365] 355 [350, 363] 
           Min, Max 161, 277 156, 268 156, 277 341, 433 345, 420 341, 433 
       
      Questionnaire completed within  
3 months of due date2 72 (72%) 71 (65%) 143 (68%) 61 (61%) 70 (64%) 131 (62%) 
       
1 – Percentages for questionnaire booklet return use the number of relative/friends agreeing to participate in the trial as the denominator.  
2 – Questionnaire completion within 9 months of randomisation at 6-month follow-up and 15 months of randomisation at 12-month follow-up. 
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Appendix 14. Sensitivity analyses for the primary outcome 
 
Figure 15: Sensitivity analysis for difference in mean EMQ-p score at 6-month follow-up  
 
 
 
Table 42. Analysis after Rasch conversion of the EMQ-p 
  
Baseline 
Mean [sd] 
 
6 months 
Mean [sd] 
Adjusted 
difference in 
means (95% CI) 
    
Usual care (n = 122) 21.7 [8.1] 20.0 [8.3]  
    
Memory Rehabilitation (n = 129)  21.3 [6.8] 17.7 [9.5] -1.2 (-3.0 to 0.5) 
    
    
For Rasch scoring, EMQ items were first rescored as 00112 and totalled. Total score then converted to Rasch score using 
conversion table for TBI patients (R. Johnson, R. das Nair, N.B. Lincoln, 2017, personal communication). Rasch 
converted scores range from 0 to 56.04.  
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Appendix 15. Sub-group analyses conducted on baseline memory 
impairment 
Figure 16: Difference in mean EMQ-p score at 6-month follow-up according to memory 
impairment at baseline 
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Appendix 16. Sub-group analyses conducted on time since TBI 
 
Note: this sub-group analysis was not pre specified in SAP.  
The categories for time since TBI were discussed at a trial management meeting prior to analysis. The 
categories initially proposed were quartiles i.e. 2 years or less, 2 to 4 years, 4 to 10 years, more than 10 years. 
However it was felt there is a minimal clinical difference between those at 2 years post injury and 4 years. 
Three categories were therefore agreed 2 years or less, 2 to 10 years and more than 10 years. 
 
Table 43. Sub-group analyses conducted on time since TBI 
 
Baseline 
Mean [sd] 
6 months 
Mean [sd] 
Adjusted difference 
in means (95% CI) 
Adjusted 
interaction effect 
(95% CI) 
     
2 years or less since TBI     
Usual care (n = 31) 50.0 [22.5] 43.1 [28.0]   
Memory Rehabilitation (n = 30)  43.4 [20.4] 34.3 [25.8]   -2.1 (-10.9 to 6.7)  
     
More than 2 years to 10 years 
since TBI 
   
 
Usual care (n = 61) 46.6 [23.9] 42.7 [24.1]     
Memory Rehabilitation (n = 58)  41.6 [20.5] 34.5 [24.0]    -4.9 (-11.3 to 1.6) -2.8 (-13.5 to 7.9) 
     
More than 10 years since TBI      
Usual care (n = 30) 52.6 [25.7]   47.8 [22.1]     
Memory Rehabilitation (n = 41)  53.8 [20.5] 48.1 [27.3] 1.5 (-6.7 to 9.7) 3.6 (-8.3 to 15.5) 
     
     
p-value for interaction effect: 0.48 
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Appendix 17. EMQ-p importance scores at 6- and 12-month follow-up 
 
Table 44. EMQ-p importance scores 
 
Baseline 
Mean [sd] 
Follow-up  
Mean [sd] 
Adjusted 
difference in 
means (95% CI) 
    
6-month follow-up    
Usual care (n = 119) 69.5 [23.0] 73.9 [24.3]  
Memory Rehabilitation (n = 124) 65.5 [24.9] 68.7 [25.8] -4.0 (-9.8 to 1.8) 
    
12-month follow-up    
Usual care (n = 106) 69.9 [23.9] 73.6 [25.2]  
Memory Rehabilitation (n = 123) 66.9 [23.2] 67.9 [24.5] -4.3 (-10.3 to 1.7) 
    
Everyday Memory Questionnaire scores range from 0 to 112 with higher scores indicating more important memory 
problems).   
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Appendix 18. Analysis of goal attainment for SMART goals 
 
Table 45. Analysis of goal attainment for SMART goals 
 6 months  12 months  
 
 
 
n Mean [sd] 
Adjusted 
difference in 
means  
(95% CI) n Mean [sd] 
Adjusted 
difference in 
means  
(95% CI) 
       
Short term goal 
achievement average 
score  
 
  
   
Usual care  126 1.2 [1.1]  119 1.6 [1.1]  
Memory Rehabilitation  126 1.8 [1.0] 0.6 (0.3 to 0.9) 117 1.9 [1.0] 0.2 (0.0 to 0.5) 
       
Long term goal 
achievement average 
score  
 
  
   
Usual care  123 1.0 [0.9]  117 1.3 [1.0]  
Memory Rehabilitation  121 1.5 [1.0] 0.6 (0.3 to 0.8) 114 1.7 [1.0] 0.4 (0.1 to 0.7) 
       
Goals attainment was assessed on a 4-point Likert scale of not met (0), met a little (1), mostly met (2), and fully met (3). The average 
achievement score across the goals set was calculated for each participant. Number of SMART goals set was included in the analysis 
model.  
Of those completing 6-month follow-up, no SMART short term goals were set for 7 participants in the usual care arm and 16 in the 
memory rehabilitation arm and no SMART long terms goals were set for 10 participants in the usual care arm and 21 participants in 
the memory rehabilitation arm. 
Of those completing 12-month follow-up, no SMART short term goals were set for 5 participants in the usual care arm and 15 in the 
memory rehabilitation arm and no SMART long term goals were set for 7 participants in the usual care arm and 18 participants in the 
memory rehabilitation arm. 
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Appendix 19. EMQ-r importance scores at 6- and 12-month follow-up 
 
Table 46. EMQ-r importance scores 
 
Baseline 
Mean [sd] 
Follow-up  
Mean [sd] 
Adjusted 
difference in 
means (95% CI) 
    
6-month follow-up    
Usual care (n = 64) 68.2 [27.8] 71.8 [25.2]  
Memory Rehabilitation (n = 69) 69.4 [22.0] 68.7 [25.3] -4.8 (-11.2 to 1.6) 
    
12-month follow-up    
Usual care (n = 57) 69.5 [27.6] 65.3 [28.2]  
Memory Rehabilitation (n = 64) 69.7 [21.4] 64.5 [26.4] -0.6 (-8.1 to 6.9) 
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Appendix 20. Unit Costs Associated with Service Resource Use 
 
Table 47. Unit costs associated with service resource use 
Resource Input 
Unit 
Cost (£) 
Source  
Notes 
Community-based Health Care 
GP Surgery Visit (Per surgery 
consultation lasting 9.22 minutes) 
£36 PSSRU 2016 page 145 
 
GP Telephone Consultation (Per 
telephone consultation lasting 
avg. 4 minutes) 
£14.60 PSSRU 2016 page 147 
 
GP Home Visit (Per out of 
surgery visit lasting 23.4 minutes) 
£120 
PSSRU 2013 page 191 
(inflated to 2016 prices 
using BOE calculator) 
 
Practice Nurse Surgery 
Consultation 
£43 PSSRU 2016 page 143 
 
Surgery Nurse Telephone 
Consultation (Per telephone 
consultation lasting avg. 6.56 
minutes) 
£7.90 PSSRU 2016 page 147 
 
Specialist Nurse (Agenda for 
Change Band 7) 
£52 PSSRU (2016) page 142 
 
Community Pharmacy £42 PSSRU 2016 page 201 
This cost is based on ‘Cost per 
working hour’ from the PSSRU. It 
was assumed that this would cover 
the cost of prescribing as well as any 
possible consultations. 
Community Physiotherapist £32 PSSRU 2016 page 200  
Community Occupational 
Therapist 
£32 PSSRU 2016 page 200 
 
Community Speech and Language 
Therapist 
£32 PSSRU 2016 page 200 
 
Podiatrist £32 PSSRU 2016 page 200  
Dietitian £32 PSSRU 2016 page 200  
Clinical psychologist, per hour of 
client contact 
£74 PSSRU 2016 page 201 
 
Assistant clinical psychologist, 
per hour of client contact 
£32 PSSRU 2016 page 201 
 
Psychiatrist £74 PSSRU 2016 page 201  
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Resource Input 
Unit 
Cost (£) 
Source  Notes 
Elective Surgery as Inpatient: 
Muscular, Balance, Cranial or 
Peripheral Nerve Disorders, 
Epilepsy or Head Injury, with CC 
Score 15+ 
£7,605 
NHS Reference Costs 
(2015/2016) AA26C 
 
Muscular, Balance, Cranial or 
Peripheral Nerve Disorders, 
Epilepsy or Head Injury, with CC 
Score 6-8 
£2,932 
NHS Reference Costs 
(2015/2016) AA26F 
 
Headache, Migraine or 
Cerebrospinal Fluid Leak, with 
CC Score 0-6 
£1,672 
NHS Reference Costs 
(2015/2016) AA31E 
 
Minor, Cataract or Lens 
Procedures 
£919 
NHS Reference Costs 
(2015/2016) BZ33Z 
 
Major, Mouth or Throat 
Procedures, 19 years and over, 
with CC Score 2+ 
£2,951 
NHS Reference Costs 
(2015/2016) CA83A 
 
Complex Maxillofacial 
Procedures with CC Score 0 
£5,507 
NHS Reference Costs 
(2015/2016) CA91B 
 
Reduction or Fixation, of Jaw £2,854 
NHS Reference Costs 
(2015/2016) CA96Z 
 
Pulmonary, Pleural or Other 
Tuberculosis, without 
Interventions, with CC Score 0-2 
£1,923 
NHS Reference Costs 
(2015/2016) DZ14J 
 
Unspecified Chest Pain with CC 
Score 11+ 
£1,345 
NHS Reference Costs 
(2015/2016) EB12A 
 
Major General Abdominal 
Procedures, 1 year and under, 
with CC Score 0-1 
£5,090 
NHS Reference Costs 
(2015/2016) FZ12U 
 
Low Back Pain without 
Interventions, with CC Score 0-2 
£1,510 
NHS Reference Costs 
(2015/2016) HC32K 
 
Foot Fracture with Single 
Intervention, with CC Score 0-1 
£5,544 
NHS Reference Costs 
(2015/2016) HE31C 
 
Intermediate Knee Procedures for 
Non-Trauma, 19 years and over, 
with CC Score 0-1 
£2,647 
NHS Reference Costs 
(2015/2016) HN24C 
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Non-Malignant Prostate Disorders 
without Interventions, with CC 
Score 6+ 
£1,926 
NHS Reference Costs 
(2015/2016) LB28E 
 
Major Open, Scrotum, Testis or 
Vas Deferens Procedures, with 
CC Score 0-1 
£2,638 
NHS Reference Costs 
(2015/2016) LB52B 
 
Labour without Specified 
Delivery 
£1,110 
NHS Reference Costs 
(2015/2016) NZ25Z 
 
Allergy or Adverse Allergic 
Reaction 
£1,288 
NHS Reference Costs 
(2015/2016) WH05Z 
 
Unspecified Oedema with CC 
Score 2+ 
£2,360 
NHS Reference Costs 
(2015/2016) WH10A 
 
Percutaneous Single Drainage of 
Abdominal Abscess, with CC 
Score 2-4 
£5,226 
NHS Reference Costs 
(2015/2016) YF04B 
 
Open Arteriovenous Fistula, Graft 
or Shunt Procedures 
£2,451 
NHS Reference Costs 
(2015/2016) YQ42Z 
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Resource Input 
Unit 
Cost (£) 
Source  Notes 
Non elective surgery as an inpatient: 
Muscular, Balance, Cranial or 
Peripheral Nerve Disorders, 
Epilepsy or Head Injury, with CC 
Score 15+ 
£6,687 
NHS Reference Costs 
(2015/2016) AA26C 
Even though the SUQ doesn’t 
distinguish between elective or non-
elective, assumptions were made 
based on the description given by the 
participant, the assumed severity 
given by the description and the 
length of stay given. All three of 
these considerations were used to 
estimate whether it was elective or 
non-elective 
Liver Failure Disorders with 
Multiple Interventions 
£6,199 
NHS Reference Costs 
(2015/2016) GC01C 
 
Very Major Knee Procedures for 
Non-Trauma with CC Score 0-1 
£6,692 
NHS Reference Costs 
(2015/2016) HN22E 
 
Allergy or Adverse Allergic 
Reaction (non elective long stay) 
£1,298 
NHS Reference Costs 
(2015/2016) WH05Z 
 
Unspecified Pain with CC Score 0 £1,537 
NHS Reference Costs 
(2015/2016) WH08B 
 
Tendency to Fall, Senility or 
Other Conditions Affecting 
Cognitive Functions, without 
Interventions, with CC Score 0-1 
£1,847 
NHS Reference Costs 
(2015/2016) WH09G 
 
Fever of Unknown Origin without 
Interventions, with CC Score 0-3 
£1,576 
NHS Reference Costs 
(2015/2016) WJ07D 
 
Allergy or Adverse Allergic 
Reaction (non-elective short stay) 
£375 
NHS Reference Costs 
(2015/2016) WH05Z 
 
Outpatient 
General Surgery £130 
NHS Reference Costs 
(2015/2016) 
Due to ambiguous description of 
outpatient visits (e.g. “gone to 
hospital”) figure has been used to 
capture items not able to be 
individually costed. 
Medications 
Prescribed Medication  Various BNF 
Various costs. See Appendix 21 for 
full list of medication. 
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Appendix 21.  Unit Costs Associated with Medication Use 
 
Table 48. Unit costs associated with medication use 
Drug Cost Drug Cost 
Adcal D3 £3.65 Co-Amilofruse £5.57 
Aladronic Acid £0.96 Co-Codamol £6.74 
Amiodarone £1.29 Codeine £1.44 
Amitriptyline £0.96 Colecaciferol £3.60 
Alipurinol £1.12 Colesevelam 625Mg Tablets £96.10 
Amlodipine £0.91 Colestyramine £31.85 
Amoxicillin  £1.30 Contraceptive Pill - Cerelle £3.17 
Amytriptyline £0.96 Cyanocobalamin £8.99 
Antenolol 50 Mg £0.87 Cyclazine £10.85 
Asacol £26.72 Depakote £17.08 
Ascorbic Acid 200Mg Tablets £18.59 Desmopressin £8.76 
Aspirin £0.81 Detrusitol Xl £30.56 
Asthma Inhaler £7.87 Diazepam £1.02 
Atenolol £0.87 Diclofenac £1.25 
Atorvastatin £1.57 Digoxin £2.44 
Avistatin £1.57 Dihydrocodeine £1.43 
Azathioprine £3.24 Diltizem £37.91 
Baclofen £1.92 Dioxepan £3.77 
Beclometasone £5.36 Disulfiram £31.00 
Bendroflumethiazide £0.80 Docusate £2.09 
Bezafibrate £3.25 Doxasozin £0.90 
Bisoprolol £0.91 Duloxatine £27.72 
Buprenorphine £1.60 Enalapril £1.15 
Buscopan £3.00 Epilim £7.70 
Butrans (Transdermal And Buprenorphine) 
Pain Patch £17.60 Erythromycin £5.61 
Cabergoline £34.93 Eumovate £1.86 
Carbamazepine £2.51 Ezetimibe £26.31 
Cardicor £2.35 Felodipine £4.21 
Cerazette £9.55 Felodipine 2.5Mg £6.31 
Certraline £1.83 Ferrous Fumarate £2.30 
Cetirizine Hydrochloride £1.87 Ferrous Sulphate £1.06 
Chlorhexidine Gluconate Mouthwash 
(Mint) 0.2% £1.26 Fexofenadine Hydrochloride £3.65 
Cholecalciferol £3.60 Finasteride £1.73 
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Cinchocaine 0.5% / Hydrocortisone 0.5% 
Ointment £10.34 Flucloxacillin Sodium £2.46 
Cinnazrizine £5.59 Fluoxetine £1.11 
Citalapram £1.21 Fluticasone £6.38 
Clomipramin £1.55 Folic Acid £1.02 
Clonazepam £6.94 Frusemide £0.83 
Clonidine £10.08 Gabapenten £4.36 
Clopidogrel £1.82 Gliclazide 80Mg £2.06 
Drug Cost Drug Cost 
Glucozamin And Condrotin (Combined) £18.40 Nortriptylene £12.06 
Hayfever Tablets £2.91 Olanzipine £1.13 
HRT £6.52 Omeprazole £13.80 
Hydrocortisone £78.50 Oxcarbazepine £9.29 
Hydroxychloroquine £5.31 Oxinorm £22.86 
Ibrupofen £0.20 Oxybutynin £2.06 
Imipramine £1.32 Pantasa Suppositories /G £36.89 
Inhaler £18.00 Pantripazole £1.18 
Insulin £30.68 Paracetamol £0.19 
Irbesartan 150Mg Tablets £2.72 Paroxetine £2.70 
Keppra £28.01 Phenytoin Sodium £15.98 
Ketovite Tablets (Essential Pharmaceuticals 
Ltd) £9.21 Phenytoin Sodium £57.38 
Lacidipine £2.95 Pizotifen £7.22 
Lactulose £1.95 Pramipexde £2.25 
Lamictal (Lamotrigine) £69.04 Pravastatin £1.85 
Lamotrigine £2.21 Prednisalone Steroid £1.24 
Lansoprazole £1.10 Prednisolone 1Mg £1.07 
Lantus £1.10 Pregabalin £64.40 
Levetiracetam £7.24 Prochlorperazine £1.12 
Levothyroxin £2.02 Propranolol £3.22 
Lisinopril £0.89 Propivetine £18.00 
Loperamide £2.15 Propranolol 10Mg £1.45 
Loratadine £1.06 Quetiapine £1.44 
Losartan Potassium £1.15 Quinine Sulphate £2.17 
Lymecyline £8.58 Rainticline £1.37 
Lyrica (Pregabalin) £64.40 Ramapril £1.07 
Mebeverine £4.22 Ranitidine 150 Mg £1.37 
Metformin £2.66 Risperidone £1.76 
Methotrexate £2.40 Rivaroxaban £58.80 
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Metronidazole £15.99 Rosuvastatin 10Mg Tablets £18.03 
Mirtazapine £2.03 Sabutomol Inhaler £1.91 
Montelukast £2.41 Senna £3.99 
Naproxen £1.54 Seratide £18.00 
Nasobec Aqueous £2.49 Sertraline £1.83 
Neproxin £1.12 Simvasstatin £2.02 
Nicorandil £3.66 Sitagliptin £33.26 
Nicotine £7.54 Sodium Valporate £4.75 
Nifedipine £1.74 Solifenacin £27.62 
Nitrazapan £1.74 Solpodol £2.20 
Oxycodeine £11.43 Statins £0.84 
Oxynorm £22.86 Suboxone £76.19 
Oxytetracycline £1.14 Sumatriptan £1.61 
Nitrofurinton £3.53 Symbicort Inhaler & Ventolin £33.00 
Drug Cost 
Tamusolin £4.47 
Tegretol £5.02 
Temazepam £10.70 
Thiamine £10.13 
Thyroxin £2.02 
Tomazepam £10.70 
Topiramate £2.37 
Tovias 8Mg £25.78 
Tramadol £1.20 
Tranexamic £6.73 
Trazadone £30.34 
Tricagrelor £54.60 
Trihexyphenidyl £8.27 
Trileptal £12.24 
Tylex £9.06 
Venlafaxine £10.44 
Venlafaxine Hydrochloride £2.35 
Ventolin £1.50 
Viagra £16.59 
Viatmin B £1.95 
Vitamin D £8.99 
Warfarin £0.31 
Zinc Sulfate Monohydrate 125Mg 
Effervescent Tablets Sugar Free £4.32 
217 
 
Zoipidem £1.19 
Zolmitriptan £1.22 
Zolpidem (7.5Mg) £1.19 
Zopalcone £1.17 
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Appendix 22. Illustration of the Cost-Effectiveness Plan 
Figure 17: Illustration of the Cost-Effectiveness (CE) Plane 
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Intervention more Costly and 
more effective than usual care 
Intervention 
More 
Effective 
South-West (SW) Quadrant 
Further Evaluation Required 
Intervention less Costly and 
less effective than usual care 
South-East (SE) Quadrant 
Intervention Dominant 
Intervention less Costly and 
more effective than usual care 
 Intervention Less Costly  
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Appendix 23. Markov model 
Figure 18. Markov model structure 
 
  
Intervention
Low GHQ Score
Moderate GHQ 
Score
High GHQ Score
Dead
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Appendix 24.  Model Parameters 
From Brooks et al. 91, for the low and moderate categories the SMR is defined by the “walks well” 
category whereas the “some walking” SMR is used for those with high GHQ-30 scores.  As detailed 
by Briggs et al. 148, in order to transform probabilities between periods of differential length requires 
the derivation of instantaneous rates from which the appropriate probability can be calculated.  To 
convert the yearly SMR adjusted mortality probability presented by Brooks et al. 91 for a cycle length 
of 6-months, the formulae below are used where pn and rn are the n-month probability and rate of 
death respectively: 
 
𝑟1 = −
[ln(1 − 𝑝12)]
12
 
(1) 
 𝑝6 = 1 − 𝑒
−6𝑟1 (2) 
Using these formulae, the 12-month mortality probability is transformed to the monthly death rate, 
which is subsequently transformed back to a 6-month probability.  The adjusted 6-month mortality 
rates are presented in the table below: 
 
Table 49. Adjusted 6-month mortality rates 
  Low/Moderate High 
Age 
Unadjusted 
Mortality 
Rate (1-Year) 
SMR – 
“Walks 
Well” 
Adjusted 
Mortality 
Rate (6-
Months) 
SMR – 
“Some 
Walking”  
Adjusted 
Mortality 
Rate (6-
Months) 
20 0.000442 3.10 0.00058 3.80 0.00071 
30 0.000464 3.10 0.00092 3.80 0.00113 
40 0.000455 2.90 0.00189 4.50 0.00294 
50 0.000530 2.90 0.00414 4.50 0.00643 
60 0.000527 1.40 0.00500 2.70 0.00966 
70 0.000557 1.40 0.01215 2.70 0.02357 
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80 0.000594 0.70 0.01808 1.50 0.03916 
90 0.000608 0.70 0.05733 1.50 0.12745 
100 0.000597 0.70 0.13712 1.50 0.32723 
Given the adjusted mortality rates presented in the table above, the table below defines the baseline 
transition probabilities for an individual aged 45 years. 
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Table 50. Baseline Transition Probability Matrix 
 
 Intervention Control   
 Transition Probability: 0-6 Months 
 Low Moderate High Death Low Moderate High Death Distribution Source 
Low 0.715 0.188 0.094 0.003 0.716 0.239 0.043 0.002 Beta 
Trial data, Brooks et al. 91, ONS 
National Life Tables 89 
Moderate 0.347 0.499 0.152 0.003 0.288 0.466 0.244 0.002 Beta 
Trial data, Brooks et al. 91, ONS 
National Life Tables 89 
High 0.159 0.358 0.478 0.004 0.199 0.299 0.498 0.004 Beta 
Trial data, Brooks et al. 91, ONS 
National Life Tables 89 
Death 0.000 0.000 0.000 1.000 0.000 0.000 0.000 1.000 Beta 
Trial data, Brooks et al. 91, ONS 
National Life Tables 89 
 Transition Probability: 6-12 Months 
 Low Moderate High Death Low Moderate High Death Distribution Source 
Low 0.802 0.117 0.078 0.003 0.696 0.162 0.139 0.002 Beta 
Trial data, Brooks et al. 91, ONS 
National Life Tables 89 
Moderate 0.332 0.526 0.138 0.003 0.374 0.561 0.062 0.002 Beta 
Trial data, Brooks et al. 91, ONS 
National Life Tables 89 
High 0.111 0.387 0.498 0.005 0.124 0.373 0.498 0.004 Beta 
Trial data, Brooks et al. 91, ONS 
National Life Tables 89 
Death 0.000 0.000 0.000 1.000 0.000 0.000 0.000 1.000 Beta 
Trial data, Brooks et al. 91, ONS 
National Life Tables 89 
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For the three non-dead health states, the mean costs and utilities, and associated standard errors, are 
presented in the table below: 
 
Table 51. Mean costs and utilities 
 INTERVENTION CONTROL   
 Mean Cost 
(£) 
Std. Err. 
(£) 
Mean Cost 
(£) 
Std. Err. 
(£) 
Distribution Source 
 0-6 Months 
Low GHQ 242.88 54.23 304.00  64.33 Gamma Trial data 
Moderate GHQ 452.06 188.14 471.43  126.69 Gamma Trial data 
High GHQ 353.17 204.01 715.58  171.38 Gamma Trial data 
 6-12 Months 
Low GHQ 242.88 76.26 204.14  37.95 Gamma Trial data 
Moderate GHQ 452.06  65.36 820.75  200.75 Gamma Trial data 
High GHQ 353.17  108.56 547.90  237.74 Gamma Trial data 
 12+ Months 
Low GHQ 343.36  104.82 211.91  49.54 Gamma Trial data 
Moderate GHQ 315.47  51.41 442.50  66.37 Gamma Trial data 
High GHQ 694.19  286.69 561.34  324.25 Gamma Trial data 
 Mean Utility Std. Err. Mean Utility Std. Err. Distribution Source 
 0-6 Months 
Low GHQ 0.710 0.029 0.653 0.037 Beta Trial data 
Moderate GHQ 0.660 0.029 0.569 0.031 Beta Trial data 
High GHQ 0.443 0.047 0.461 0.046 Beta Trial data 
 6-12 Months 
Low GHQ 0.742 0.025 0.672 0.032 Beta Trial data 
Moderate GHQ 0.626 0.017 0.559 0.027 Beta Trial data 
High GHQ 0.428 0.076 0.410 0.059 Beta Trial data 
 12+ Months 
Low GHQ 0.724 0.028 0.699 0.027 Beta Trial data 
Moderate GHQ 0.635 0.016 0.595 0.024 Beta Trial data 
High GHQ 0.442 0.063 0.530 0.056 Beta Trial data 
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Appendix 25.  Costs associated with the training and delivery of the 
ReMemBrIn intervention 
 
Table 52. Costs associated with training and delivery of the ReMemBrIn intervention 
  
Based on 9 sites, 35 groups, 350 sessions (10 sessions per group), 
171 Participants 
  
Resource 
Unit 
cost 
Resource 
Usage 
Cost TOTAL 
Unit cost 
source/Description 
Training Costs 
Training Costs 
Training Psychologist 
Band 8a 
£66 2 Hours £132   
PSSRU (2016) Band 5 
- Band 8 Page 185 
 AP training  (mid-
band 5) 
£35 2 Hours £70   
PSSRU (2016) Band 5 
- Page 185 
Cost per Site     £202     
One off training cost 
(sub-total)  
    
  
£1,818 Based on 9 sites 
Delivery Costs 
Per Group 
Variable Costs 
Admin Staff (Band 3) £25 
1 Hour 
per group 
£25   
PSSRU (2016) Band 3 
Page 188 & Page 199 
Cost per Group     £25     
Total admin cost for 
groups (sub-total) 
    
  
£875 Based on 35 groups 
Per Session 
Variable Costs 
AP Band (mid-band 5) £35 
2 Hours 
per 
session 
£70   
PSSRU (2016) Band 5 
- Page 185 
Total per Session     £70     
Total cost of sessions 
(sub-total) 
    
  
£24,500 Based on 350 sessions 
Per Participant 
Variable Costs 
Cost per manual £2.20 
1 manual 
per 
participant 
£2.20   
As advised by trial 
team 
Refreshments £0.50 
£0.50 per 
participant 
per 
session 
£5.00   
As advised by trial 
team 
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Stationery Costs 
(e.g.Pens, misc) 
£1.00 
Est. total 
£1 per 
participant 
for all 
sessions 
£1.00   
As advised by trial 
team 
Total per Participant     £8.20     
Per participant costs 
(sub-total) 
    
  
£1,402 
Based on 171 
participants 
TOTAL COST 
OF 
INTERVENTION 
Overall cost of 
rehabilitation 
intervention 
  £28,595   
Cost of rehabilitation 
per participant 
£167 
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Appendix 26.  Resource utilisation and service usage costs (available cases) 
 
Table 53. Resource utilisation at baseline (available cases) 
Resource Utilisation (No.) Arm N Sum Mean 
Std. 
Deviation 
95% Confidence Interval 
of the Difference 
p-value 
No.of GP consultations (linked to memory problems) per patient  
Usual care 130 19 0.12 0.44 0.056 
(-0.024, 0.137) 
0.168 
Intervention 137 11 0.06 0.29 
No.of GP consultations (for other reasons) per patient  
Usual care 151 283 1.80 2.05 0.311 
(-0.168, 0.790) 
0.202 
Intervention 157 255 1.49 2.33 
No.of Practice Nurse consultations (linked to memory problems) per patient  
Usual care 129 5 0.03 0.29 0.008 
(-0.056, 0.073) 
0.797 
Intervention 134 4 0.02 0.31 
No.of Practice Nurse consultations (for other reasons) per patient  
Usual care 137 68 0.43 1.01 -0.456 
(-0.954, 0.042) 
0.073 
Intervention 147 152 0.89 3.02 
No.of consultations with other Healthcare professionals (linked to memory 
problems) per patient  
Usual care 131 66 0.42 2.22 0.046 
(-0.346, 0.434) 
0.817 
Intervention 139 64 0.37 1.31 
No.of consultations with other Healthcare professionals (for other reasons) per 
patient  
Usual care 144 349 2.22 5.23 0.0241 
(-1.035, 1.083) 
0.964 
Intervention 156 376 2.20 4.52 
No.of times being an in-patient due to memory problems  
Usual care 157 0 0 0 
- - 
Intervention 171 0 0 0 
No.of Days being an in-patient due to memory problems  
Usual care 157 0 0 0 
- - 
Intervention 171 0 0 0 
No.of times being an in-patient due to other reasons  
Usual care 134 11 0.07 0.28 -0.006 
(-0.070, 0.058) 
0.855 
Intervention 139 13 0.08 0.31 
No.of Days being an in-patient due to other reasons   
Usual care 24 33 0.21 0.99 -0.094 
(-0.447, 0.259) 
0.601 
Intervention 27 52 0.30 2.04 
No.of GP Home consultations (linked to memory problems) per patient  Usual care 157 0 0 0 - - 
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Intervention 171 0 0 0 
No.of GP Home consultations (for other reasons) per patient  
Usual care 129 5 0.03 0.21 -0.003 
(-0.063, 0.057) 
0.915 
Intervention 136 6 0.04 0.32 
No.of Practice Nurse Home consultations (linked to memory problems) per 
patient  
Usual care 128 0 0.00 0.00 -0.006 
(-0.018, 0.006) 
0.339 
Intervention 134 1 0.01 0.08 
No.of Practice Nurse Home consultations (for other reasons) per patient  
Usual care 130 73 0.46 3.35 0.436 
(-0.070, 0.941) 
0.091 
Intervention 137 5 0.03 0.23 
No.of Home consultations with other Healthcare professionals (linked to 
memory problems) per patient  
Usual care 128 26 0.17 0.72 -0.829 
(-2.059, 0.402) 
0.186 
Intervention 136 170 0.99 7.81 
No.of Home consultations with other Healthcare professionals (for other 
reasons) per patient  
Usual care 132 169 1.08 3.61 -0.198 
(-1.072, 0.675) 
0.655 
Intervention 143 218 1.27 4.35 
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Table 54. Service Usage Costs associated with resource utilisation at 6-months (available cases) 
 
  
Mean (£) 
[std. err.] 
95% CI (£) Difference in Means (£) 
(95% CI)a 
p-value 
Primary Care Visits  
 
  
Usual care 
(n = 155) 
206.06 
(28.20) 
(150.346, 261.780) 
-3.54 
(-73.53, 66.44) 
0.921 
Memory Rehabilitation 
(n = 170) 
202.52 
(22.19) 
(158.71, 246.33) 
Primary Care Home Visits 
Usual care 
(n = 155) 
74.172 
(17.55) 
(39.494, 108.850) 
-2.84 
(-53.05, 47.37) 
0.911 
Memory Rehabilitation 
(n = 170) 
71.33 
(18.38) 
(35.05, 107.60) 
Inpatient 
Usual care 
(n = 155) 
156.85 
(56.10) 
(46.023, 267.668) 
54.90 
(-134.78, 244.59) 
0.570 
Memory Rehabilitation 
(n = 170) 
211.75 
(76.54) 
(60.64, 362.85 
Medication 
Usual care 
(n = 155) 
16.24 
(2.04) 
(12.21, 20.28) 
-2.52 
(-8.13, 3.08) 
0.376 
Memory Rehabilitation 
(n = 170) 
13.72 
(1.98) 
(9.81, 17.63) 
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Table 55. Resource utilisation at 6-months (available cases) 
Resource Utilisation (No.) Arm N Sum Mean 
Std. 
Deviation 
95% Confidence Interval 
of the Difference 
p-value 
No.of GP consultations (linked to memory problems) per 
patient at 6 Months 
Usual care 84 44 0.28 0.75 0.076 
(-0.089, 0.240) 
0.368 
Intervention 102 35 0.20 0.77 
No.of GP consultations (for other reasons) per patient at 6 
Months 
Usual care 85 132 0.84 1.55 0.133 
(-0.159, 0.426) 
0.371 
Intervention 101 121 0.71 1.12 
No.of Practice Nurse consultations (linked to memory 
problems) per patient at 6 Months 
Usual care 83 19 0.12 0.57 0.033 
(-0.076, 0.143) 
0.549 
Intervention 97 15 0.09 0.43 
No.of Practice Nurse consultations (for other reasons) per 
patient at 6 Months 
Usual care 74 47 0.30 1.06 -0.011 
(-0.249, 0.228) 
0.931 
Intervention 88 53 0.31 1.13 
No.of consultations with other Healthcare professionals 
(linked to memory problems) per patient at 6 Months 
Usual care 86 83 0.53 1.76 0.218 
(-0.099, 0.537) 
0.177 
Intervention 101 53 0.31 1.13 
No.of consultations with other Healthcare professionals (for 
other reasons) per patient at 6 Months 
Usual care 79 84 0.54 1.72 -0.395 
(-0.857, 0.067) 
0.094 
Intervention 87 159 0.93 2.44 
No.of times being an in-patient due to memory problems at 6 
Months 
Usual care 80 4 0.03 0.19 0.008 
(-0.032, 0.048) 
0.694 
Intervention 97 3 0.02 0.17 
No.of Days being an in-patient due to memory problems at 6 
Months 
Usual care 33 9.5 0.61 0.64 0.043 
(-0.058, 0.143) 
0.401 
Intervention 32 3 0.18 0.17 
No.of times being an in-patient due to other reasons at 6 
Months 
Usual care 77 14 0.09 0.41 0.025 
(-0.050, 0.100) 
0.516 
Intervention 85 11 0.06 0.27 
No.of Days being an in-patient due to other reasons at 6 
Months 
Usual care 13 27 0.17 1.06 -0.027 
(-0.251, 0.197) 
0.814 
Intervention 12 34 0.20 1.00 
No.of GP Home consultations (linked to memory problems) 
per patient at 6 Months 
Usual care 81 7 0.04 0.36 0.009 
(-0.065, 0.084) 
0.803 
Intervention 104 6 0.04 0.32 
No.of GP Home consultations (for other reasons) per patient 
at 6 Months 
Usual care 75 11 0.07 0.54 0.017 
(-0.079, 0.114) 
0.724 
Intervention 86 9 0.05 0.33 
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No.of Practice Nurse Home consultations (linked to memory 
problems) per patient at 6 Months 
Usual care 83 3 0.02 0.24 0.019 
(-0.017, 0.055) 
0.297 
Intervention 102 0 0.00 0.00 
No.of Practice Nurse Home consultations (for other reasons) 
per patient at 6 Months 
Usual care 76 99 0.63 5.57 0.607 
(-0.231, 1.445) 
0.155 
Intervention 87 4 0.02 0.19 
No.of Home consultations with other Healthcare professionals 
(linked to memory problems) per patient at 6 Months 
Usual care 84 52 0.33 1.61 0.214 
(-0.042, 0.471) 
0.102 
Intervention 100 20 0.12 0.55 
No.of Home consultations with other Healthcare professionals 
(for other reasons) per patient at 6 Months 
Usual care 74 43 0.27 1.65 -0.036 
(-0.365, 0.292) 
0.829 
Intervention 84 53 0.31 1.37 
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Table 56. Service Usage Costs associated with resource utilisation at 6-months (available cases) 
 
  
Mean (£) 
[std. err.] 
95% CI (£) Difference in Means (£) 
(95% CI)a 
p-value 
Primary Care Visits  
 
  
Usual care 
(n = 112) 
127.88 
(17.30) 
(93.61, 162.16) 
-23.83 
(-64.05, 16.39) 
0.244 
Memory Rehabilitation 
(n = 121) 
104.05 
(11.38) 
(81.52, 126.58) 
Primary Care Home Visits 
Usual care 
(n = 112) 
85.27 
(29.26) 
(27.28, 143.26) 
-47.20 
(-106.70, 12.30) 
0.119 
Memory Rehabilitation 
(n = 121) 
38.07 
(10.51) 
(17.26, 58.89) 
Inpatient 
Usual care 
(n = 112) 
356.47 
(130.23) 
(98.41, 279.26) 
-189.00 
(-461.57, 83.57) 
0.173 
Memory Rehabilitation 
(n = 121) 
167.46 
(56.47) 
(55.67, 279.26) 
Medication 
Usual care 
(n = 112) 
13.76 
(2.21) 
(9.37, 18.15) 
3.41 
(-3.82, 10.63) 
0.353 
Memory Rehabilitation 
(n = 121) 
17.17 
(2.87) 
(11.48, 22.85) 
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Table 57. Resource utilisation at baseline (available cases) 
Resource Utilisation (No.) Arm N Sum Mean 
Std. 
Deviation 
95% Confidence Interval of the 
Difference 
p-value 
No.of GP consultations (linked to memory problems) per patient 
at 12 Months 
Usual care 75 39 0.25 1.01 0.044 
(-0.147, 0.235) 
0.652 
Intervention 101 35 0.20 0.73 
No.of GP consultations (for other reasons) per patient at 12 
Months 
Usual care 88 105 0.67 1.23 -0.138 
(-0.424, 0.147) 
0.341 
Intervention 101 138 0.81 1.38 
No.of Practice Nurse consultations (linked to memory problems) 
per patient at 12 Months 
Usual care 81 12 0.08 0.40 0.018 
(-0.066, 0.102) 
0.674 
Intervention 98 10 0.06 0.37 
No.of Practice Nurse consultations (for other reasons) per 
patient at 12 Months 
Usual care 82 66 0.42 1.86 -0.012 
(-0.440, 0.415) 
0.955 
Intervention 97 74 0.43 2.06 
No.of consultations with other Healthcare professionals (linked 
to memory problems) per patient at 12 Months 
Usual care 83 58 0.37 1.40 0.019 
(-0.281, 0.318) 
0.903 
Intervention 95 60 0.35 1.36 
No.of consultations with other Healthcare professionals (for 
other reasons) per patient at 12 Months 
Usual care 77 92 0.59 1.82 -0.209 
(-0.664, 0.246) 
0.366 
Intervention 91 136 0.80 2.32 
No.of times being an in-patient due to memory problems at 12 
Months 
Usual care 79 5 0.03 0.21 -0.003 
(-0.055, 0.049) 
0.902 
Intervention 99 6 0.04 0.26 
No.of Days being an in-patient due to memory problems at 12 
Months 
Usual care 33 11 0.70 0.61 -0.012 
(-0.203, 0.180) 
0.904 
Intervention 32 14 0.08 1.07 
No.of times being an in-patient due to other reasons at 12 
Months 
Usual care 70 4 0.03 0.16 -0.027 
(-0.076, 0.022) 
0.275 
Intervention 87 9 0.05 0.27 
No.of Days being an in-patient due to other reasons at 12 
Months 
Usual care 12 7 0.04 0.29 -0.037 
(-0.138, 0.063) 
0.466 
Intervention 14 14 0.08 0.58 
No.of GP Home consultations (linked to memory problems) per 
patient at 12 Months 
Usual care 74 3 0.02 0.24 0.019 
(-0.017, 0.055) 
0.297 
Intervention 102 0 0.00 0.00 
No.of GP Home consultations (for other reasons) per patient at 
12 Months 
Usual care 73 11 0.07 0.43 -0.000 
(-0.088, 0.089) 
0.998 
Intervention 96 12 0.07 0.38 
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No.of Practice Nurse Home consultations (linked to memory 
problems) per patient at 12 Months 
Usual care 77 4 0.03 0.32 -0.507 
(-1.600, 0.587) 
0.363 
Intervention 103 91 0.53 6.96 
No.of Practice Nurse Home consultations (for other reasons) per 
patient at 12 Months 
Usual care 71 44 0.28 2.91 0.269 
(-0.170, 0.707) 
0.229 
Intervention 94 2 0.01 0.11 
No.of Home consultations with other Healthcare professionals 
(linked to memory problems) per patient at 12 Months 
Usual care 73 24 0.15 1.25 -0.017 
(-0.278, 0.245) 
0.900 
Intervention 99 29 0.17 1.16 
No.of Home consultations with other Healthcare professionals 
(for other reasons) per patient at 12 Months 
Usual care 71 46 0.29 2.06 0.024 
(-0.343, 0.392) 
0.898 
Intervention 93 46 0.27 1.26 
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Table 58. Service Usage Costs associated with resource utilisation at 6-months (available cases) 
 
  
Mean (£) 
[std. err.] 
95% CI (£) Difference in Means 
(£) 
(95% CI)a 
p-value 
Primary Care Visits  
 
  
Usual care (n = 105) 
127.87 
(19.06) 
(90.08, 165.67) 
-0.31 
(-53.10, 52.49) 
0.991 
Memory Rehabilitation (n = 122) 
127.56 
(18.67) 
(90.60, 164.53) 
Primary Care Home Visits 
Usual care (n = 105) 
49.30 
(19.83) 
(9.98, 88.62) 
7.65 
(-70.70, 86.00) 
0.848 
Memory Rehabilitation (n = 122) 
56.95 
(32.70) 
(-7.78, 121.67) 
Inpatient 
Usual care (n = 105) 
162.77 
(72.56) 
(18.89, 306.66) 
6.46 
(-196.61, 209.53) 
0.950 
Memory Rehabilitation (n = 122) 
169.23 
(72.38) 
(25.93, 312.54) 
Medication 
Usual care (n = 105) 
15.09 
(2.94) 
(9.26, 20.91) 
3.26 
(-5.56, 12.08) 
0.467 
Memory Rehabilitation (n = 122) 
18.35 
(3.29) 
(11.83, 24.87) 
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Appendix 27. Service Use Questionnaire Completion 
 
Table 59: Completeness of SUQ 
 BASELINE 6-MONTHS 12-MONTHS 
 Control 
(n=157) 
Intervention 
(n=171) 
Control 
(n=157) 
Intervention 
(n=171) 
Control 
(n=157) 
Intervention 
(n=171) 
Complete 154 
(98.09%) 
170 
(99.42%) 
111 
(70.70%) 
120 
(70.18%) 
101 
(64.33%) 
121 
(70.76%) 
Missing 
(assumed zero) 
2 
(1.27%) 
1 
(0.64%) 
1 
(0.64%) 
2 
(1.17%) 
0 
(0.00%) 
1 
(0.58%) 
Missing 1 
(0.64%) 
0 
(0.00%) 
45 
(28.66%) 
49 
(28.65%) 
56 
(35.67%) 
49 
(28.65%) 
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Appendix 28. EQ-5D-5L Missing Data 
Table 60: Missing Data in EQ-5D-5L Questionnaires at 6- and 12-Month Follow-Up 
  Control 
(𝒏 = 𝟏𝟓𝟕) 
Intervention 
(𝒏 = 𝟏𝟕𝟏) 
E
Q
-5
D
-5
L
 6
-M
o
n
th
 
Q
u
es
ti
o
n
n
a
ir
e
 
 EQ-5D-5L 12-Month Questionnaire 
 Complete Missing TOTAL Complete Missing TOTAL 
Complete 99 
(63.1%) 
20 
(12.7%) 
119 
(75.8%) 
110 
(64.3%) 
18 
(10.5%) 
128 
(74.9%) 
Missing 7 
(4.5%) 
31 
(19.7%) 
38 
(24.2%) 
13 
(7.6%) 
30 
(17.5%) 
43 
(25.1%) 
TOTAL 106 
(67.5%) 
51 
(32.5%) 
157 123 
(71.9%) 
48 
(28.1%) 
171 
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Appendix 29.  EQ-5D-5L utilities and QALY gained over time (mean 
imputed data) 
 
Table 61. EQ-5D-5L utilities and QALY gained over time (mean imputed data) 
Control 
(𝒏 = 𝟏𝟓𝟕) 
Intervention 
(𝒏 = 𝟏𝟕𝟏) 
  
Time 
period 
EQ-5D 
score 
Change over 
time 
Time 
period 
EQ-5D 
Score 
Change over 
time 
Mean and 
95% 
Confidence 
Interval of 
Difference 
p-value 
Baseline 0.581  Baseline 0.637  
  
6 Months 0.581 
0.000 
6 Months 0.639 
0.002 0.002 0.935 
(-0.041, 0.040) (-0.036, 0.039) (-0.052, 0.057) 
12 Months 0.628 
0.047 
12 Months 0.644 
0.007 -0.040 0.148 
(0.004, 0.090) (-0.027, 0.041) (-0.093, 0.014) 
QALY 
Gain 6 
months 
0.000 
(-0.020, 0.020) 
QALY 
Gain 6 
Months 
0.001 
(-0.018, 0.020) 
0.001 0.935 
(-0.026, 0.028) 
QALY 
Gain at 12 
Months 
0.023 
(0.002, 0.045) 
QALY 
Gain at 12 
Months 
0.004 
(-0.013, 0.020) 
-0.020 0.148 
(-0.047, 0.007) 
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Appendix 30.  EMQ-p over time (mean imputed data) 
 
Table 62. EMQ-p over time (mean imputed data) 
Control 
(𝒏 = 𝟏𝟓𝟕) 
Intervention 
(𝒏 = 𝟏𝟕𝟏) 
  
Time 
period 
EQ-5D 
score 
Change over 
time 
Time 
period 
EQ-5D 
Score 
Change over 
time 
Mean and 
95% 
Confidence 
Interval of 
Difference 
p-value 
Baseline 
50.075 
(1.953) 
 Baseline 
47.363 
(1.606) 
 
  
6 Months 
43.679 
(1.749) 
-6.397 
6 Months 
39.572 
(1.800) 
-7.791 -1.394 0.528 
(-9.681, -3.112) 
(-10.678, -
4.903) 
(5.735, 2.946) 
12 Months 
43.268 
(1.774) 
-6.807 
12 Months 
38.323 
(1.707) 
-9.049 -2.242 0.324 
(-10.119, -
3.495) 
(-12.081, -
6.015) 
(-6.707, 2.224) 
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Appendix 31.  GHQ over time (mean imputed data) 
 
Table 63. GHQ over time (mean imputed data) 
Control 
(𝒏 = 𝟏𝟓𝟕) 
Intervention 
(𝒏 = 𝟏𝟕𝟏) 
  
Time 
period 
EQ-5D 
score 
Change over 
time 
Time 
period 
EQ-5D 
Score 
Change over 
time 
Mean and 
95% 
Confidence 
Interval of 
Difference 
p-value 
Baseline 9.601  Baseline 9.670  
  
6 Months 8.811 
-0.790 
6 Months 8.693 
-0.976 -0.186 0.830 
(-2.003, 0.422) (-2.177, 0.224) (-1.889, 1.517) 
12 Months 8.089 
-1.512 
12 Months 8.492 
-1.179 0.373 0.728 
(-2.867, -0.158) (-2.494, 0.135) (-1.549, 2.215) 
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Appendix 32.  One-way sensitivity analysis of cost-effectiveness 
(multiple imputed data) 
 
Table 64. OWSA of incremental cost per QALY analysis (Multiple Imputed) 
 
 Inc. Diff. 
(Int – 
Usual 
Care) 
Inc. Diff. 
(Int – 
Usual 
Care) 
ICER 
(£) 
6-MONTHS 
Basecase 
-35.612 0.004 -8,903 
Intervention 
Dominant 
U95% Bound Net Cost 
57.519 0.005 11,504 
North-East 
Quadrant U95% Bound QALY 
L95% Bound Net Cost 
-128.744 0.003 -42,915 
Intervention 
Dominant L95% Bound QALY 
U95% Bound Net Cost 
57.519 0.003 57.519 
North-East 
Quadrant L95% Bound QALY 
L95% Bound Net Cost 
-128.744 0.005 -25,749 
Intervention 
Dominant U95% Bound QALY 
12-MONTHS 
Basecase 
-26.895 -0.011 2,445 
South-West 
Quadrant 
U95% Bound Net Cost 
59.94 -0.008 -7,493 
Usual Care 
Dominant U95% Bound QALY 
L95% Bound Net Cost 
-280.73 -0.013 21,595 
South-West 
Quadrant L95% Bound QALY 
U95% Bound Net Cost 
59.94 -0.013 -4,611 
Usual Care 
Dominant L95% Bound QALY 
L95% Bound Net Cost 
-280.73 -0.008 35,091 
South-West 
Quadrant U95% Bound QALY 
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Table 65. OWSA of incremental cost per improvement EMQ-p (Multiple Imputed) 
 
 Inc. Diff. 
(Int – 
Usual 
Care) 
Inc. Diff. 
(Int – 
Usual 
Care) 
ICER 
(£) 
6-MONTHS 
Basecase 
-35.612 -2.322 -15.34 
Intervention 
Dominant 
U95% Bound Net Cost 
57.519 -2.667 21.56 
North-East 
Quadrant U95% Bound EMQ-p 
L95% Bound Net Cost 
-128.744 -1.976 -65.16 
Intervention 
Dominant L95% Bound EMQ-p 
U95% Bound Net Cost 
57.519 -1.976 29.11 
North-East 
Quadrant L95% Bound EMQ-p 
L95% Bound Net Cost 
-128.744 -2.667 -48.26 
Intervention 
Dominant U95% Bound EMQ-p 
12-MONTHS 
Basecase 
-26.895 -1.410 -19.07 
Intervention 
Dominant 
U95% Bound Net Cost 
59.94 -1.496 40.07 
North-East 
Quadrant U95% Bound EMQ-p 
L95% Bound Net Cost 
-280.73 -1.325 -211.93 
Intervention 
Dominant L95% Bound EMQ-p 
U95% Bound Net Cost 
59.94 -1.325 45.25 
North-East 
Quadrant L95% Bound EMQ-p 
L95% Bound Net Cost 
-280.73 -1.496 187.68 
Intervention 
Dominant U95% Bound EMQ-p 
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Table 66. OWSA of incremental cost per improvement GHQ (Multiple Imputed) 
 
 Inc. Diff. 
(Int – 
Usual 
Care) 
Inc. Diff. 
(Int – 
Usual 
Care) 
ICER 
(£) 
6-MONTHS 
Basecase 
-35.612 -0.998 -35.70 
Intervention 
Dominant 
U95% Bound Net Cost 
57.519 -1.058 54.37 
North-East 
Quadrant U95% Bound GHQ 
L95% Bound Net Cost 
-128.744 -0.937 -137.35 
Intervention 
Dominant L95% Bound GHQ 
U95% Bound Net Cost 
57.519 -0.937 61.36 
North-East 
Quadrant L95% Bound GHQ 
L95% Bound Net Cost 
-128.744 -1.058 -121.71 
Intervention 
Dominant U95% Bound GHQ 
12-MONTHS 
Basecase 
-26.895 -0.737 -36.49 
Intervention 
Dominant 
U95% Bound Net Cost 
59.94 -0.439 136.54 
North-East 
Quadrant U95% Bound GHQ 
L95% Bound Net Cost 
-280.73 -1.037 -270.71 
Intervention 
Dominant L95% Bound GHQ 
U95% Bound Net Cost 
59.94 -1.037 57.80 
North-East 
Quadrant L95% Bound GHQ 
L95% Bound Net Cost 
-280.73 -0.439 -639.48 
Intervention 
Dominant U95% Bound GHQ 
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Appendix 33.  One-way sensitivity analysis of longer-term cost-
effectiveness – 5-year horizon 
 
Table 67. One-way sensitivity analysis of longer-term cost-effectiveness – 5-year horizon 
 Intervention Control Incremental  
Analysis Cost (£) QALY Cost (£) QALY Cost (£) QALY ICER (£) 
 Base Case Analysis 
Base-case analysis 3,599.08 2.952 3,404.27 2.651 194.81 0.301 646.36 per QALY 
 One-Way Sensitivity Analysis 
Age 30 3,644.67  2.990 3,442.43  2.681 202.24 0.309 655.35 per QALY 
Age 65 3,422.51 2.848 3,280.97 2.552 141.54 0.296 477.62 per QALY 
Discount Rate 
1.5% 
3,770.16  3.096  3561.15 2.780  209.01 0.316 661.17 per QALY 
Discount Rate 
5.0% 
3,479.91  2.852  3294.90 2.561  185.01 0.291 635.50 per QALY 
+30% Intervention 
Cost 
3,649.18 2.952 3,404.27 2.651 244.91 0.301 812.59 per QALY 
-30% Intervention 
Cost 
3,548.98 2.952 3,404.27 2.651 144.71 0.301 480.13 per QALY 
+30% Cost per 
Cycle in GHQ 
State 
4,628.70  2.952  3404.27 2.651  1224.43 0.301 4062.58 per QALY 
-30% Cost per 
Cycle in GHQ 
State 
2,569.45  2.952  3404.27 2.651  -834.82 0.301 -2769.87 per QALY 
+30% Utility per 
Cycle in GHQ 
State 
3,599.08  3.838  3404.27 3.446  194.81 0.392 497.20 per QALY 
-30% Utility per 
Cycle in GHQ 
State 
3,599.08  2.067  3404.27 1.856  194.81 0.211 923.37 per QALY 
+20% Transition 
Prob. Higher 
GHQ State 
3,674.46  2.904  3526.14 2.612  148.31 0.292 507.06 per QALY 
+20% Transition 
Prob. Lower GHQ 
State 
3,526.03  3.001  3277.91 2.690  248.12 0.311 797.73 per QALY 
-20% Transition 3,521.44  3.004  3263.71 2.695  257.73 0.309 834.92 per QALY 
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Prob. Higher 
GHQ State 
-20% Transition 
Prob. Lower GHQ 
State 
3,697.16  2.891  3553.60 2.603  143.56 0.288 498.47 per QALY 
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Appendix 34.  One-way sensitivity analysis of longer-term cost-
effectiveness – 10-year horizon 
 
Table 68. One-way sensitivity analysis of longer-term cost-effectiveness – 10-year horizon 
 Intervention Control Incremental  
Analysis Cost (£) QALY Cost (£) QALY Cost (£) QALY ICER (£) 
 Base Case Analysis 
Base-case analysis 6,451.25 5.340 5976.51 4.806 474.73 0.535 887.76 per QALY 
 One-Way Sensitivity Analysis 
Age 30 6,627.24  5.486 6,120.75 4.924 506.49 0.562 900.57 per QALY 
Age 65 5,905.55 4.931 5,503.20 4.417 402.35 0.514 782.30 per QALY 
Discount Rate 1.5% 7,066.71  5.856  6534.38 5.271  532.33 0.586 908.93 per QALY 
Discount Rate 5.0% 6,044.64  4.999  5607.79 4.498  436.86 0.501 871.83 per QALY 
+30% Intervention 
Cost 
6,501.35 5.340 5,976.51 4.806 524.83 0.535 981.44 per QALY 
-30% Intervention 
Cost 
6,401.15 5.340 5,976.51 4.806 424.63 0.535 794.07 per QALY 
+30% Cost per Cycle 
in GHQ State 
8,336.52  5.340  5976.51 4.806  2,360.01 0.535 4413.23 per QALY 
-30% Cost per Cycle 
in GHQ State 
4,565.97   5.340  5976.51 4.806  -1410.54 0.535 -2637.72 per QALY 
+30% Utility per 
Cycle in GHQ State 
6,451.25  6.942  5976.51 6.247  474.73 0.695 682.89 per QALY 
-30% Utility per 
Cycle in GHQ State 
6,451.25  3.738  5976.51 3.364  474.73 0.374 1,268.22 per QALY 
+20% Transition 
Prob. Higher GHQ 
State 
6,596.52  5.248  6196.88 4.732  399.64 0.516 774.87 per QALY 
+20% Transition 
Prob. Lower GHQ 
State 
6,318.55  5.430  5753.57 4.878  564.99 0.552 1023.36 per QALY 
-20% Transition 
Prob. Higher GHQ 
State 
6,301.55  5.442  5717.64 4.891  583.91 0.551 1059.79 per QALY 
-20% Transition 
Prob. Lower GHQ 
State 
6,635.93  5.224  6246.03 4.716  389.90 0.509 766.74 per QALY 
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Appendix 35. Semi-structured interview schedule 
Remembrin feedback interviews topic guide and prompts v01 10.08.12 
[Note: The following is only a guide of the topics that will be covered during the interview. In line with 
qualitative research guidelines, the interviews guide is likely to change slightly following each interview, as 
this is an iterative process.] 
For all participants: 
1. Please tell us about your experience of being involved in this study. 
For the intervention group participants: 
1. What was it like being a part of the intervention group?  
2. What did you find must useful about the group sessions? 
3. What did you find least useful about the group sessions? 
4. What improvements/changes would you like seen made to the group sessions? 
For the control group participants: 
1. What was it like being part of a group that did not receive any active intervention?  
2. What kinds of treatment did you receive (as part of usual care) from the time you were recruited to the 
study and now?  
Possible prompts  
1. Please could you tell us more about …? 
2. And how did that make you feel? 
3. What are your thoughts about …? 
4. Could you give me some examples about …?  
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Appendix 36. Qualitative interview recruitment 
 
Table 69: Recruitment sites of participants for qualitative interviews 
Study site Usual care Intervention Total 
Site 1  4 3 7 
Site 2  0 0 0 
Site 3  3 4 7 
Site 4  4 2 6 
Site 5  1 2 3 
Site 6  1 1 2 
Site 7  1 1 2 
Site 8  1 1 2 
Site 9  1 2 3 
Total  16 16 32 
 
 
